wxy wxy 2020-02-21T15:25:01Z 16.00 6770 19200 32767 32767 False False Gene symble Title Curated description Category Literature category Pubmed ID ABCB1 Exosomes mediate drug resistance transfer in MCF7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein Exosomes are effective in transferring drug resistance as well as P-gp from drug-resistant breast cancer cells to sensitive ones. The delivery of P-gp via exosomes may be a mechanism of exosome-mediated drug resistance transfer molecular function MFBCE 25077924 ABCB1 Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women Genetic variants in ABCB1 and BRCA1 may modify the effect of Menopausal hormone therapy(HT) on postmenopausal breast cancer risk. molecular function CBC 19672706 ABCB1 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to Doxorubicin and cyclophosphamide(AC) therapy in the treatment of breast cancer. molecular function CBC 20179710 ABCB1 The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment ABCB1 gene may be potential candidate in pharmacogenetic evaluation of breast cancer treatment outcomes and optimizing individualized therapy. biomarker CBC 27175090 ABCB1 The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment ABCB1 is highly polymorphic, and three well-known single-nucleotide polymorphisms such as 1236C>T, 2677G>T/A, and 3435C>T have been found to be associated with altered messenger RNA levels, protein folding, and drug pharmacokinetics.And these polymorphisms are found to be correlated with phenotypic variation in P-gp expression levels of various tissues.P-gp is widely expressed in the tissues essential in drug disposition such as the intestinal epithelium, adrenal glands, canalicular membrane of the hepatocytes of the liver, kidney proximal tubules, and blood鈥揵rain barrier.Major functions of P-gp proteins include the transport of drugs such as colchicine, tacrolimus, and quinidine; chemotherapeutic agents such as etoposide, doxorubicin, taxol, and vinblastine; and various lipids, bile salts, toxic compounds, and peptides for antigen presentation across the membranes. molecular function CBC 27175090 ABCB1 ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines ABCB1 and ABCC11 expression may be used as a biomarker for predicting the response to eribulin in patients with breast cancer biomarker CBC 27588398 ABCB1 Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis The loss of constitutive ABCB1 expression in breast cancer, especially in triple-negative tumors, seems to indicate a subgroup of worse prognosis. biomarker CBC 28670140 ABCB1 Development of high resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma Our data suggest the existence of functional epigenetic changes in the ABCB1 gene with prognostic value in tumor tissues of patients with breast and ovarian carcinoma biomarker CBC 31173253 ABCB11 Description of two new ABCB11 mutations responsible for type 2 benign recurrent intrahepatic cholestasis in a French-Canadian family The present report describes two individuals from the same family whose symptoms were typical of the clinical characteristics of type 2 benign recurrent intrahepatic cholestasis. Sequencing of the?ABCB11?gene revealed two previously unreported mutations that predict the absence of expression of the protein molecular function CBC 21766090 ABCB11 The role of ABC transporters in progression and clinical outcome of colorectal cancer ABCC11 may be a promising candidate marker for a validation study on 5-FU therapy outcome biomarker CBC 22294766 ABCB11 Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations This is the first study to identify somatic CTNNB1 and NFE2L2 mutations in early childhood arisen in the setting of inherited bi-allelic ABCB11 mutations molecular function CBC 25016225 ABCB5 ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma Our findings show that ABCB5 is a novel molecular marker for a distinct subset of chemoresistant, stem cell phenotype-expressing tumor cells among melanoma bulk populations and indicate that these chemoresistant cells can be specifically targeted via ABCB5 to enhance cytotoxic efficacy molecular function CBC 15899824 ABCB5 p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance Our work provides valuable insight into the drug induced cell fusion event and outcome, and suggests YB-1, GST, ABCB5 and ERK3 could be potential targets for the anti-cancer drug development against drug resistant breast cancer cells molecular function CBC 20649952 ABCB5 Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres The potential clinical significance of our findings is based on the ability of parthenolide to affect both bulk and melanoma stem-like cells with clonogenic capacity and high expression of the ABCB5 transporter molecular function CBC 23192276 ABCB5 △Np73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report In addition, we found that exogenous expression of △Np73 led to an increase in the expression of ABCB1 and ABCB5 in the breast cancer-derived cell lines tested, while knocking down of △Np73 resulted in a reduction in ABCB1 and ABCB5 expression molecular function CBC 28677036 ABCB5 ABCB5-ZEB1 Axis Promotes Invasion and Metastasis in Breast Cancer Cells The expression of ZEB1 in tissues is positively relevant to ABCB5 in breast cancer. Knocking down ZEB1 inhibits ABCB5 ectopic expression-induced migration and invasion, as well as EMT molecular function CBC 28281973 ABCC9 Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma ABCA2, ABCA9, ABCA10, ABCC9, ABCG2 and SLC16A14 present novel putative markers of EOC progression and together with the revealed relationship between ABCA12, ABCC3, ABCC6, ABCD3, ABCG1 and SLC22A5 expression, and high grade serous type of EOC should be further examined by larger follow-up study molecular function CBC 26820484 AC092620.3 LncRNA expression profiling and its relationship with DNA damage in Cr (VI)-treated 16HBE cells AC092620.3 were nonlinearly decreasing with the change of the DNA content of comet tails (Tail DNA), tail length (TLL), tail moment (TM) and Olive Tail Moment (OTM), and the fitting results of Tail DNA and TM were statistically significant (P?<?0.05) molecular function CBC 30476843 ADAM10 Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients The mature ADAM10 in exosomes and its proteolytic activity is regulated by tetraspanins CD9, CD81, CD82, which was associated with breast cancer molecular function MFBCE 30678441 ADAM10 Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells Consistent with ADAM10 being a major determinant of HER2 shedding, the inhibition of which, may provide a novel therapeutic approach for treating a variety of cancers with active HER2 signalin molecular function CBC 16627989 ADAM10 ADAM10: a new player in breast cancer progression? ADAM10 is likely to be involved in breast cancer progression, especially in the basal subtype molecular function CBC 26284334 ADAM10 Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells ES independently potentiates the activity of ADAM10 and NEP enzymes in 4T1 and 4THMpc breast cancer cells molecular function CBC 27430992 ADAM10 Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells?In Vitro The inhibition of ADAM17 enhanced the purity of expanded NK cells and the ADCC activity of these cells against trastuzumab treated breast cancer cell lines molecular function CBC 28982863 ADAM10 Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer ADAM10 was the key α-secretase. APP and ADAM10 co-expression was associated with worse survival in non-luminal breast cancers molecular function CBC 30470613 ADAM10 Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression Serum HER-2 ECD could be a biomarker to identify the subgroup of poorer outcome among HER-2 overexpression breast cancer patients. Inhibition of ADAM10 activity may have potential therapeutic benefit for this most aggressive tumor subgroup molecular function CBC 30661303 ADCYAP1 DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression Forced overexpression of Adcyap1 by plasmid transfection or knockdown of Bank1 expression by small interfering RNA in insulinoma NIT-1 cells protected them from cytokine-triggered apoptosis, indicating that indeed DcR3 protects beta cells via the action of these two downstream molecules molecular function CBC 20007581 ADCYAP1 The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer ADCYAP1 gene expression was reactivated by the treatment of a DNA methyltransferase inhibitor of 5'-aza-2'deoxycytidine and/or a histone deacetylase inhibitor of trichostain A in cervical cancer cells suggesting that hypermethylation in the ADCYAP1 promoter is responsible for the transcriptional silencing of the ADCYAP1 gene in cervical cancer cells molecular function CBC 21109983 ADCYAP1 DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer DNA methylation status of MAL, ADCYAP1, PAX1 and CADM in 205 patients with low-grade or high-grade CIN and cervical cancer demonstrated that ADCYAP1 and PAX1 had a relatively better discriminatory ability than did methylated MAL and CADM1, which illustrates that the best panel still needs to be discovered molecular function CBC 26768780 ADCYAP1 Human Papillomavirus Genotypes and Methylation of CADM1, PAX1, MAL and ADCYAP1 Genes in Epithelial Ovarian Cancer Patients In HR-HPV infected cancers, DNA methylation may be one of the mechanisms triggering the alteration in CADM1, PAX1, MAL and ADCYAP1 gene expression levels molecular function CBC 28240513 ADH1A Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Genetic variants at ADH1 and ALDH2 loci may influence gastric cancer(GC) risk, and alcohol intake may further modify the effect of ADH1 rs1230025. biomarker CBC 22144473 ADH1A Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma. ADH1A, ADH5, and ADH6 expression may be potential prognostic markers of pancreatic adenocarcinoma(PAAD) and in combination have a strong interaction and better predictive value for PAAD prognosis. biomarker CBC 28769575 ADH1A Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma. The potential mechanism of ADH1A and ADH6 in pancreatic adenocarcinoma(PAAD) prognosis was that a high expression of ADH1A and ADH6 was involved in the P450 pathway and biological processes molecular function CBC 28769575 ADH1A Prognostic value of alcohol dehydrogenase mRNA expression in gastric cancer ADH1A and ADH1B may be potential prognostic biomarkers of GC biomarker CBC 29552190 ADRA1B Frequent reduced expression of alpha-1B-adrenergic receptor caused by aberrant promoter methylation in gastric cancers ADRA1B gene is an important tumour-related gene frequently involved in the development and progression of gastric cancer molecular function CBC 17242706 ADRA1B beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration The ADRA1B expression was found to be higher in MCF7 cells, which is expressed 2-fold higher than HT-29 cells and 10-fold higher than HepG2 cells molecular function CBC 25026350 ADRA1B The prognostic value of ADRA1 subfamily genes in gastric carcinoma Multivariate survival analysis revealed that low expression levels of ADRA1A (HR, 0.595; 95% CI, 0.426 0.831; adjusted P=0.002) ADRA1B (HR, 0.576; 95% CI, 0.412 0.805; adjusted P=0.001) and ADRA1D (HR, 0.559; 95% CI, 0.398 0.787; adjusted P=0.001) were associated with a favourable OS biomarker CBC 31452791 ALDH9A1 Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer ALDH9A1 is implicated in RCC development, further studies are required to determine the variants that are functionally relevant molecular function CBC 25826619 ALDH9A1 High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer Relatively high expression of certain ALDH isoforms (e.g., ALDH3A2, ALDH4A1, ALDH7A1, ALDH9A1, and ALDH18A1) in primary cultures in a comparable manner as in established human prostate cancer cell line molecular function CBC 20516116 ALDH9A1 13C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede c-Myc-Induced Tumor Formation and Regression We also examined other alanine pathway genes whose expression was altered in the pretumor state and found that two genes,?Aldh2?and?Aldh9a1, are known to be direct MYC targets molecular function CBC 21723511 ANAPC1 Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer ANAPC1 and TP53 methylation was probably not implicated in gastric carcinogenesis in our samples molecular function CBC 18622497 ANAPC1 A comparison between genetic portraits of normal osteoblasts and osteosarcoma cell lines Interesting genes with elevated expression in OCLs are involved in cell cycle regulation (ANAPC1, TUBG1, NUP214) and cell proliferation (IGFBP4, FTH1). ANAPC1 regulates the metaphase-to-anaphase transition, TUBG1 is a gamma-tubulin component of microtubule organizing centers, and NUP214 encodes a protein localized to the cytoplasmic face of the nuclear pore complex required for proper cell cycle progression and nucleo-cytoplasmic transport molecular function CBC 19336861 ANAPC1 A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer ANAPC1 rs3814026C>T, ETS2 rs461155A>G, SORBS1 rs7081076C>A and POLR2A rs2071504C>T could predict both chemotherapy response and survival biomarker CBC 26893365 APC1 SCaMC-1 Promotes Cancer Cell Survival by Desensitizing Mitochondrial Permeability Transition via ATP/ADP-mediated Matrix Ca(2+) Buffering Knockdown of APC1 increased cancer cell sensitivity to oxidative stress-induced?apoptosis, while its overexpression protected them from death;Selective inhibition of APC1 was thus suggested to be a promising anticancer strategy molecular function CBC 22015608 ARF6 The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis GEP100 (BRAG2) to be responsible for the Arf6 activation to induce invasion and metastasis, by directly binding to ligand-activated epidermal growth factor receptor (EGFR) molecular function CBC 19416474 ARF6 ARF6 promotes the formation of Rac1 and WAVE-dependent ventral F-actin rosettes in breast cancer cells in response to epidermal growth factor A role for ARF6 in linking EGF-receptor signaling to Rac1 recruitment and activation at the plasma membrane to promote breast cancer cell directed migration molecular function CBC 25799492 ARF6 Requirement for Arf6 in breast cancer invasive activities GTP hydrolysis-defective mutant Arf6(Q67L) and the GTP-binding defective mutant Arf6(T27N) both blocked these invasive activities but not cell adhesion, suggesting the necessity of continued activation and cycling of the Arf6 GTPase cycle in invasion molecular function CBC 25799492 ARF6 Roles of Arf6 in cancer cell invasion, metastasis and proliferation The ability of tumor invasion and metastasis can be suppressed when Arf6 activity is blocked by the inhibitors or small-interfering RNAs of Arf6;the ability of tumor invasion and metastasis can be suppressed when Arf6 activity is blocked by the inhibitors or small-interfering RNAs of Arf6 molecular function CBC 28625359 BARD1 BARD1, a possible biomarker for breast and ovarian cancer A blood test based on BARD1, a protein that interacts with the breast cancer gene product BRCA1, is a promising candidate for fulfilling these conditions molecular function CBC 19959210 BARD1 Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk molecular function CBC 21393566 BARD1 Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms Germline mutations of BARD1 may predispose to breast and/or ovarian cancer molecular function CBC 26329992 BARD1 Dualistic Role of BARD1 in Cancer Further evidence for a dualistic role came with the identification of BARD1 as a neuroblastoma predisposition gene in our genome wide association study which has demonstrated that single nucleotide polymorphisms in BARD1 can correlate with risk or can protect against cancer based on their association with the expression of FL and splice variants of BARD1 molecular function CBC 29292755 BARD1 BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation Substantial evidence for the association of a deleterious BARD1 mutation with BC as a low/moderate risk allele molecular function CBC 31142030 BDKRB2 Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells The bradykininin receptor B2 (BDKRB2) gene is known to induce mitosis in breast cells and enhance progression of cancer. molecular function CBC 15281091 BDKRB2 Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture The mitogenic effects of BK are retained in peritumour and tumour cells; hence, it is likely that BK has an important role in cancer endorsement and progression. molecular function CBC 16079255 BDKRB2 Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines Tissue kallikrein was found in malignant human breast tissue and bradykinin (BK) stimulates the proliferation of immortalised breast cancer cells. molecular function CBC 19584277 BDKRB2 CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses BDKRB2 (2.1-fold decrease, Q = 1.63 E 3), which induces proliferation in human epithelial breast cells. molecular function CBC 20124474 BID Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis We report here that BID, a BH3 domain-containing proapoptotic Bcl2 family member, is a specific proximal substrate of Casp8 in the Fas apoptotic signaling pathway molecular function CBC 9727492 BID BID-deficient breast cancer MCF-7 cells as a model for the study of autophagy in cancer therapy BID(+) and BID(-) breast cancer MCF-7 cells could be considered to be a useful model for the study of the molecular interdependences between apoptosis and autophagy and the role of both processes in cancer therapy. molecular function CBC 16874058 BID Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis TAT-BID may be delivered to cancer cells in controlled manner and efficiently sensitizes PC3 and A549 cells to TRAIL molecular function CBC 25326334 BID Synergy of BID with doxorubicin in the killing of cancer cells TAT-BID and doxorubicin may thus be considered as a potential therapeutic combination for cervical carcinoma and advanced prostate cancer treatment molecular function CBC 25760094 BIRC5 Early diagnostic value of survivin and its alternative splice variants in breast cancer Differential expression of exosomal-Survivin, particularly Survivin-2B, may serve as a diagnostic and/or prognostic marker biomarker BBCE 24620748 BIRC5 The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. BIRC5 expression may induce breast tumor proliferation by promoting genetic instability. biomarker CBC 18181175 BIRC5 BIRC5 Genomic Copy Number Variation in Early-Onset Breast Cancer BIRC5 gene has the potential to be a marker for the detection and prognosis of cancer at an early age. biomarker CBC 27372966 BIRC5 BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. BIRC5 (survivin) as a main pejorative prognostic factor in patients with breast cancers with no pCR. biomarker CBC 27592112 BIRC5 Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway BIRC5 is able to inhibit the migration and invasion of tumor cells, and regulate the expression of angiogenesis?associated factors. biomarker CBC 30127937 BLZF1 A Role for the Nucleosome Assembly Proteins TAF-Iβ and NAP1 in the Activation of BZLF1 Expression and Epstein-Barr Virus Reactivation Quantification of the percentage of BLZF1-expressing cells showed that, like TAF-Iβ, NAP1 overexpression can induce BZLF1 expression, whereas TAF-Iα overexpression did not induce BZLF1 expression, despite being expressed at a higher level than TAF-Iβ molecular function CBC 23691099 BLZF1 BLZF1 expression is of prognostic significance in hepatocellular carcinoma BLZF1 is a novel unfavorable biomarker for prognosis of patients with HCC biomarker CBC 26342799 BLZF1 BLZF1 expression is of prognostic significance in hepatocellular carcinoma The prognostic value of BLZF1 was further confirmed by stratified analyses molecular function CBC 26342799 CACNB2 Randomness and preserved patterns in cancer network CACNB2 was downregulated in breast cancer cells, thereby causing poor signaling by negatively affecting the calcium metabolism molecular function CBC 25220184 CASC3 Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines The amplification of the HER2/TOP2A region has been correlated with the overexpression of several additional genes, such as CASC3, CDC6, RARA, and?SMARCE1 molecular function CBC 18332872 CASC3 Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling ?In the luminal-A loss related Bayesian network motif, BRCA1 showed the most links with other biomarkers, including two miRNAs (miR-143 and miR-145) and 4 genes (CASC3, ITGA2B, BID, and LMNB1) molecular function CBC 25961039 CASC3 Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3 MiR-124-1-mediated downregulation of CASC3 resulted in the inactivation of p38-MAPK, JNK and ERK molecular function CBC 27029030 CASP7 IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis This molecular signaling is associated with the activation of signal transducer and activator of transcription 1 and leads to increased mitochondrial membrane permeability; activation of caspase-7 (CASP7), CASP8, and CASP9; and induction of apoptosis but not autophagy. Whereas antiestrogen-resistant cells are capable of inducing autophagy through IFN-mediated signaling, their ability to do so through antiestrogen-regulated signaling is lost molecular function CBC 20457620 CASP7 Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins Such pattern might be an indication of hsa-miR-29c miRNA functioning as a repressor of translation of CASP7 within the luminal-A subtype molecular function CBC 23562353 CASP7 Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies CASP3/DR combined with p19/p12-CASP7 accumulation correlated with the aggressive evolution of clinical malignancies and a poor prognosis in cancer patients molecular function CBC 23979166 CASP7 Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip) CASP7 is aberrantly expressed in breast cancer and contributes to cell growth and proliferation by downregulating p21(Cip) protein, suggesting that targeting CASP7-positive breast cancer could be one of the potential therapeutic strategies molecular function CBC 27089142 CASP7 Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers BCL2 levels are elevated in breast cancer where they are marker of good prognosis. BCL2 and active caspase levels correlate negatively; yet, active caspases indicate good outcome. Low BCL2 and low caspase-7 are highly prognostic of unfavourable outcome across all breast cancers. BCL2 levels indicate molecular subtype and tumour proliferation status in breast cancer molecular function CBC 30069746 CCKBR A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer Single nucleotide polymorphism (SNP) in the cholecystokinin B receptor (CCKBR) gene predicts survival and risk of pancreatic cancer biomarker CBC 22277584 CCKBR A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer Growth of human pancreatic cancer is stimulated by gastrin through the CCKBR and an alternatively spliced isoform of the CCKBR gene called CCKCR molecular function CBC 22277584 CCKBR MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2 MiR-148a's targeting of CCKBR and Bcl-2 in the regulation of pancreatic cancer growth and apoptosis molecular function CBC 23975374 CCKBR Heterogeneous expression of cholecystokinin and gastrin receptor in stomach and pancreatic cancer: An immunohistochemical study Significantly higher expression of CCKAR and down regulation of CCKBR in PC as compared to control while CCKBR/GR was detected in majority of SC samples molecular function CBC 27072272 CCKBR Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells All eight NENs expressed CCKBR and neuroendocrine markers in a majority of tumor cells molecular function CBC 28980157 CCKBR Low serum gastrin associated with ER+ breast cancer development via inactivation of CCKBR/ERK/P65 signaling CCKBR/ERK/P65 signaling function is generally tumor suppressive in ER+ BC, indicating therapies should focus on restoring, not inhibiting, CCKBR/ERK/P65 pathway activity molecular function CBC 30115027 CD24 Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage We suggest that CD24 could be an additional marker for the enrichment of tumor-derived exosomes from blood biomarker BBCE 21601258 CD24 CD24 expression is a new prognostic marker in breast cancer. CD24 expression in primary breast cancer as detected by immunohistochemistry might be a new marker for a more aggressive breast cancer biology. biomarker CBC 14581365 CD24 CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. CD24 overexpression is an independent unfavourable prognostic factor in breast cancer, especially for luminal A and TNBC subtypes, and CD24 may be a promising therapeutic target for specific subtypes of breast cancer. biomarker CBC 26444008 CD24 CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. CD24 gene expression was associated with histone acetylation independent of DNA methylation, suggesting its epigenetic regulation in breast cancer. molecular function CBC 26444008 CD24 Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis. CD24 may play a role in tumorigenesis and cancer progression. biomarker CBC 27470135 CD24 CD24 is a Potential Biomarker for Prognosis in Human Breast Carcinoma. CD24 and SDC1 can serve as prognostic indicators for breast cancer. biomarker CBC 30001552 CD47 A rapid,automated surface protein profiling of single circulating exosomes in human blood A differential CD47 expression in blood-derived individual circulating exosomes that is correlated with breast cancer status, demonstrating a great potential of individual exosome profiles in biomarker discovery biomarker BBCE 27819324 CD47 HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells High CD47 expression is correlated with increased HIF target gene expression and decreased patient survival. biomarker CBC 26512116 CD47 HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1. molecular function CBC 26512116 CD47 Significance of CD47 expression in gastric cancer. Low expression of CD47 was associated with the advancement of gastric cancer, in contrast to other cancers, and it may be associated with a decrease in lymphocytes during later stages. biomarker CBC 28693236 CD47 Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. Combined detection of CD47 and CD68 may provide guidance for the prognosis of breast cancer, especially hormone receptor-negative breast cancer. biomarker CBC 31528120 CD47 Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis CD47 could be a useful prognostic indicator in cancer patients and may be a useful therapeutic target. biomarker CBC CD47 Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients. The detection of high CD47 and/or PD-L1 expression on CTCs is associated with triple-negative tumors, disease progression and poor patient outcome and could serve for the refinement of prognosis in mBC. biomarker CBC CD82 Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer CD82 expression in exosomes from breast cancer samples is a sensitive biomarker biomarker BBCE 30604894 CD82 Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. The expression of MRP-1/CD9 and KAI1/CD82genes are useful indicators of a poor prognosis in breast cancer patients. biomarker CBC 9736046 CD82 Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. KAI1 may be used as a promising prognostic marker and a possible therapeutic target for human melanoma. biomarker CBC 24130172 CD82 Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Overexpression of KAI1 significantly inhibited melanoma cell migration through suppression of Rho-associated kinase-mediated formation of stress fiber.overexpression of KAI1 significantly inhibited melanoma cell invasion by reducing the activity of metalloproteinase-2.melanoma cell migration by KAI1 is mediated by another tumor-suppressor protein called inhibitor of growth 4 through the regulation of p65. molecular function CBC 24130172 CD82 Effect and prognostic significance of the KAI1 gene in human gastric carcinoma. The expression of KAI1 protein and mRNA was associated with the differentiation degree of gastric cancer, presence of lymph node metastasis, tumor-node-metastasis stage, depth of invasion and the survival time of patients.Patients that expressed KAI1 may demonstrate an improved prognosis. biomarker CBC 26622792 CD82 Effect and prognostic significance of the KAI1 gene in human gastric carcinoma. The tumor suppressor gene KAI1 inhibits the migration and invasion of gastric carcinoma cells, possibly by suppressing the expression of uPA. molecular function CBC 26622792 CD82 Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies CD82 could be a promising biomarker for predicting the prognosis of patients with malignant neoplasms, and the biological functions of CD82 are of great research value of the subject. biomarker CBC 29263677 CD82 Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. CD82 expression in breast cancer tissue was significantly lower than that in healthy and benign breast disease tissues. There was a significant negative correlation between CD82 expression in tissues and CD82 content in exosomes, which indicated that CD82 expression was redistributed from tissues to the blood with the development and metastasis of breast cancer. biomarker CBC 30604894 CDC23 CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer CDC23 is a critical regulator of cell cycle and cell growth, and may be involved in thyroid cancer initiation and progression, and may explain the different tumor biology observed by gender molecular function CBC 21990323 CDC23 Expression of miR-34c induces G2/M cell cycle arrest in breast cancer cells The levels of CDC23, an important mediator in mitotic progression, were suppressed following miR-34c expression, and siRNAs targeting CDC23 mimicked the effect of miR-34c on G2/M arrest molecular function CBC 25064703 CDC23 Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia The PKC-α-dependent G2/M phase arrest was induced by down-regulation of CDC23, an important regulator of mitotic progression molecular function CBC 30618318 CDC42 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 CDC42 Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer Rac1/Cdc42 is a vascular regulator of tumor angiogenesis and that it may reduce stability of the p53 protein to promote VEGF expression by enhancing p53 protein ubiquitin. molecular function CBC 23750283 CDC42 Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration Cdc42 overexpression disrupts mammary gland branching morphogenesis by altering Rho GTPase and MAPK signaling, leading to increased MEC contractility and migration in association with stromal alterations molecular function CBC 24074261 CDC42 Role of p-21-activated kinases in cancer progression PAK1, MLC, ERK1/2 and Cyclin D1 are the downstream effectors of Cdc42. The expression of the PAKs can be seen in all sorts of tissues and plays an essential role in promoting tumorigenesis in various human neoplasms including breast cancer molecular function CBC 24529727 CDC42 Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation CdcC42 induces invasiveness and metastatic activity by breast cancer cells molecular function CBC 25264923 CDC42 MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42 MALAT1 influenced the expression of Cdc42 by binding miR-1 competitively. There were ceRNA networks that co-regulated cell migration and invasion in breast cancer patients by MALALT1, miR-1 and Cdc42of the PAKs can be seen in all sorts of tissues and plays an essential role in promoting tumorigenesis in various human neoplasms including?breast cancer? molecular function CBC 26926567 CHEK2 Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband The risk of cancer in a carrier of a CHEK2 mutation is dependent on the family history of cancer molecular function CBC 19401704 CHEK2 Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer Women with a truncating mutation in CHEK2 and a positive family history of breast cancer have a lifetime risk of breast cancer of greater than 25% and are candidates for magnetic resonance imaging screening and for tamoxifen chemoprevention biomarker CBC 21876083 CHEK2 CHEK2 contribution to hereditary breast cancer in non-BRCAfamilies CHEK2 alleles make an appreciable contribution to breast cancer susceptibility, and their identification could help in the clinical management of patients carrying a?CHEK2?mutation molecular function CBC 22114986 CHEK2 Genomic Biomarkers for Breast Cancer Risk Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as?CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes biomarker CBC 26987529 CHEK2 Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer Detection of mutations in CHEK2 can be used as a prognostic factor for patient response to treatment and for targeting downstream molecules of CHEK2 that are involved in the proliferation of breast tumor cells biomarker CBC 31220302 CP Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 CP Evidence for increased non-ceruloplasmin copper in early-stage human breast cancer serum This high serum copper-to-ceruloplasmin ratio in BC patients may reflect disordered copper metabolism in this disease, which could also have implications for the origin of, or the response to, the cancer proces biomarker CBC 1584712 CP Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer In following patients with breast cancer, we noted that in those patients that recurred, the CP level became elevated 16-34 weeks prior to any clinical evidence of metastases molecular function CBC 6616078 CP Copper and ceruloplasmin levels in serum of women with breast cancer Levels copper and ceruloplasmin may help in prognosis & diagnosis of disease biomarker CBC 9808908 CP Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study With 2D-nanoLC-MS/MS, afamin, apolipoprotein E and isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 (ITIH4) were found to be higher in pre-diagnostic breast cancer (p < 0.05), while alpha-2-macroglobulin and ceruloplasmin were lower (p < 0.05 biomarker CBC 21871081 CP The relationship between serum level of copper and ceruloplasmin and pathologic and clinical characteristics in early breast cancer patients Copper and ceruloplasmin might also play an important role in early procedure of breast cancer, and need collect more data in the future to validate molecular function CBC CSTB Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma CSTB or the combination of CSTB and alpha-fetoprotein may be a useful marker for diagnosing patients with HCC with a high sensitivity biomarker CBC 18281540 CSTB Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma CSTB is specifically overexpressed in most HCCs and is also elevated in the serum of a large proportion of HCC patients molecular function CBC 18281540 CSTB Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway CSTB may become a novel diagnostic intracellular biomarker for the early detection of ovarian cancer biomarker CBC 24452274 CSTB Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway The increased CSTB expression in ovarian tissue represents tumor progression and is dysregulated by the TGF-β signaling pathway. molecular function CBC 24452274 CSTB Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer CSTB might be a potential prognostic marker for patients with primary lung cancer biomarker CBC 29037838 CSTB Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer In colorectal tumors, CSTB was not linked to any clinicopathological parameters including age, size of tumor, lymph node metastasis and tumor grading molecular function CBC 29037838 CSTB Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer Assessing the protein profiles of large and small neoplastic islands and their surrounding stroma by combining laser microdissection (LMD) and proteomics reveals several proteins-including CSTB, NDRG1, LTA4H, PGK1, COL6A1, ITGAV, and MB-ith distinct expression patterns between ITF and inner tumor, suggesting a potential prognostic value by clinicopathological association analysis molecular function CBC 30185791 CTSB Cathepsin B: a potential prognostic marker for inflammatory breast cancer CTSB may initiate proteolytic pathways crucial for IBC invasion. Thus, our data demonstrate that CTSB may be a potential prognostic marker for lymph node metastasis in IBC molecular function CBC 21199580 CTSB Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression IL-6-induced CTSB may play a role in lymph node metastasis, and that may possess future therapeutic implications for HRP-breast cancer patients with pLNs molecular function CBC 27482469 CTSB TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA SAHA may stimulate TRAIL DR5-CTSB crosstalk, influence the activity of downstream TOR signalling pathway mainly through the AKTs pathway, and initiate the autophagy of breast cancer cells molecular function CBC 29018571 CTSB Proteomic analysis of lung metastases in a murine breast cancer model reveals divergent influence of CTSB and CTSL overexpression TgCTSB and tgCTSL both display a strong and distinct impact on proteome composition of lung macrometastases in the PyMT model molecular function CBC 29187882 CTSB Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice Double deficiency of Ctsb and Ctsz exerts significant synergistic anticancer effects, whereas the single deficiencies demonstrate at least partial reciprocal compensation molecular function CBC 20133781 CTSB ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression The identified signaling network activates the transcription of cathepsin B gene (CTSB) via myeloid zinc finger-1 transcription factor that binds to an ErbB2-responsive enhancer element in the first?intron?of?CTSB molecular function CBC 22464443 CUL4A A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors CUL4A and CUL4B are therefore components of a conserved Wnt-induced proteasome targeting (WIPT) complex that regulates p27KIP1 levels and cell cycle progression in mammalian cells. molecular function CBC 19056892 CUL4A Analysis of DNA Repair-related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response Our observations support the notion of greater trabectedin activity in tumors exhibiting BRCAness and reveal CUL4A as a potential biomarker for definition of trabectedin target patients biomarker CBC 23364677 CUL4A CUL4A?contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response In particular, we report a putative role of CUL4A in bypassing the immune system in breast cancer through the down-regulation of several molecules involved in the immune surveillance. These findings provide insight into the oncogenic properties of CUL4A in basal-like breast cancer and highlight the therapeutic opportunities to target CUL4A molecular function CBC 24870930 CUL4A Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer CUL4A and CUL4B are differentially associated with etiologic factors for pulmonary malignancies and are independent prognostic markers for the survival of distinct lung cancer subtypes biomarker CBC 27974468 CUL4A CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma Overexpression of CUL4A plays an oncogenic role in iCCA and adversely affects disease-free survival. Thus, it may prove to be a powerful prognostic factor and a potential therapeutic target molecular function CBC 28576144 CUL4A miR-377 targets CUL4A and regulates metastatic capability in ovarian cancer MiR-377 is a significant negative regulator of CUL4A that controls cancer cell progression in ovarian cancer cell lines molecular function CBC 29512715 CXCL13 Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients CXCL13 is overexpressed within breast cancer tissues, and increased serum levels of this cytokine can be found in breast cancer patients with metastatic disease pointing to a role of CXCL13 in the progression of breast cancer, suggesting that CXCL13 might serve as a useful therapeutic target and/or diagnostic marker in this malignancy biomarker CBC 18781150 CXCL13 Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients CXCL13 is overexpressed within breast cancer tissues at the mRNA and protein levels and that increased serum levels of this cytokine can be found in breast cancer patients. molecular function CBC 18781150 CXCL13 Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression CXCL13-CXCR5 axis with classic determinants of poor prognosis, such as high grade, hormone receptor negativity, and axillary node involvement. biomarker CBC 22607768 CXCL13 Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression CXCL13 were found to be negatively associated with estrogen receptor and microtubule-associated protein tau mRNA expression and with dense lymphocytic infiltration, and were positively associated with nuclear grade. CXCL13 was positively associated with HER2. Multivariate analysis revealed an association between high CXCL13 mRNA expression and improved DFS (hazard ratio [HR] 0.48 [95% CI, 0.25-0.90]; Wald, P = .023) but not OS; In the HER2 mRNA overexpressing subgroup, high CXCL13 mRNA expression was associated with improved DFS (P < .001). molecular function CBC 22607768 CXCL13 CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis The EMT-inducing potential of CXCL13 as well as demonstrated the prognostic value of CXCL13-CXCR5 co-expression in primary BC. Moreover, CXCL13-CXCR5-RANKL-Src axis may present a therapeutic target in LNM positive BC patients biomarker CBC 24337540 CXCL13 CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis In CXCL13-stimulated BC cells, expression of various mesenchymal markers (Vimentin, N-cadherin), EMT regulators (Snail, Slug), and matrix metalloproteinase-9 (MMP9) was increased, whereas the expression of epithelial marker E-cadherin was found to be decreased. In addition, expression of receptor activator of nuclear factor kappa-B ligand (RANKL), which is known to regulate MMP9 expression via Src activation, was also significantly increased after CXCL13 stimulation. Using specific protein kinase inhibitors, we confirmed that CXCL13 stimulated EMT and MMP9 expression via RANKL-Src axis in BC cell lines. To further validate this observation, we examined gene expression patterns in primary breast tumors and detected significantly higher expression of various mesenchymal markers and regulators in CXCL13-CXCR5 co-expressing patients molecular function CBC 24337540 CYC1 CYC1 Silencing Sensitizes Osteosarcoma Cells to TRAIL-Induced Apoptosis CYC1 plays an important role in OS tumorigenesis, and modulation of CYC1 may be an effective strategy to potentiate OS to apoptotic induction by TRAIL biomarker CBC 25562155 CYC1 CYC1 Predicts Poor Prognosis in Patients with Breast Cancer CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis biomarker CBC 27239088 CYC1 Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia These subtype-specific breast cancer metabolism signatures contained a common set of five genes (SQLE, PYCRL, TSTA3, CYC1 and SLC39A4) which were co-amplified with?MYC?on chromosome 8q24 and showed a positive correlation with hypoxia molecular function CBC 27358048 CYC1 Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis CYC1 plays important roles in cell proliferation and comedo necrosis through the elevated oxidative phosphorylation activity in human DCIS molecular function CBC 28394473 CYP11A1 Population-based case-control study of CYP11A gene polymorphism and breast cancer risk The TAAAA repeat polymorphism near the promoter region of the CYP11A gene may be an important susceptibility factor for breast cancer risk. molecular function CBC 15159300 CYP11A1 Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women Our findings support the possibility that common allelic variation at the CYP11A1 D15S520 locus alters breast cancer risk in Chinese women. molecular function CBC 18483327 CYP11A1 Risk-Association of CYP11A1 Polymorphisms and Breast Cancer Among Han Chinese Women in Southern China Polymorphisms of CYP11A1 are related to breast cancer susceptibility in Han Chinese women of South China. molecular function CBC 22606018 CYP19A1 Positive Association of Polymorphisms in Estrogen Biosynthesis Gene, CYP19A1, and Metabolism, GST, in Breast Cancer Susceptibility The effect of CYP19A1 T/C polymorphism in susceptibility to breast cancer development can be modulated by the presence of GSTM1 and GSTT1, but not GSTP1 molecular function CBC 22300440 CYP19A1 SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression SIRT1 occupies the promoter regions PI.3/PII and PI.4, and its inhibition leads to increased acetylation of estrogen-related receptor伪, a transcription factor that positively regulates CYP19A1 transcription in epithelial cells molecular function CBC 23340254 CYP19A1 Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis The effects of CYP19A1 polymorphisms on clinical outcomes were most often detected in individual studies, suggesting that longer-term studies will better clarify these associations molecular function CBC 26067721 CYP19A1 The rs4646 and rs12592697 Polymorphisms in CYP19A1?Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds The rs4646 and the rs12592697 SNPs in CYP19A1 are associated with differences in disease progression in postmenopausal women. However, treatment appears to mitigate the differences in genetic risk. molecular function CBC 27994616 CYP19A1 Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer AI treatment itself selects for acquired CYP19A1amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients molecular function CBC 28112739 DCT The Role of DCT/TYRP2 in Resistance of Melanoma Cells to Drugs and Radiation Melanoma cells expressing very low levels of DCT are highly susceptible to either type of treatment. Overexpression of DCT in melanoma cells by transfection could confer both radioresistance and chemoresistance molecular function CBC Del-1 Exosomal Del-1 as a potent diagnostic marker for breast cancer: A prospective cohort study As the current prospective cohort study demonstrated a normalization of exosomal Del-1 after curative surgery, exosomal Del-1 can be confirmed as a potent diagnostic biomarker for breast cancer. Plus, a high Del-1 level after surgery seems related with early relapse suggesting a potential prognostic marker by identifying the existence of residual tumor biomarker BBCE Del-1 Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection. Del-1 on circulating EVs is a promising marker to improve identification of patients with early-stage breast cancer and distinguish breast cancer from benign breast tumors and noncancerous diseases. biomarker CBC 26603257 Del-1 Del-1 Expression as a Potential Biomarker in Triple-Negative Early Breast Cancer. Based on its relationship to an unfavorable histology and worse survival trend, Del-1 could act as a molecular target in TNBC patients. biomarker CBC 29393238 Del-1 Del-1 Expression as a Potential Biomarker in Triple-Negative Early Breast Cancer. A correlation was found between Del-1 expression and an aggressive histological grade, nuclear mitosis, and polymorphism, suggesting a possible role in tumor progression. molecular function CBC 29393238 Del-1 Exosomal Del-1 as a potent diagnostic marker for breast cancer: A prospective cohort study. Exosomal Del-1 can be confirmed as a potent diagnostic biomarker for breast cancer. biomarker CBC Del-1 Del-1 promotes the proliferation and migration of tamoxifen-resistant MCF7 breast cancer cells The expression of Del-1 promote tamoxifen resistance in breast cancer celils and coud be a novel targed for anti-breast cancer treatment biomarker CBC Del-1 Del-1 promotes the proliferation and migration of tamoxifen-resistant MCF7 breast cancer cells Down-regulation of Del-1 inhibited the proliferation and migration of TAM MCF 7 cells. molecular function CBC Dicer Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Cancer exosomes induce tumor formation in a Dicer-dependent manner molecular function MFBCE 25446899 Dicer Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Assessment of Dicer expression may facilitate prediction of distant metastases for patients suffering from breast cancer. biomarker CBC 19672267 Dicer Dysregulated expression of dicer and drosha in breast cancer. The decreased expression of Dicer and Drosha may play a role in down-regulation of miRNAs in breast cancer. biomarker CBC 21898071 Dicer Loss of Dicer expression is associated with breast cancer progression and recurrence. Dicer protein plays a role in human BC progression and behaviour, and assessment of its expression could provide prognostic information in BC including the HER2-positive class.In invasive BC, loss of Dicer expression was associated with features of aggressive behaviour including higher histological grade, loss of hormone receptor and BRCA1 protein expression and with shorter disease-free survival (DFS). Moreover, loss of Dicer was predictive of better response to chemotherapy and to endocrine therapy. biomarker CBC 22821364 Dicer Prognostic Significance of Deregulated Dicer Expression in Breast Cancer Dicer is an important prognostic marker in breast cancer and that its prognostic role may be subtype specific. biomarker CBC 24386264 DMRT1 Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene Based on the region of amplification defined on 9p and the associated expression plus confirmatory immunohistochemistry, DMRT1 (a male-specific transcriptional regulator) was identified as a likely candidate gene for involvement in the development of spermatocytic seminomas molecular function CBC 16397242 DMRT1 Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer A locus on chromosome 9 (rs755383, OR=1.37, P=1.12x10(-23)), containing the sex determination gene DMRT1, which has been linked to teratoma susceptibility in mice molecular function CBC 20543847 DMRT1 A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility In combined analysis that mutually conditions on both DMRT1 single nucleotide polymorphism markers, TGCT cases had elevated odds of carriage of the rs7040024 major A allele [per-allele odds ratio (OR) = 1.48, 95% confidence interval (CI) 1.23, 1.78; P = 2.52 脳 10(-5)] compared with controls, while the association with rs755383 persisted (per allele OR = 1.26, 95% CI 1.08, 1.47, P = 0.0036) molecular function CBC 21551455 DMRT1 Associations between variants in?KITLG,?SPRY4,?BAK1, and?DMRT1?and pediatric germ cell tumors Recent genome wide association studies have identified susceptibility loci for adult testicular germ cell tumors (GCT) near KITLG, SPRY4, BAK1, and DMRT1 molecular function CBC 22072546 DMRT1 Interaction between DMRT1 function and genetic background modulates signaling and pluripotency to control tumor susceptibility in the fetal germ line Involvement of DMRT1 in human TGCT, the downstream genes and pathways identified in this study provide potentially useful candidates for roles in the human disease molecular function CBC 23473982 DOK1 Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer These analyses were also indicative for DOK1 protective role in EOC tumorigenesis, linked to DOK1-mediated induction of some tumor suppressor factors and its suppression of pro-metastasis genes molecular function CBC 21856257 DOK1 Transcriptional regulation of the human tumor suppressor DOK1 by E2F1 E2F1 is a key factor in DOK1 expression and provide novel insights into the regulation of these events in cancer cells molecular function CBC 23028047 DOK1 BRK Targets Dok1 for Ubiquitin-Mediated Proteasomal Degradation to Promote Cell Proliferation and Migration A novel mechanism of action of BRK in the promotion of tumor formation, which involves the targeting of tumor suppressor Dok1 for degradation through the ubiquitin proteasomal pathway molecular function CBC 24523872 DOK1 A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling Knockdown of DOK1 and Rap1 inhibited PDGF-BB-induced chemotactic cell migration, and knockdown of DOK1 and Rap1 and expression of DOK1FF inhibited PDGF-mediated three-dimensional (3D) spheroid invasion molecular function CBC 24762811 DOK1 Dok1 and Dok2 Proteins Regulate Cell Cycle in Hematopoietic Stem and Progenitor Cells Dok1 and Dok2 proteins are involved in the control of hematopoietic stem cell cycle regulation molecular function CBC 27183638 DOK1 Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer DOK1 was identified as a prognostic factor for non-metastatic CRC, and, via its drugability by PPARγ-agonist, may constitute a potential target for future cancer treatments biomarker CBC 27428427 DOK7 DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker Hypermethylation of DOK7 occurs years before tumor diagnosis, suggesting a role as a powerful epigenetic blood-based biomarker as well as providing insights into breast cancer pathogenesis. biomarker CBC 23054610 DOK7 The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer. DOK7 was reduced in lung cancer and reduced DOK7 expression was associated with poorer survival. biomarker CBC 28393246 DOK7 The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer. DOK7 isoform 1 plays an inhibitory role on the proliferation and migration of lung cancer cells in which Akt pathway may be involved. molecular function CBC 28393246 DOK7 Evidence for Tumour Suppressor Function of DOK7 in Human Breast Cancer Higher DOK-7 expression was correlated with longer disease free and overall survival times. biomarker CBC DTX3L DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Our data strongly indicate that a crosstalk between STAT1, DTX3L and ARTD-like mono-ADP-ribosyltransferases mediates proliferation and survival of metastatic Pca(mPCa) cells. biomarker CBC 24886089 DTX3L DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. DTX3L and ARTD9 act together as repressors of the tumor suppressor IRF1 in mPCa cells. Furthermore, the present study shows that DTX3L together with STAT1 and STAT3 is implicated in cell migration of mPCa cells. molecular function CBC 24886089 DTX3L DTX3L is upregulated in glioma and is associated with glioma progression. DTX3L could be a potential prognostic biomarker for glioma. biomarker CBC 28627634 DTX3L DTX3L is upregulated in glioma and is associated with glioma progression. Knockdown of DTX3L by siRNA transfection increased glioma cell apoptosis. Moreover, suppression of DTX3L expression was shown to significantly inhibit the migration and invasion of glioma cells. molecular function CBC 28627634 DUSP1 DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine Gemcitabine-mediated upregulation of DUSP1 contributes to a negative feedback loop that attenuates its beneficial actions on stress pathways and apoptosis, raising the possibility that targeting DUSP1 in PDAC may have the advantage of enhancing gemcitabine chemosensitivity while suppressing angiogenesis molecular function CBC 24409315 DUSP1 Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy As a protein phosphatase, DUSP1 also downregulates p38?MAPKs and?JNKs signaling through directly dephosphorylating threonine and tyrosine. It has been detected that?DUSP1 is involved in various functions, including proliferation, differentiation, and apoptosis in normal cells. In various human cancers, abnormal expression of?DUSP1 was observed which was associated with prognosis of tumor patients molecular function CBC 27227569 DUSP1 DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer The DUSP1-pERK-MMP2/VEGF signals may provide new biomarkers and/or therapeutic targets to better suppress GBC metastasis in the future molecular function CBC 28129656 DUSP1 DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system DUSP1 may be a promising target to overcome chemoresistance in GBC therapy molecular function CBC 30008878 DUSP1 DUSP1 is involved in the progression of small cell carcinoma of the prostate DUSP1 is involved in the progression of SCCP and may provide a new therapeutic target for SCCP treatment molecular function CBC 30108432 EEF1A1 Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing EEF1A1 distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 EEF1A1 Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression Eukaryotic elongation factor 1A2 switch-on, observed in cultured tumour prostate cells and in human prostate tumour samples, may represent a feature of prostate cancer; in contrast, a minor involvement is assigned to EEF1A1 molecular function CBC 22095224 EEF1A1 P21 activated kinase 4 binds translation elongation factor eEF1A1 to promote gastric cancer cell migration and invasion PAK4 interacted with eEF1A1 to promote migration and invasion of gastric cancer cells, thereby providing new insights into the function of PAK4 and eEF1A1 in the progression of gastric cancer molecular function CBC 28393218 EEF1A1 Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress EEF1A1 mRNA levels in breast carcinomas are low due to EEF1A1 allelic copy number loss, found in 27% of tumors, and cell cycle-specific expression, because mRNA levels are high in G1 and low in proliferating cells molecular function CBC 30224719 EEF1A1 Genome-wide target interactome profiling reveals a novel EEF1A1 epigenetic pathway for oncogenic lncRNA MALAT1 in breast cancer Knockdown of MALAT1 reduced cell proliferation and invasion by arresting cells at the G0/G1 phase. Ectopic overexpression of EEF1A1 reversed the altered tumor phenotypes induced by MALAT1 shRNA treatment molecular function CBC 31105998 EEF1A1 Isoforms of elongation factor eEF1A may be differently regulated at post-transcriptional level in breast cancer progression EEF1A1 and EEF1A2 mRNAs contain distinct motifs in the UTRs and are differently regulated in cancer suggesting the possibility of their control by different cellular signals molecular function CBC ELK1 Estrogen Receptor-mediated Activation of the Serum Response Element in MCF-7 Cells through MAPK-dependent Phosphorylation of Elk-1 Transcriptional activation of the SRE by E2 was due to ERα activation of the MAPK pathway and increased binding of the serum response factor and Elk-1 to the SRE. molecular function CBC 11145955 ELK1 c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos molecular function CBC 11313879 ELK1 Genome-Wide Analysis Reveals PADI4 Cooperates with Elk-1 to Activate?c-Fos?Expression in Breast Cancer Cells PADI4 interacts with Elk-1 at the c-Fos promoter and that, following Epidermal Growth Factor (EGF) stimulation, PADI4 catalytic activity facilitates Elk-1 phosphorylation, histone H4 acetylation, and c-Fos transcriptional activation. molecular function CBC 21655091 ELK1 Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes MiR-135a regulates cell proliferation in breast cancer by targeting ELK1 and ELK3 oncogenes, and suggests that miR-135a potentially can act as a tumor suppressor molecular function CBC 29892795 ELK1 Suppression of Elk1 inhibits thyroid cancer progression by mediating PTEN expression Elk1 inhibition induced thyroid cancer cell apoptosis and restrained their proliferation by regulating Egr-1/PTEN, indicating a potential role for Elk1 in thyroid cancer treatment molecular function CBC 30015900 ENPP1 Enpp1: A Potential Facilitator of Breast Cancer Bone Metastasis By both routes of administration, increased expression of Enpp1 enhanced the ability of MDA-MB-231 cells to form tumors in the bone relative to cells expressing vector alone, as determined by digital radiography and histological analysis锛泃hese data suggest a potential role for Enpp1 in the development of breast cancer bone metastasis molecular function CBC 23861746 ENPP1 Identification of Gene Expression Signature in Estrogen Receptor Positive Breast Carcinoma Significant over-expression of all the six genes in ERα (+) breast tumors as compared to ERα (-) breast tumors. In vitro studies using T-47D breast cancer cell line confirmed the estrogen dependant expression of four of the above six genes (SLC7A8, ENPP1, LAMB2, and PLAT) molecular function CBC 24179381 ENPP1 Functional characterization of ENPP1 reveals a link between cell cycle progression and stem-like phenotype in glioblastoma A high-throughput phenotypic screen in glioblastoma stem-like cells (GSCs) identified a novel molecular mechanism in which ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) plays an important role in balancing the pool of nucleotides, thus maintaining GSCs in an undifferentiated proliferative state molecular function CBC 27308351 ENPP1 Functional characterization of ENPP1 reveals a link between cell cycle progression and stem-like phenotype in glioblastoma A novel molecular mechanism in which ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) plays an important role in balancing the pool of nucleotides, thus maintaining GSCs in an undifferentiated proliferative state molecular function CBC 27308351 ENPP1 Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast Cancer ENPP1 mRNA expression in tissue samples from patients with triple-negative breast cancer was significantly inversely related to recurrence-free survival (RFS) and overall survival (OS) biomarker CBC 31536342 EPCAM Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC Tumour-derived exosomes interfere with the tumour-specific function of immune cells and constitute an additional mechanism how tumours escape from immune surveillance molecular function MFBCE 21293856 EPCAM Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells EpCAM may be an attractive strategy to treat breast cancer.This study implicates the potential value of EpCAM as a molecular marker for breast cancer. biomarker CBC 25205054 EPCAM Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells EpCAM participated in TGF-β1-induced EMT. TGF-β1 treatment of MCF-7 breast cancer cells was shown to induce EpCAM expression, which promoted the EMT and cell migration. EpCAM overexpression further enhanced TGF-β1-induced EMT and EpCAM knockdown inhibited TGF-β1-induced EMT. We further demonstrated that TGF-β1 treatment induced the phosphorylation of JNK that was in turn responsible for the increased expression of Jun and Fos. This result suggests an important role of the JNK to AP-1 signaling to EpCAM downstream of TGF-β1 for the induction of EMT in the breast cancer cells. molecular function CBC 25205054 EPCAM By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis Overexpression of EpCAM in breast cancer cells enhanced tumor cell growth in vitro and increased invasiveness, whereas small interfering RNA-mediated silencing of EpCAM (si-EpCAM) had the opposite effect. EpCAM knockdown led to decreased phosphorylation of Raf and ERK, suppression of malignant behavior of breast cancer cells, and inhibition of the Ras/Raf/ERK signaling pathway. molecular function CBC 26356670 EPCAM EpCAM and COX?2 expression are positively correlated in human breast cancer EpCAM may serve a role in the regulation of cancer cell growth and may hold potential as a prognostic marker in breast cancer. biomarker CBC 28393249 ERBB2 Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC Tumour-derived exosomes interfere with the tumour-specific function of immune cells and constitute an additional mechanism how tumours escape from immune surveillance molecular function MFBCE 21293856 ERBB2 Genetic alterations in ERBB2-amplified breast carcinomas Breast tumors showing erbB2 overexpression or gene amplification are genetically distinct from erbB2-negative tumors molecular function CBC 10632352 ERBB2 ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction ERBB2 gene expression was associated with the MFI only in estrogen receptor-positive carcinomas, whereas ERBB2 protein expression (P = 0.032) was associated with MFI in the entire cohort molecular function CBC 20371687 ERBB2 The extracellular domain of Her2 in serum as a biomarker of breast cancer SHER2 ECD should be considered as a promising biomarker to detect cancer recurrence and metastasis biomarker CBC 29491426 ERBB2 Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance molecular function CBC 30898150 FAM162A The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types The gene expression analysis demonstrated cell line specific differences in the hypoxia response of the 15 genes, with BNIP3 not being upregulated at hypoxic conditions in 3 out of 6 colon cancer cell lines, and ALDOA in OE21 and FAM162A and SLC2A1 in SW116 only showing limited hypoxia induction molecular function CBC 26169282 FAM87A Comprehensive analysis of lncRNA-associated competing endogenous RNA network in tongue squamous cell carcinoma FAM87A was identified as novel, potential prognostic biomarkers and therapeutic targets for tongue squamous cell carcinoma biomarker CBC 30755833 FAM87A CNV Primed lncRNAs Deregulation Contributes to Poor Prognosis in Colorectal Cancer Comparing lncRNAs expression patterns between copy-deleted or copy-amplified and the normal samples, we identify 9 lncRNAs(FAM87A, LOC101927752, KBTBD11-OT1, LOC100287015, LOC101929066, CASC11, HM13-AS1, ABALON, NKILA),? molecular function CBC FGF9 Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling Estrogen or FGF9 pretreatment induced CSC properties of breast cancer cell lines and freshly isolated breast cancer cells, whereas cotreatment of cells with tamoxifen or a small molecule inhibitor of FGFR signaling was sufficient to prevent the estrogen-induced expansion of CSCs molecular function CBC 21098263 FGF9 Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC molecular function CBC 24239165 FGF9 FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells FGF9 is a possible mediator secreted by CAFs that promotes the anti-apoptosis and invasive capability of gastric cancer cells molecular function CBC 25925261 FGF9 The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer FGF9 may provide the anti-apoptotic function and be useful as a novel independent marker for evaluating GC prognosis biomarker CBC 27166269 FGF9 FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells FGF9 interacts with FGFR2 to activate ERK1/2, Rb/E2F1 and cell cycle pathways to induce MA-10 cell proliferation in?vitro and tumor growth in vivo molecular function CBC 30191630 FGFR2 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 FGFR2 The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-κB Signaling FGFR2 serves as a scaffold for multiple components of the NF-κB signaling complex molecular function CBC 22988296 FGFR2 Activating somatic FGFR2 mutations in breast cancer Somatic breast cancer mutations in FGFR2 providing evidence for the activating nature of FGFR2-mediated signalling in the pathogenesis of breast cancer molecular function CBC 23527311 FGFR2 Master regulators of FGFR2 signalling and breast cancer risk Fibroblast growth factor receptor 2 signalling has an important role in mediating breast cancer risk molecular function CBC 24043118 FGFR2 FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor GFR2 amplification to treatment with nab-paclitaxel and an mTOR inhibitor, whilst showing no significant benefit from endocrine therapy or treatment with a CDK4/6 inhibitor molecular function CBC 28430863 FGFR2 FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness FGFR2 can confer increased breast cancer risk that is consistent with oestrogen exposure as a major driver of breast cancer risk molecular function CBC 27236187 FGFR2 Association of FGFR2 and TOX3 Genetic Variants With the Risk of Breast Cancer in Iranian Women Genetic variants of FGFR2 (rs1219648 AG) and TOX3 (rs8051542 TC) can be potential candidate biomarkers for breast cancer risk biomarker CBC FGFR3 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 FGFR3 Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Genomic alterations of FGFR3 are among the best described oncogenic pathway in UC molecular function CBC 10471491 FGFR3 Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis FGFR3 expression in invasive breast cancer was not found to be significantly associated with specific clinicopathological/molecular parameters, but might be used as a candidate marker for a poor prognosis biomarker CBC 21116113 FGFR3 Mechanisms of FGFR3 actions in endocrine resistant breast cancer FGFR3 activation in MCF7 cells stimulated activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signalling pathways, both of which have been implicated in tamoxifen resistance in breast cancer molecular function CBC 21792889 FGFR3 FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium Some SNPs in FGFR3 gene were closely related to breast cancer risk biomarker CBC 24548884 FIBP Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 FIBP Proteomic Analysis of the Human Cyclin-dependent Kinase Family Reveals a Novel CDK5 Complex Involved in Cell Growth and Migration CDK5-, KIAA0528-, or FIBP-depleted breast cancer cells displayed impaired proliferation and decreased migration, suggesting that this complex is required for cell growth and migration in non-neural cells molecular function CBC 25096995 FIBP A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene These findings provide convincing evidence implicating FIBP aberrations in the newly recognized overgrowth syndrome and expand the associated phenotypes to include possible Wilms tumor predisposition molecular function CBC 27183861 FIBP FIBP knockdown attenuates growth and enhances chemotherapy in colorectal cancer via regulating GSK3β-related pathways DNA methylation profiling suggested that FIBP regulated the stemness of CRC cells via methylation activity that was dependent on GSK3β but independent of β-catenin signaling molecular function CBC 30275459 FRS2 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 FRS2 MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor-positive breast cancer patients receiving tamoxifen as an adjuvant endocrine therapy biomarker CBC 27533459 FRS2 MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy Fibroblast growth factor receptor substrate 2 (FRS2, also known as FRS2alpha) is a member of the adaptor/scaffold protein family. It was considered as an essential-conning center in FGFR signaling . FSR2 binds through its N-terminal phosphotyrosine-binding domain (PTB) to FGFR, resulting in phosphorylation of multiple tyrosine residues of FRS2 and subsequent activation of the downstream signaling (e.g., RAS/MAPK/ERK, PI3K/AKT/mTOR) and ubiquitination/degradation pathways . FRS2 acts as an oncogene in a variety of cancers, which regulates tumor cell differentiation, proliferation, and tumorigenesis . Inhibition of FRS2 could block the FGFR signaling and downstream biological functions molecular function CBC 27533459 FRS2 Targeting FGFR pathway in breast cancer Activated FRS2 promotes downstream signaling through the RAS-mitogen-activated protein kinase (MAPK) or the phosphoinositide 3-kinase (PI3K)-AKT pathways that regulate cell proliferation, differentiation, and survival molecular function CBC 29156384 FTH1 Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing FTH1 distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 FTH1 Ferritin binds and activates p53 under oxidative stress Our findings show that ferroxidase activity is not required for FTH1 to increase p53 transcriptional activity molecular function CBC 19716362 FTH1 Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response Our data provide evidence toward new immune regulatory properties of FTH1 in TNBC, which may facilitate development of novel therapeutic targets molecular function CBC 24742827 FTH1 Regulation of iron homeostasis by the p53-ISCU pathway In response to DNA damage, p53 induced FTH1 and suppressed transferrin receptor, which regulates iron entry into cells. HCT116 p53+/+ cells were resistant to iron accumulation, but HCT116 p53 / cells accumulated intracellular iron after DNA damage molecular function CBC 26560363 FTH1 Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells Real time quantitative polymerase chain reaction showed that iron up-regulated the expression of FTH1 and iron chelator DFOM reduced FTH1 expression of MCF-7 and MDA-MB-231 cells molecular function CBC 28476795 FTH1 A FTH1 gene:pseudogene:microRNA network regulates tumorigenesis in prostate cancer ?In this study, we utilize an unbiased screen to identify the ferritin heavy chain 1 (FTH1) transcript and multiple FTH1 pseudogenes as targets of several oncogenic miRNAs in prostate cancer (PCa). We characterize the critical role of this FTH1 gene:pseudogene:miRNA network in regulating tumorigenesis in PCa, whereby oncogenic miRNAs downregulate the expression of FTH1 and its pseudogenes to drive oncogenesis molecular function CBC 29240947 FTL Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing FTL distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 FTL Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study The validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM biomarker CBC 21898387 FTL Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin The increased levels of FTL in breast cancer indicate that FTL may be used as a diagnostic and prognostic marker for breast cancer biomarker CBC 23969999 FTL Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin Targeted downregulation of FTL protein by the microRNA miR-133a increases sensitivity of MCF-7/DOX and MCF-7/CDDP cells to doxorubicin and cisplatin molecular function CBC 23969999 FTL Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response We observed that protein expression of FTH1 was significantly higher in good prognostic patients (n = 82) than those with poor prognosis (n = 44) (p = 0.001), whereas neither expression of FTL (p = 0.054) nor FTH1/FTL ratio (p = 0.566) showed significant difference between patients with different clinical outcome biomarker CBC 24742827 FTL Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway FTL regulates the growth of GBM cells via the GADD45/JNK pathway molecular function CBC 26871431 FZD5 Expression and regulation of WNT5A and WNT5B in human cancer: Up-regulation of WNT5A by TNFα in MKN45 cells and up-regulation of WNT5B by β-estradiol in MCF-7 cells Up-regulation of WNT5A and WNT5B in several types of human cancer expressing FZD5 might lead to more malignant phenotype through activation of the β-catenin - TCF pathway molecular function CBC 12165812 FZD5 Microrna-224 inhibits proliferation and migration of breast cancer cells by down-regulating fizzled 5 expression MiR-224 inhibited cell proliferation and migration by targeting FZD5 and inhibiting WNT/β-catenin signaling in breast cancer molecular function CBC 27323393 FZD5 MicroRNA-671-3p inhibits the development of breast cancer: A study based on in vitro experiments, in-house quantitative polymerase chain reaction and bioinformatics analysis WNT3A, CCND2, SFRP1, PRICKLE2, FZD5 and FZD4 were markedly downregulated in BC, suggesting that they may function as tumor suppressor genes in this tumor molecular function CBC 29620195 FZD5 Role of WNT5A receptors FZD5 and RYK in prostate cancer cells WNT5A/FZD5 and WNT5A/RYK signaling are both involved in mediating the pro-apoptotic and anti-proliferative effects of WNT5A in prostate cancer molecular function CBC 29930766 GATA4 A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells In agreement with a repressor role of GATA4 on ERBB2 gene expression balanced by ERBB2 activation of the GATA4 gene, a negative correlation between the relative levels of ERBB2 and GATA4 mRNA was observed in breast cancer cell lines and breast tumor samples molecular function CBC 19276186 GATA4 GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3 GATA4 is therefore a potential therapeutic target or biomarker for progression in HB patients biomarker CBC 27788486 GATA4 GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3 GATA4/miR125b/DKK3 axis may be a major regulator of growth, migration, invasion, and survival in hepatoma cells molecular function CBC 27788486 GATA4 GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition Thus, disruption of GATA4-mediated transactivation in HCC suppresses hepatocyte epithelial differentiation to sustain replicative precursor phenotype molecular function CBC 28758902 GATA4 GATA4 inhibits cell differentiation and proliferation in pancreatic cancer GATA4 gene might play a role in cell proliferation and differentiation during the progression of pancreatic cancer molecular function CBC 30142155 GATA4 Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-κB signaling GATA4 is a potential prognostic biomarker and gene therapeutic target for human BrCa biomarker CBC 30187949 GATA4 Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-κB signaling GATA4 plays a tumor-suppressive role via repression of NF-κB signaling in BrCa cells molecular function CBC 30187949 GATA4 GATA4 is upregulated in nasopharyngeal cancer and facilitates epithelial-mesenchymal transition and metastasis through regulation of?SLUG GATA4 acts as an oncogene and serves crucial roles in NPC and GATA4 may find a potential application as therapeutic option in NPC molecular function CBC 30542490 GPBAR1 Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis TGR5 antagonizes the STAT3 pathway through suppressing STAT3 phosphorylation, its transcription activity, and DNA binding activity, which suggests that TGR5 antagonizes liver tumorigenesis at least in part by inhibiting STAT3 signaling molecular function CBC 22911633 GPBAR1 Pancreatic acinar cell nuclear factor κB activation because of bile acid exposure is dependent on calcineurin Acinar cell exposure to bile acids and activation of Gpbar1 cause cell injury mediated by Ca2+?signaling and downstream NF-κB translocation molecular function CBC 23744075 GPBAR1 TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro TGR5 is an important mediator of BA-induced cholangiocyte proliferation in vivo and in vitro. Furthermore, TGR5 protects cholangiocytes from death receptor-mediated apoptosis molecular function CBC 26420419 GPBAR1 Membrane bile acid receptor TGR5 predicts good prognosis in ampullary adenocarcinoma patients with hyperbilirubinemia TGR5 functions as a tumor-suppressor in patients with ampullary adenocarcinoma and preoperative hyperbilirubinemia molecular function CBC 27510297 GPBAR1 The deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis TGR5 antagonizes STAT3 pathway through suppressing STAT3 phosphorylation, its transcription activity and DNA binding activity, which suggests that TGR5 antagonizes liver tumorigenesis at least in part by inhibiting STAT3 signaling molecular function CBC 22911633 GSTP1 Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer Affecting drug metabolism---Anthracycline/taxane-based neoadjuvant chemotherapy molecular function MFBCE 28438694 GSTP1 Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk Cruciferous vegetable intake consistent with high isothiocyanate exposure may reduce breast cancer risk. Cruciferous vegetable intake also may ameliorate the effects of the GSTP1 genotype molecular function CBC 18326615 GSTP1 GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients GSTP1 methylation is a major event in breast carcinogenesis and may act as a tumor-specific biomarker biomarker CBC 23226781 GSTP1 The GSTP1 105Val Allele Increases Breast Cancer Risk and Aggressiveness but Enhances Response to Cyclophosphamide Chemotherapy in North China GSTP1 Ile105Val genotype may help screen for high-risk populations and direct individualized therapy molecular function CBC 23826324 GSTP1 Association of GSTP1 Methylation with Aggressive Phenotype in ER-positive Breast Cancer GSTP1 methylation may well be associated with the pathogenesis of the biologically-aggressive phenotype in ER-positive breast cancer molecular function CBC 24324107 GSTP1 GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity GSTP1 inhibitors as a novel therapeutic strategy for combatting TNBCs through impairing key cancer metabolism and signaling pathways molecular function CBC 27185638 GSTP1 Prognostic significance of GSTP1 in patients with triple negative breast cancer GSTP1 protein may be a novel prognosis marker for TNBC patients in China biomarker CBC 28978147 GSTP1 CLDN6 promotes chemoresistance through GSTP1 in human breast cancer High expression of CLDN6 confers chemoresistance on breast cancer which is mediated by GSTP1, the activity of which is regulated by p53 molecular function CBC 29116019 GTF2I A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors GTF2I mutation correlated with better survival. GTF2I β and δ isoforms were expressed in TETs, and both mutant isoforms were able to stimulate cell proliferation in vitro molecular function CBC 24974848 GTF2I GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis The frequency of the GTF2I mutation is higher in more indolent TETs, and correlates with better prognosis. molecular function CBC 28676218 GTF2I GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies GTF2I mutation is not present or is uncommon in these diseases molecular function CBC 28982856 GTF2I The Integrated Genomic Landscape of Thymic Epithelial Tumors The Integrated Genomic Landscape of Thymic Epithelial Tumors molecular function CBC 29438696 GTF2I Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer TFAP2C, GTF2I and LMO4 were found to have potential prognostic value for lung metastasis free (LMF) survival of breast cance biomarker CBC 31215771 HDC Histamine synthesis and content in benign and malignant breast tumours. Its effects on other host tissues The HDC-activity of cancerous tissue was significantly higher (P < 0.01) than that registered in the healthy mammary gland tissue of the same patient, being even more pronounced in benign tumour tissue (P < 0.001) molecular function CBC 7952401 HDC Concentration of histamine in serum and tissues of the primary ductal breast cancers in women The activity of HDC was significantly higher in cancerous tissues than in adjacent healthy tissues (54.7+/-17.1 vs. 34.5+/-24.3 pmol/min per mg; P<0.001), but there was no difference in the activity of DAO (14.0+/-6.4 vs. 14.4+/-10.9 pmol/min per mg) molecular function CBC 15927833 HDC The Role of Cyclooxygenase-2 in Mediating the Effects of Histamine on Cell Proliferation and Vascular Endothelial Growth Factor Production in Colorectal Cancer Histidine decarboxylase activity and histamine content were also significantly higher in metastatic tumors than in nonmetastatic ones molecular function CBC 16203768 HDC Metabolism of histamine in tissues of primary ductal breast cancer A significant increase in the concentration of histamine in plasma (P < .01) and tissues of ductal breast cancers (P < .001), and in the activity of histidine decarboxylase (P < .01), aromatic L-amino acids (P < .05), and histamine methyltransferase (P < .05) was found molecular function CBC 19375125 HDC Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer Polymorphisms of HDC gene were significantly associated with breast cancer in Chinese Han population and may be novel diagnostic or therapeutic targets for breast cancer biomarker CBC 24835231 HER2 Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification The exosomal HER2 expression levels were almost consistent with that in tumor tissues assessed by immunohistochemical staining molecular function MFBCE 28369094 HER2 The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors molecular function CBC 23320171 HER2 HER2-targeted therapies -a role beyond breast cancer HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer molecular function CBC 30922362 HER2 Activating HER2 mutations in HER2 gene amplification negative breast cancer The majority of HER2 somatic mutations in breast cancer patients are activating mutations that likely drive tumorigenesis molecular function CBC 23220880 HER2 HER2 and responsiveness of breast cancer to adjuvant chemotherapy Amplification of HER2 in breast-cancer cells is associated with clinical responsiveness to anthracycline-containing chemotherapy molecular function CBC 16707747 HER2 Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Intratumoral heterogeneity of HER2 gene amplification is present in a subset of HER2-amplified breast cancers, especially in cases with low-grade HER2 amplification and equivocal HER2 expression, indicating a need for HER2 testing on more representative, larger tumor samples for accurate assessment of HER2 status in such cases molecular function CBC 22388760 HER2 HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells HER2-mediated prosurvival signaling network is responsible for the aggressive phenotype of BCSCs that could be targeted to control the therapy-resistant HER2(-/low) breast cancer molecular function CBC 23091114 HER2 HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Although HER2 amplification and combined TOP2A amplification and deletion may have some value in the prediction of responsiveness to anthracycline-based chemotherapy, our findings do not support the use of anthracyclines only in patients with HER2-amplified or TOP2A-aberrated tumours molecular function CBC 21917518 HEXA Hypermethylation contributes to down-regulation of lysosomal β-hexosaminidase α subunit in prostate cancer cells The HEXA promoter region in LNCaP and PC3 cell lines had methylated CpG islands, as confirmed by 5'-Aza-2'-deoxycitidine treatment, in PC3 cells, used as cell cancer model molecular function CBC 24389457 HLA-DQA1 Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma Genotypes for two DNA repair genes, TP53 and OGG1, showed significant associations with SQC risk (p < 0.05), and those for two GWAS genes, CHRNA3 and HLA-DQA1, showed significant associations with SQC risk (P < 0.05) with odds ratios between 1.65 (95% confidence interval = 1.06-2.57 for OGG1) and 2.57 (95% confidence interval = 1.03-6.87 for CHRNA3) molecular function CBC 21623257 HLA-DQA1 HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer HLA-DQA1*0301 allele is mainly associated with increased risk of breast cancer including early-onset of the disease. HLA-DQA1*0505 and HLA-DRB1*1301 are involved in protection. We conclude that specific alleles of HLA class II influence breast cancer risk molecular function CBC 21720852 HLA-DQA1 Association between HLA-DQA1, HLA-DQB1 and oral cancer Both HLA-DQA1* and HLA-DQB1* allele frequencies in oral cancer patients revealed no significant difference from those of control groups molecular function CBC 21943816 HLA-DQA1 HLA-DQA1 & DQB1 variants associated with hepatitis B virus-related chronic hepatitis, cirrhosis & hepatocellular carcinoma Our results revealed HLA-DQA1*0101/2/4 - DQA1*0103 - DQB1*0302/3 and DQB1*0601 as protective and DQB1*0402 as risk alleles. The study suggests that various subtypes of HLA-DQA1 and DQB1 are associated with both HBV clearance and development of chronic HBV infections molecular function CBC 30168489 HLA-DQA1 High expression of HLA-DQA1 predicts poor outcome in patients with esophageal squamous cell carcinoma in Northern China HLA-DQA1 plays an important role in ESCC progression and may be a biomarker for ESCC diagnosis and prognosis, as well as a potential target for the treatment of patients with ESCC molecular function CBC 30813145 HOXC6 Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer Stemness markers and enhance proliferation,migration and invasion abilities of neighboring cells molecular function MFBCE 26528758 HOXC6 Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer HOXC6, which is a critical player in mammary gland development, is upregulated in multiple cases of breast cancer, and is transcriptionally regulated by E2 and BPA, in vitro and in vivo molecular function CBC 25725483 HOXC6 The role of HOXC6 in prostate cancer development HOXC6 is a novel candidate biomarker for PCa not only in early detection but also for monitoring of progression or response to therapy biomarker CBC 26310814 HOXC6 Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits HOXC6 and DLX1 are associated with different clusters of prostate tumor-specific enhancers and confer distinct transcriptomic changes upon knockdown in C42B prostate cancer cells molecular function CBC 27833659 HOXC6 Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-77-p/HOXC6 signaling pathway Linc00339/miR-377-3p/HOXC6 axis played a critical role in TNBC progression and might be a promising therapeutic target for TNBC treatment molecular function CBC 30618083 HOXC6 Overexpression of HOXC6 promotes cell proliferation and migration via MAPK signaling and predicts a poor prognosis in glioblastoma HOXC6 promoted proliferation and migration of GBM cells via the activation of MAPK pathway molecular function CBC 31564976 HRNR Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma HRNR promotes tumor progression and is correlated with a poor HCC prognosis. HRNR may contribute to HCC progression via the regulation of the AKT pathway. biomarker CBC 30103712 HRNR Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma The knockdown of HRNR by shRNAs significantly inhibited the proliferation, colony formation, migration and invasion of HCC tumor cells. HRNR silencing led to the decreased phosphorylation of AKT signaling. molecular function CBC 30103712 hsa-let-7a Plasma exosome microRNAs are indicative of breast cancer Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer biomarker BBCE 27608715 hsa-let-7a MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7 Targeting of CCL21-CCR7 signaling is a valid approach for breast cancer therapy and that let-7a directly binds to the 3'UTR of CCR7 and blocks its protein expression, thereby suppressing migration and invasion of human breast cancer cells molecular function CBC 22251626 hsa-let-7a Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1 Let-7a plays an important role as a tumor suppressor gene by targeting HMGA1, which may open novel perspectives for clinical treatments against breast cancer molecular function CBC 25846193 hsa-let-7a Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer MiR-195 and let-7a can be used as a non-invasive biomarker for breast cancer detection biomarker CBC 29995098 hsa-let-7a Role of let-7 family microRNA in breast cancer This article will provide the in-depth insight into the biology of let-7 miRNA and its role in the breast cancer progression molecular function CBC 30159414 hsa-let-7a Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patient Hsa-let-7a might be considered as a respectable diagnostic tool for monitoring of breast cancer patients biomarker CBC 30568292 hsa-let-7a Robust expression of tumor suppressor miRNA- let-7 and miR-195 detected in plasma of Saudi female breast cancer patients In order to facilitate earlier detection of breast cancer, blood based screening of hsa-miR-195 and let-7 may be beneficial in a female patient cohort molecular function CBC 29183284 hsa-miR-100 Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs Target gene prediction and pathway analysis showed the involvement of miR-100, miR-222, and miR-30a in pathways implicated in cancer pathogenesis, membrane vesiculation and therapy failure.The transmition of chemoresistance by a horizontal transfer of miRNAs molecular function MFBCE 24740415 hsa-miR-100 EphB6 receptor modulates micro RNA profile of breast carcinoma cells MiR-100 and EphB6 involve in PI3K/Akt/mTOR pathways which is capable of initiating signal transduction from the cell surface to the nucleus resulting in the altered expression of a variety of genes involved in tumorigenesis and invasion molecular function CBC 21811619 hsa-miR-100 miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling MiR-100 as a context-dependent master regulator of the IGF/mTOR pathway and a potential target for therapeutic approaches molecular function CBC 22926517 hsa-miR-100 By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy MiR-100 is a negative prognostic factor and is associated with gene signatures of high grade undifferentiated tumors biomarker CBC 25537513 hsa-miR-100 The role of miR-100 in regulating apoptosis of breast cancer cells Antagonism of miR-100 in SK-BR-3 cells increased the expression of MTMR3, a target gene of miR-100, which resulted in the activation of p27 and eventually led to G2/M cell-cycle arrest and apoptosi molecular function CBC 26130569 hsa-miR-101 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients In conclusion, our findings suggest cell-free miR-101 and miR-373 as breast cancer-specific markers biomarker BBCE 25333260 hsa-miR-101 miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2 MiR-101 suppressed proliferation and promoted apoptosis in breast cancer cells by targeting Jak2. These findings indicate that manipulation of miR-101 expression may represent a novel therapeutic strategy in the treatment of breast cancer molecular function CBC 25059472 hsa-miR-101 MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7 STAT3 signaling downstream of CXCR7 is involved in miR-101 regulation of breast cancer cell behaviors. These findings have implications for the potential application of miR-101 in breast cancer treatment molecular function CBC 26360780 hsa-miR-101 MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 SOX2 knockdown mimicked the effects of miR-101 overexpression on the malignant behaviors of BC cells, while SOX2 overexpression mitigated the miR-101-induced inhibition of these effects;miR-101 plays a critical role in suppressing tumor progression by directly targeting SOX2 molecular function CBC 28946143 hsa-miR-101 MiR-101 may be a novel marker for diagnosis and prognosis in breast cancer, which might improve the clinical outcomes of patients with breast cancer MicroRNA-101 is a novel biomarker for diagnosis and prognosis in breast cancer biomarker CBC hsa-miR-103 Blood Circulating Exosomes Contain Distinguishable Fractions of Free and Cell-Surface-Associated Vesicles Preliminary data indicated that detection of cancer-specific miRNA (miR-103, miR-191, miR-195) in exosomes associated with the fraction of red blood cells allowed to discriminate HFs and BCPs more precisely compared to cell-free exosomes circulating in plasma biomarker BBCE 30868953 hsa-miR-103 A MicroRNA targeting dicer for metastasis control In human primary breast tumors, miR-103/107, but not Dicer mRNA, as prognostic marker. miR-103/107 with a better patient stratification capacity than Dicer transcripts. biomarker CBC 20603000 hsa-miR-103 A MicroRNA targeting dicer for metastasis control In metastatic cells, high levels of miR-103/107 attenuate Dicer expression: this empowers invasive and metastatic properties without major impact on primary tumor growth.At the cellular level, a key event fostered by miR-103/107 is induction of epithelial-to-mesenchymal transition (EMT), attained by downregulating miR-200 levels. molecular function CBC 20603000 hsa-miR-103 Upregulation of serum miR-103 predicts unfavorable prognosis in patients with colorectal cancer. Serum miR-103 was significantly correlated with worse clinical factors, as well as poorer recurrence-free survival or overall survival. Finally, multivariate analysis confirmed that serum miR-103 was an independent prognostic marker for CRC. biomarker CBC 30058684 hsa-miR-105 Cancer-secreted hsa-miR-105 destroys vascular endothelial barriers to promote metastasis Hsa-miR-105 has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 24735924 hsa-miR-105 Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy Higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells;Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis biomarker BBCE 30728048 hsa-miR-105 Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis MiR-105 can be detected in the circulation at the pre-metastatic stage, and its levels in the blood and tumor are associated with ZO-1 expression and metastatic progression in early-stage breast cancer molecular function CBC 24735924 hsa-miR-105 miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer MiR-105/93-3p levels represent a prime candidate for development into a diagnostic biomarker for both early- and late-stage TNBC biomarker CBC 29258605 hsa-miR-105 Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells MiR-105-mediated metabolic reprogramming of stromal cells contributes to sustained tumour growth by conditioning the shared metabolic environment molecular function CBC 29662176 hsa-miR-105 miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer MiR-105, and miR-340 expression levels were associated with a poor prognosis in patients with breast cancer biomarker CBC 30607158 hsa-miR-105 The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer This review may provide new ideas for applying miR-105 as a diagnostic and prognostic biomarker biomarker CBC 31281797 hsa-miR-105 The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer We emphasize the characteristics of miR-105 in cancer to elucidate various deadly tumors and discuss transcriptional regulations that may explain fluctuations in miR-105 expression molecular function CBC 31281797 hsa-miR-106b Molecular characterization of exosome-like vesicles from breast cancer cells The mir-106b is found in higher levels in MCF-Eox as well, which can promote breast cancer invasion and metastasis by targeting BRMS1 and RB molecular function MFBCE 24468161 hsa-miR-106b The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer MiR-106b-25 may provide a novel molecular explanation, through the Six1 regulated miR-106b-25 cluster, by which TGF-β signaling shifts from tumor suppressive to tumor promoting molecular function CBC 22286770 hsa-miR-106b Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2 MMP2 upregulation plays an important role in BC bone metastasis through ERK pathways, and miR-106b directly regulates MMP2 expression molecular function CBC 24164962 hsa-miR-106b Prognostic value of miR-106b expression in breast cancer patients MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer biomarker CBC 25619461 hsa-miR-10a Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-10a has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-10a Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment MiR-126 and miR-10a are independent predictors for tumour relapse in early postmenopausal breast cancer patients treated with adjuvant tamoxifen. biomarker CBC 23968733 hsa-miR-10a The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer Higher expression of RUNX2 and miR-10a/b was associated with adverse outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. biomarker CBC 25266482 hsa-miR-10a miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis Higher miR-10a levels are significantly correlated with less aggressive CRC phenotypes in patients, which may have prognostic and therapeutic value for CRC patients in the future. biomarker CBC 28383561 hsa-miR-10a miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis MiR-10a promoted migration and invasion in vitro but inhibited metastasis in vivo by regulating the epithelial-to-mesenchymal transition and anoikis.Furthermore, matrix metalloproteinase 14 (MMP14) and actin gamma 1 (ACTG1) were validated as target genes of miR-10a in CRC cells.Ectopic expression of MMP14 and ACTG1 counteracted the decreased cell adhesion and anoikis resistance activities induced by miR-10a. molecular function CBC 28383561 hsa-miR-10b Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-10b has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-10b Exosome-mediated transfer of hsa-miR-10b promotes cell invasion in breast cancer Hsa-miR-10b secretes protein levels that inhibit its target genes such as HOXD10 and KLF4 and induces invasion of breast cancer cells molecular function MFBCE 25428807 hsa-miR-10b Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. MicroRNA-10b (miR-10b) is highly expressed in metastatic breast cancer cells and positively regulates cell migration and invasion.Overexpression of miR-10b in otherwise non-metastatic breast tumours initiates robust invasion and metastasis. The level of miR-10b expression in primary breast carcinomas correlates with clinical progression. biomarker CBC 17898713 hsa-miR-10b Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Expression of miR-10b is induced by the transcription factor Twist, which binds directly to the putative promoter of mir-10b (MIRN10B). The miR-10b induced by Twist proceeds to inhibit translation of the messenger RNA encoding homeobox D10, resulting in increased expression of a well-characterized pro-metastatic gene, RHOC. molecular function CBC 17898713 hsa-miR-10b MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. MiR-10b might play some role in the invasion of glioma cells. biomarker CBC 19536818 hsa-miR-10b MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. MiR-10b expression pattern in glioma. miR-10b inhibits the translation of mRNA encoding HOXD10, which modulates many genes that promote invasion, migration, extracellular matrix remodeling and tumor progression, including uPAR, RhoC, α3 integrin, β integrin and matrix metalloprotease-4 (MMP-4). molecular function CBC 19536818 hsa-miR-10b The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Circulating miRNA-10b and miRNA-373 are potential biomarkers for detecting the lymph node status of breast cancer. biomarker CBC 23238818 hsa-miR-1207-5p miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase MiR-1207-5p and miR-1266 were determined to be hTERT suppressors in gastric cancer, and the delivery of these two miRNAs represents a novel therapeutic strategy for gastric cancer treatment molecular function CBC 24481448 hsa-miR-1207-5p miR-1207-5p suppresses lung cancer growth and metastasis by targeting CSF1 MiR-1207-5p-CSF1 axis maybe a new regulator of lung cancer development through modulating the tumor microenvironment molecular function CBC 27107415 hsa-miR-1207-5p PVT1-derived miR-1207-5p promotes breast cancer cell growth by targeting STAT6 PVT1-derived miR-1207-5p promotes the proliferation of breast cancer cells by targeting STAT6, which in turn controls CDKN1A and CDKN1B expression;miR-1207-5p might be a potential target for breast cancer therapy molecular function CBC 28235236 hsa-miR-1207-5p miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression There was a notable elevation in the expression of miR-1207-5p and a reduction in the expression of LZTS1 in the Taxol non-responsive TNBC tissues when compared with the Taxol-responsive TNBC tissues molecular function CBC 30655858 hsa-miR-1207-5p MicroRNA miR-1207-5p-repression of ATRA receptors determine retinoid-resistance in breast cancer MiR-1207-5p in the regulation of retinoid-resistance in the BLBC cells and reflects on potential use of a combination of miR-1207-5p antagonists (antagomir and sponges) and ATRA as potent chemotherapy against hard-to-cure BLBC molecular function CBC hsa-miR-122 Breast-cancer-secreted hsa-miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis Hsa-miR-122 suppresses glucose uptake by downregulating the glycolytic enzyme pyruvate kinase (PKM)to promote metastasis molecular function MFBCE 25621950 hsa-miR-122 Plasma exosome microRNAs are indicative of breast cancer Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer biomarker BBCE 27608715 hsa-miR-122 De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer Certain miRNAs can serve as potential blood-based biomarkers for NCT response, and that miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients biomarker CBC 22400902 hsa-miR-122 MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R MiR-122 may serve as a novel therapeutic or diagnostic/prognostic-target for treating BC biomarker CBC 23056576 hsa-miR-122 MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R MiR-122 functions as a tumor suppressor and plays an important role in inhibiting the tumorigenesis through targeting IGF1R and regulating PI3K/Akt/mTOR/p70S6K pathway molecular function CBC 23056576 hsa-miR-122 Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis By modifying glucose utilization by recipient premetastatic niche cells, cancer-derived extracellular miR-122 is able to reprogram systemic energy metabolism to facilitate disease progression biomarker CBC 25621950 hsa-miR-122 Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies Serum miR-122 levels can be utilized as a biomarker of hepatotoxicity in acute and subacute rat toxicology studies, and its performance can rival or exceed those of standard enzyme biomarkers such as the liver transaminases biomarker CBC 26123229 hsa-miR-122 Inhibition of breast cancer cell proliferation and tumorigenesis by long non-coding RNA RPPH1 down-regulation of miR-122 expression Breast cancer progression can be promoted by directly targeting miR-122 through lncRNA RPPH1 molecular function CBC 29200969 hsa-miR-1228-5p A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus Tan and colleagues identified a serum of miRNA panel (hsa-miR-206, hsa-miR-141-3p, hsa-miR-433-3p, hsa-miR-1228-5p, hsa-miR-199a-5p, hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-26a-5p) that has considerable clinical value in HCC diagnosis biomarker CBC 25238238 hsa-miR-1233-5p Significance of microRNA-based biomarkers for pancreatic cancer Fifteen miRNAs (miR-106b-3p, miR-1233*, miR-1271-5p, miR-1285-3p, miR-15b-3p*, miR-181c-5p, miR-26b-3p, miR-30d-3p, miR-335-3p*, miR-454-5p*, miR-589-3p, miR-616-3p, miR-663b, miR-664-3p, and miR-744-3p) were significantly dysregulated in patients with PC compared to HC on normalization to both U6 and miR-16 molecular function CBC 26605323 hsa-miR-124-3p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-124-3p Decreased miR-124-3p Expression Prompted Breast Cancer Cell Progression Mainly by Targeting Beclin-1 Decreased miR-124-3p expression prompted breast cancer cell progression mainly by enhancing the expression of autophagy related protein, Beclin-1 molecular function CBC 27468577 hsa-miR-124-3p miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL MiR-124-3p and CBL regulate the proliferation and invasion of breast cancer cells molecular function CBC 27842510 hsa-miR-124-3p miR-124-3p acts as a potential marker and suppresses tumor growth in gastric cancer The underlying mechanism for the regulation of gastric cancer by miR-124-3p via targeting of Rac1 and SP1 molecular function CBC 30013778 hsa-miR-124-3p miR-124-3p could be used as biomarkers for HNSCC diagnosis in the high altitude mestizo Ecuadorian population Salivary MicroRNAs for Early Detection of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in the High Altitude Mestizo Ecuadorian Population biomarker CBC 30584540 hsa-miR-1246 Exosomal MicroRNA hsa-miR-1246 Promotes Cell Proliferation,Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer Hsa-miR-1246 promotes cell proliferation,invasion and drug resistance by targeting CCNG2 in breast cancer molecular function MFBCE 29216623 hsa-miR-1246 Plasma exosome microRNAs are indicative of breast cancer Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer biomarker BBCE 27608715 hsa-miR-1246 Selective release of microRNA species from normal and malignant mammary epithelial cells MiR-1246 were also reported as valuable potential biomarkers of breast cancer biomarker CBC 20976003 hsa-miR-1246 MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2 MiR-1246 might promote CSCC tumorigenesis and progression by the suppression of its target gene THBS2 molecular function CBC 24806621 hsa-miR-1246 Novel combination of serum microRNA for detecting breast cancer in the early stage Combination of five miRNA (miR-246, miR-307-p, miR-634, miR-861-p and miR-875-p) was found to be able to detect breast cancer biomarker CBC 26749252 hsa-miR-1246 Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5 MiR-1246 could act as a signaling messenger between irradiated and non-irradiated cells, more importantly, it contributes to cell radioresistance by directly suppressing the DR5 gene molecular function CBC 27129166 hsa-miR-1246 Serum expression levels of microRNA-382-3p, -598-3p, -1246 and -184 in breast cancer patients MiR-382-3p, -598-3p, -1246 and -184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection biomarker CBC 27347136 hsa-miR-1246 miRNA-1246 induces pro-inflammatory responses in mesenchymal stem/stromal cells by regulating PKA and PP2A MiR-1246 led to a p65-dependent increase in transcription and release of pro-inflammatory mediators IL-6, CCL2 and CCL5 in MSCs, and increased NF-κB activity and promote inflammatory by direct targeting of the tumor-suppressors PRKAR1A and PPP2CB molecular function CBC 28159925 hsa-miR-1246 MicroRNA-1246 inhibits cell invasion and epithelial mesenchymal transition process by targeting CXCR4 in lung cancer cells. miR-1246 inhibited cell invasion and EMT process by targeting CXCR4 and blocking JAK/STAT and PI3K/AKT signal pathways in lung cancer cells. biomarker CBC 29171984 hsa-miR-1246 MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β Mediated Wnt/β-Catenin Pathway miR-1246 regulates Wnt/β-catenin pathway through targeting GSK-3β/β-catenin, which partly contributing to tumor metastasis.MiR-1246 may play an essential role in the diagnosis and therapeutic of lung cancer. molecular function CBC 30913872 hsa-miR-1246 microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer Ex-miR-1246 expression correlated with increasing pathologic grade, positive metastasis, and poor prognosis biomarker CBC 29437039 hsa-miR-1246 microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer Overexpression of miR-1246 in a prostate cancer cell line significantly inhibited xenograft tumor growth in vivo and increased apoptosis and decreased proliferation, invasiveness, and migration in vitro miR-1246 inhibited N-cadherin and vimentin activities, thereby inhibiting epithelial-mesenchymal transition molecular function CBC 29437039 hsa-miR-1246 Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4. MiR-1246 packaged in exosomes could act as a transfer messenger and contribute to DNA damage by directly repressing the LIG4 gene molecular function CBC 30038324 hsa-miR-1246 In Situ Detection of Plasma Exosomal MicroRNA-1246 for Breast Cancer Diagnostics by a Au Nanoflare Probe Using plasma miR-1246 level detected by our assay as a marker, we differentiated 46 breast cancer patients from 28 healthy controls with 100% sensitivity and 92.9% specificity at the best cutoff biomarker CBC 30350935 hsa-miR-1268a Polymorphisms in the precursor microRNAs and aflatoxin B1-related hepatocellular carcinoma Polymorphisms in pre-miRNAs, such as rs28599926 in miR-1268a, can be used as biomarkers for AFB1-related HCC biomarker CBC 26152337 hsa-miR-1268a Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma MicroRNA-1268a may be an independent prognostic factor for HCC patients, and that decreasing microRNA-1268a expression may be beneficial for post-operative adjuvant TACE treatment in HCC biomarker CBC 27796321 hsa-miR-1268a miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma MiR-1268a and elucidated its role in modulating TMZ-resistance of GBM cells by targeting ABCC1 molecular function CBC 29876787 hsa-miR-1268a Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer MiR-1268a was specifically enriched in SW480-Exos and miR-107 was enriched in only SW480-CL released EVs molecular function CBC 30608951 hsa-miR-1268a The microRNA-1268a rs28599926 polymorphism modified diffusely infiltrating astrocytoma risk and prognosis MiR-1268a rs28599926 polymorphism may be associated with DIA risk and prognosis biomarker CBC hsa-miR-128 Shikonin Inhibits the Proliferation of Human Breast Cancer Cells by Reducing Tumor-Derived Exosomes Hsa-miR-128 negatively regulates the level of Bax in MCF7recipient cells and inhibits cell proliferation molecular function MFBCE 27322220 hsa-miR-128 Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5 Reduction in miR-128 leading to Bmi-1 and ABCC5 overexpression is a stem cell-like feature of BT-ICs, which contributes to chemotherapeutic resistance in breast cancers. Ectopic expression of miR-128 sensitizes BT-ICs to the proapoptotic and DNA-damaging effects of doxorubicin, indicating therapeutic potential molecular function CBC 21953503 hsa-miR-128 Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells In summary, we have identified a novel TGF-β/SNAIL/miR-128 axis that provides a new avenue to understand the basis for oncogenic transformation of mammary epithelial cells molecular function CBC 23019226 hsa-miR-128 miR-128 and its target genes in tumorigenesis and metastasis Aberrant expression of miR-128 has been detected in many types of human tumors and its validated target genes are involved in cancer-related biological processes such as cell proliferation, differentiation and apoptosis molecular function CBC 23958464 hsa-miR-128 miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma The expression of miR-128 and miR-149 was downregulated in glioblastoma, and their overexpression inhibited the invasion of glioblastoma cells by targeting Rap1B-mediated cytoskeletal and related molecular alterations molecular function CBC 25017996 hsa-miR-128 MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer MiR-128 might be a prognostic marker and possible molecular target for therapy in patients with TNBC biomarker CBC 29116653 hsa-miR-128 MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer MiR-128 targeting inhibition of the insulin receptor and insulin receptor substrate 1 molecular function CBC 29116653 hsa-miR-130a Molecular characterization of exosome-like vesicles from breast cancer cells Comparing the miRNAs in MDA-Exo to MCF-Exo showed a higher expression of tumorigenic mir-130a in MDA-Exo. it has been shown that mir-130a contribute to tumorigenesis of colon cancer by regulating TGB-尾/Smad signaling molecular function MFBCE 24468161 hsa-miR-130a MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A MiR-130a is an important tumor suppressor in breast cancer, and imply that miR-130a/RAB5A axis have potential as therapeutic targets for breast cancer molecular function CBC 25755726 hsa-miR-130a MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells The deregulation of miR-374a and miR-130a may be involved in the development and regulation of cisplatin resistance in ovarian cancer cells; miR-130a may be achieved by regulating the MDR1 and PTEN gene expression molecular function CBC 26043084 hsa-miR-130a miR-130a Deregulates PTEN and Stimulates Tumor Growth MiR-130a overexpression in human breast cancer cells promoted Akt phosphorylation, cell survival, and tumor growth;MiR-130a as an oncogenic miRNA that targets PTEN to drive malignant cell survival and tumor growth molecular function CBC 28935812 hsa-miR-130a microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1 MiR-130a directly targets FOSL1 and suppresses the inhibition of ZO-1, thus inhibiting cancer cell migration and invasion, in TNBCs molecular function CBC 29384218 hsa-miR-130a miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity MiR-130a targeted molecular networks including TGFβ and IGF1R pathways were correlated with higher tumor stages in cancer patients to enhance host antitumor immunity molecular function CBC 29973593 hsa-miR-130a The MYB/miR-130a/NDRG2 axis modulates tumor proliferation and metastatic potential in salivary adenoid cystic carcinoma MYB/miR-130a/NDRG2 axis, which modulates proliferation and metastasis in SACC, provides promising targets for the treatment of SACC molecular function CBC 30206227 hsa-miR-130a MicroRNA-130a modulates a radiosensitivity of rectal cancer by targeting SOX4 MiR-130a functions as a radiosensitizer in rectal cancer and reveals a potential therapeutic target and preoperative prognostic marker for radiotherapy biomarker CBC 31387015 hsa-miR-130a-3p hsa-miR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells Hsa-miR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells molecular function MFBCE 29746865 hsa-miR-130a-3p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-130a-3p miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program MiR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation molecular function CBC 26436920 hsa-miR-130a-3p LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4 CCAT1/miR-130a-3p axis enhanced DDP resistance of NSCLC cells by targeting SOX4, providing potential targets to overcome DDP resistance and improve efficacy of chemotherapy for patients with NSCLC molecular function CBC 29020498 hsa-miR-130a-3p MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells MiR-130a-3p may act as a disease progression monitoring indicator and therapeutic target in breast cancer molecular function CBC 29746865 hsa-miR-130a-3p H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in Glioma H19 and SOX4 are both direct target of miR-130a-3p. H19 could compete with SOX4 via sponging miR-130a-3p molecular function CBC 30282068 hsa-miR-130a-3p Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma A similar effect was observed for miR-130a-3p regulating Bcl-2 and XIAP. Our data provide the first evidence that miRNA modulation in both directions may lead to similar effects on chemotherapy response and tumor biology in esophageal squamous cell carcinoma molecular function CBC 30510209 hsa-miR-135a-3p MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer MiR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer biomarker CBC 28231414 hsa-miR-135a-3p miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway MiR-135a is a novel downstream gene of tumor suppressor p53;the expression and function of miR-135a in gastric cancer and uncovers a novel regulatory mechanism of miR-135a molecular function CBC 28415713 hsa-miR-135a-3p MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2 MiR-135a-3p serves as a tumour suppressor gene in ovarian cancer by regulating CCR2 molecular function CBC 30138893 hsa-miR-135a-3p miR-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer MiR-135a-3p expression could be used as a noninvasive biomarker in serum of patients with ovarian carcinoma in the diagnosis and follow-up of the disease biomarker CBC hsa-miR-145 Presence of Circulating hsa-miR-145, hsa-miR-155, and hsa-miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors Our study showed that serum-circulating miR-145, miR-155, and miR-382 are present in exosomes. These miRNAs were previously proposed as noninvasive biomarkers to distinguish between BC patients and healthy individuals biomarker BBCE 30891102 hsa-miR-145 MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. MiR-145 as a potential new diagnostic and therapeutic target for the treatment of breast cancer. biomarker CBC 26715279 hsa-miR-145 MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. MiR-145 acts as a tumor suppressor and its downregulation in tumor tissues may contribute to the progression of breast cancer through a mechanism involving ROCK1 molecular function CBC 26715279 hsa-miR-145 MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer. MiR-145 might be potential therapeutic and diagnostic targets for TNBC. biomarker CBC 27364572 hsa-miR-145 MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer. MiR-145 has an inhibitory role in TNBC malignancy by targeting MMP11 and Rab27a molecular function CBC 27364572 hsa-miR-145 miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Ectopic expression of miR-145 significantly inhibited breast cancer cell migration. biomarker CBC 27508031 hsa-miR-145 miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. MiR-145 mimic transfection enhanced the expression of FSCN-1 in Bcap-37 and HCC-1937 cells,up-regulation of miR-145 blocked EMT and decreased the expression of MMP-2/9 in breast cancer cells. molecular function CBC 27508031 hsa-miR-145 miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. MiR-145 may act as a tumor-suppressor miRNA in breast cancer through inhibiting proliferation and migration of breast cancer cells. In addition, miR-145 inhibits the protein expression of TGF-β1 which may in turn contribute to tumor formation. molecular function CBC 28393176 hsa-miR-149-3p 18β-glycyrrhetinic acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1 signaling GRA inhibits the initiation and progression of gastric tumors by ameliorating the inflammatory microenvironment through downregulation of COX-2 expression and by inhibiting Wnt-1 expression through the upregulation of tumor suppressor miR-149-3p molecular function CBC 27713126 hsa-miR-149-3p Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p HnRNPK regulates PLK1 expression by competing with the PLK1-targeting miRNAs, miR-149-3p and miR-193b-5p molecular function CBC 28708135 hsa-miR-149-3p Dual Strands of Pre-miR-149?Inhibit Cancer Cell Migration and Invasion through Targeting?FOXM1?in Renal Cell Carcinoma Dual strands of pre-miR-149 (miR-149-5p and miR-149-3p) acted as antitumor miRNAs through the targeting of FOXM1 in ccRCC cells molecular function CBC 28902136 hsa-miR-149-3p Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4 S100A4 promotes cell growth, migration, and invasion and can by reversed by miR-149-3p in BCa molecular function CBC 29218245 hsa-miR-149-3p Characterizing the landscape of peritoneal exosomal microRNAs in patients with ovarian cancer by high-throughput sequencing MiR-149-3p and miR-222-5p might be novel biomarkers for evaluating the prognosis of patients with EOC and that these two miRNAs might have potential therapeutic values biomarker CBC 30655799 hsa-miR-149-3p ZEB1-AS1 initiates a miRNA-mediated ceRNA network to facilitate gastric cancer progression ZEB1-AS1 can interact with specific miRNAs, forming a miRNA-mediated ceRNA network and promoting GC progress, partly through a ZEB1-AS1/miR-149-3p axis molecular function CBC 30774556 hsa-miR-150-3p Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma Downregulation of both strands of pre-miR-150 (miR-150-5p and miR-150-3p) and overexpression of SPOCK1 contribute to the aggressive nature of HNSCC. The involvement of passenger strand miRNA in the regulation of HNSCC pathogenesis is a novel concept in RNA research molecular function CBC 29233721 hsa-miR-150-3p MiR-150-3p targets SP1 and suppresses the growth of glioma cells The abundance of phosphatase and tension homolog deleted on chromosome ten (PTEN), a negative downstream target of SP1, was increased with the ectopic?miR-150-3p. Collectively, these results suggested that?miR-150-3p?suppressed the growth of glioma cells partially via regulating SP1 and possibly PTEN molecular function CBC 29654167 hsa-miR-150-3p Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma Expression of TNS4 was directly regulated by miR-150-3p in LUAD cells. Aberrant expression of TNS4 was detected in LUAD clinical specimens and its aberrant expression increased the aggressiveness of LUAD cells molecular function CBC 31052206 hsa-miR-155 Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-155 has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-155 Presence of Circulating hsa-miR-145, hsa-miR-155, and hsa-miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors Our study showed that serum-circulating miR-145, miR-155, and miR-382 are present in exosomes. These miRNAs were previously proposed as noninvasive biomarkers to distinguish between BC patients and healthy individuals biomarker BBCE 30891102 hsa-miR-155 miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. The location of tumor cells overexpressing miR-155 is a critical factor: in mammary fat pads miR-155 prevents tumor dissemination; whereas in the lung miR-155 apparently maintains the epithelial phenotype of tumor cells that is critical for macroscopic tumor formation. biomarker CBC 21460854 hsa-miR-155 miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Stable expression of miR-155 in 4T1 breast tumor cells reduces significantly the aggressiveness of tumor cell dissemination as a result of preventing epithelial-to-mesenchymal transition (EMT) of tumor cells in vivo. Further, miR-155 directly suppresses the expression of the transcription factor TCF4, which is an important regulator of EMT. However, when tumor cells are injected directly into the bloodstream, miR-155 remarkably promotes macroscopic tumor formation in the lung. molecular function CBC 21460854 hsa-miR-155 MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer MiR-155 is a critical therapeutic target in breast cancer. biomarker CBC 27825093 hsa-miR-155 MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer The critical role of miR-155 in regulation of cell survival and chemosensitivity through down-regulation of FOXO3a in breast cancer. Ectopic expression of miR-155 induces cell survival and chemoresistance to multiple agents, whereas knockdown of miR-155 renders cells to apoptosis and enhances chemosensitivity. molecular function CBC 27825093 hsa-miR-155 MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer A transcriptional axis of FOXP3-BRCA1-miR-155 in breast cancer cells and show that plasma miR-155 may serve as a non-invasive biomarker for detection of early stage breast cancer. biomarker CBC 28562349 hsa-miR-155 MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer There was a positive correlation between expression of FOXP3 and miR-155 in breast cancer cell lines and primary breast cancers. In breast cancer cells, FOXP3 induced miR-155 through transcriptional repression of BRCA1. molecular function CBC 28562349 hsa-miR-16 MicroRNAs are exported from malignant cells in customized particles Hsa-miR-16 is characterized by excessive release from breast cancer cells while retaining relatively low concentrations of miRNA in the cells and could be used to detect the presence of malignant cells in the body molecular function MFBCE 22772984 hsa-miR-16 Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells miR-16, a miRNA known to target VEGF, was enriched in MSC-derived exosomes and it was partially responsible for the anti-angiogenic effect of MSC-derived exosomes molecular function MFBCE 24391924 hsa-miR-16 Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development MiR-16 is a tumor suppressor in progestin- and growth factor-induced growth in breast cancer molecular function CBC 22583478 hsa-miR-16 Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection MiR-16, miR-21 and miR-451 in plasma of breast cancer patients has been reported as biomarker biomarker CBC 23301032 hsa-miR-16 MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis The clinical application of miR-16 family profiling for cancers diagnosis still needs further large-scale studies and additional improvements of substantiation biomarker CBC 25932099 hsa-miR-16 miR-16 promotes the apoptosis of human cancer cells by targeting FEAT MiR-16 is a tumor suppressor in cancer cells through the inhibition of FEAT translation molecular function CBC 26031775 hsa-miR-16 Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis Hsa-miR-17-5p targeted mRNAs [such as BCL2, SMAD3,SOCS1 ]and pathways associated with epithelial-esenchymal transitions and other processes linked with cancer metastasis biomarker CBC 28739740 hsa-miR-16 MiR-16-5p targets SESN1 to regulate the p53 signaling pathway, affecting myoblast proliferation and apoptosis, and is involved in myoblast differentiation MiR-16-5p directly targets SESN1 to regulate the p53 signaling pathway, and therefore affecting myoblast proliferation and apoptosis molecular function CBC 29511169 hsa-miR-17-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-17-5p Mir-17-5p Regulates Breast Cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA Mir-17-5p, a potential translational repressor of the AIB1 oncogene, in the control of breast cancer cell proliferation molecular function CBC 16940181 hsa-miR-17-5p miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1 MiR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/β-catenin molecular function CBC 20505989 hsa-miR-17-5p Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis Hsa-miR-17-5p targeted mRNAs such as BCL2, SMAD3,SOCS1 and pathways associated with epithelial-esenchymal transitions and other processes linked with cancer metastasis molecular function CBC 28739740 hsa-miR-17-5p miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer MiR-17-5p acts as a tumour suppressor in TNBC by targeting ETV1, and a low-abundance of miR-17-5p may be involved in the pathogenesis of triple-negative breast cancer molecular function CBC 29126392 hsa-miR-17-5p miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway MiR-106b-5p and miR-17-5p might have a role in breast cancer recurrence and progression by suppressing TGF-β activity, leading to early breast cancer carcinogenesis molecular function CBC 30989460 hsa-miR-181a-2-3p let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer While the EGF pathway promotes CSC formation in cervical cancer by inducing SOX2, miR-181a-2-3p/let-7i-5p counteracts the EGF pathway by inhibiting SOX2, thereby reducing the CSC population molecular function CBC 29777148 hsa-miR-181d-3p Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets For seven miRNAs (hsa-miR-134-3p, hsa-miR-134-5p, hsa-miR-181d-3p, hsa-miR-181d-5p, hsa-miR-494-3p, hsa-miR-494-5p, hsa-miR-517c-3p,hsa-miR-98-3p, hsa-miR-98-5p) the target mRNAs were found in micro-T-CDS only molecular function CBC 28984201 hsa-miR-181d-3p Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients MiR 125b-5p, miR 181d-3p, and miR 221-3p are useful in predicting poor prognosis in patients with MGMT-unmethylated glioblastomas biomarker CBC 29538610 hsa-miR-181d-3p MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients Out of these miRNAs, miR-488-3p, miR-186-3p, miR-122-5p, miR-181d-3p, miR-615-5p and miR376b-3p were selected for further validation based on the pvalue, fold-change, average expression and available literature evidence molecular function CBC 31467229 hsa-miR-182 hsa-miR-182,of the hsa-miR-183 cluster family,is packaged in exosomes and is detected in human exosomes from serum,breast cells and prostate cells Hsa-miR-182 expression and secretion changes with breast cancer cell line aggressiveness.dependent mechanism;detectable in exosomes from human sera and may be transferred between cells via a microvesicle-dependent mechanism molecular function MFBCE 27446418 hsa-miR-182 Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK Our data demonstrate for the first time that miR-182 expression is controlled by β-catenin. In addition, we identify a new miR-182 target RECK which is important for miR-182-induced tumorigenesis molecular function CBC 23333633 hsa-miR-182 Higher expression of circulating miR-182 as a novel biomarker for breast cancer The current study highlights results consistent with miR-182 as a novel and valuable biomarker for the diagnosis of BC biomarker CBC 24260062 hsa-miR-182 High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer Our findings improve our understanding of the expression level of the miR-183/182/96 cluster in breast cancer and clarify the role of the miR-183/182/96 cluster as a novel prognostic biomarker for breast cancer biomarker CBC 27071841 hsa-miR-182 MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7 In conclusion, our study explores a novel mechanism by which miR-182 elevates HIF-1α expression to promote breast cancer progression molecular function CBC 27648365 hsa-miR-182 MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer MiR-182 plays an important role in the initiation and progression of TNBC by targeting FOXF2 and the miR-182/FOXF2 axis may present a new therapeutic strategy for TNBC in the future molecular function CBC 29085483 hsa-miR-187-5p MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression In silico prediction revealed that miR-498 and miR-187-5p target BRCA1, and these results were confirmed by luciferase reporter assay,while miR-187-5p was found overexpressed in a luminal B cell line, miR-498 was highly expressed in a triple negative cell line, Hs578T, and its expression was negatively correlated with the levels of?BRCA1 molecular function CBC 26933805 hsa-miR-187-5p miR-187-5p Regulates Cell Growth and Apoptosis in Acute Lymphoblastic Leukemia via DKK2 MiR-187-5p-DKK2 pathway regulates Wnt/β-catenin signaling, cell growth, and apoptosis. Our findings provide the first evidence of a role for miR-187-5p in promotion of B-cell ALL molecular function CBC 27296949 hsa-miR-187-5p Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer molecular function CBC 29883941 hsa-miR-187-5p MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines By doing so hsa-miR-187-5p was linked to the cell cycle G2-M checkpoint in line with this checkpoint being the target of taxanes molecular function CBC 31063487 hsa-miR-18a-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-18a-5p MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer MiR-18a-5p can not only promote NSCLC by suppressing IRF2, but also will be a promising target in the near future molecular function CBC 28471447 hsa-miR-18a-5p SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2 Due to crucial role of miR-18a-5p and SREBP1 in the EMT and metastasis, they provide promising drug targets for tailored therapy in the advanced breast cancer setting molecular function CBC 29988076 hsa-miR-18a-5p Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p One miR-18a-5p-binding site within exon 2 of GAS5 that is partially responsible for the tumor-suppressor functions of GAS5 molecular function CBC 30078184 hsa-miR-18a-5p Carcinogenesis of miR-18a-5p was reversed by the overexpression of IRF2 in OS MiR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2 biomarker CBC 30127908 hsa-miR-18a-5p miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2 MiR-18a-5p promoted the invasion and migration of OS cells through inhibiting IRF2 expression molecular function CBC 30127908 hsa-miR-191 Blood Circulating Exosomes Contain Distinguishable Fractions of Free and Cell-Surface-Associated Vesicles Preliminary data indicated that detection of cancer-specific miRNA (miR-103, miR-191, miR-195) in exosomes associated with the fraction of red blood cells allowed to discriminate HFs and BCPs more precisely compared to cell-free exosomes circulating in plasma biomarker BBCE 30868953 hsa-miR-191 Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Two miRNA (miR-125b/miR-191 and miR-21/miR-191) can discriminate between breast cancer and non-tumor tissue with high specificity and sensitivity. biomarker CBC 22898264 hsa-miR-191 Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. MiR-191 and miR-425 reduced proliferation, impaired tumorigenesis and metastasis, and increased expression of epithelial markers in aggressive breast cancer cells. biomarker CBC 23505378 hsa-miR-191 Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. MiR-191 protects ERα positive breast cancer cells from hormone starvation-induced apoptosis through the suppression of tumor-suppressor EGR1. molecular function CBC 23505378 hsa-miR-191 MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. MiR-191 as an estrogen-inducible onco-miR in breast cancer, which promotes several hallmarks of cancer including enhanced cell proliferation, migration, chemoresistance and survival in tumor microenvironment. biomarker CBC 23542418 hsa-miR-191 MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. The identification of estrogen/ER/miR-191/SATB1 cascade seems to be a significant pathway in estrogen signaling in breast cancer with miR-191 as oncogenic player. molecular function CBC 23542418 hsa-miR-191 HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. MiR-191 enhances breast cancer aggressiveness by promoting cell proliferation, migration and survival under hypoxia. biomarker CBC 25867965 hsa-miR-191 HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. MiR-191 is a critical regulator of transforming growth factor beta (TGFβ)-signaling and promotes cell migration by inducing TGFβ2 expression under hypoxia through direct binding and indirectly by regulating levels of a RNA binding protein, human antigen R (HuR). molecular function CBC 25867965 hsa-miR-195 Blood Circulating Exosomes Contain Distinguishable Fractions of Free and Cell-Surface-Associated Vesicles Preliminary data indicated that detection of cancer-specific miRNA (miR-103, miR-191, miR-195) in exosomes associated with the fraction of red blood cells allowed to discriminate HFs and BCPs more precisely compared to cell-free exosomes circulating in plasma biomarker BBCE 30868953 hsa-miR-195 Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. MiR-212 and miR-195 could be independent biomarkers in predicting the gastric cancer with metastasis to lymph node(LN). biomarker CBC 21987613 hsa-miR-195 Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1 Induction of miR-195 expression promoted tumor cell apoptosis and inhibited breast cancer cell viability, but induced the sensitivity of breast cancer cells to Adriamycin treatment and was associated with inhibition of Raf-1 expression in breast cancer cells. biomarker CBC 23760062 hsa-miR-195 Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1 Expression of miR-195 or knockdown of Raf-1 can similarly reduce tumor cell survival but increase apoptosis through downregulation of Raf-1 and Bcl-2 and P-glycoprotein expression. molecular function CBC 23760062 hsa-miR-195 MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 Hsa-miR-195 targets the genes of de novo lipogenesis, inhibits cell proliferation, migration, and invasion which potentially opens new avenues for the treatment of breast cancer. biomarker CBC 26632252 hsa-miR-195 MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 Ectopic expression of hsa-miR-195 in MCF-7 and MDA-MB-231 cells not only altered cellular cholesterol and triglyceride levels significantly but also resulted in reduced proliferation, invasion and migration. Over expression of hsa-miR-195 decreased the Mesenchymal markers expression and enhanced Epithelial markers. molecular function CBC 26632252 hsa-miR-195 Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer The analysis of miR-195 and let-7a can be used as a non-invasive biomarker for breast cancer detection. biomarker CBC 29995098 hsa-miR-195-3p Identification of miR-195-3p as an oncogene in RCC Knockdown of miR-195-3p induces cell apoptosis;miR-195-3p promotes cell proliferation and increases cell mobility molecular function CBC 28260025 hsa-miR-195-3p Prostate cancer small non-coding RNA transcriptome in Arabs Five miRNAs are newly found to be associated with PCa namely, miR-671-3p, miR-143-5p, miR-145-3p, miR-195-3p and miR-320b. Except for miR-671-3p, all other miRNAs were found down-regulated in tumor tissues molecular function CBC 29268752 hsa-miR-195-3p Chemokine CCL4 induces vascular endothelial growth factor C expression and lymphangiogenesis by miR-195-3p in oral squamous cell carcinoma MiR-195-3p mimic reversed CCL4-enhanced VEGF-C expression. CCL4 stimulation of oral cancer cells augmented JAK2 and STAT3 phosphorylation molecular function CBC 29599774 hsa-miR-195-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-195-5p Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1 Expression of miR-195 or knockdown of Raf-1 can similarly reduce tumor cell survival but increase apoptosis through downregulation of Raf-1 and Bcl-2 and P-glycoprotein expression molecular function CBC 23760062 hsa-miR-195-5p MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer Overexpression of miR-195-5p inhibited cell proliferation, reduced cell colony formation, suppressed cell migration and caused an accumulation of cells in the G1 phase of the cell cycle molecular function CBC 24402230 hsa-miR-195-5p Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2 Exogenetic miR-195 expression could significantly enhance the radiosensitivity of human breast cancer cells; this finding may be attributed to BCL-2 downregulation to promote radiation-induced apoptosi molecular function CBC 26309570 hsa-miR-195-5p MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 Hsa-miR-195 targets the genes of de novo lipogenesis, inhibits cell proliferation, migration, and invasion which potentially opens new avenues for the treatment of breast cancer molecular function CBC 26632252 hsa-miR-1972 Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells MiR-1972 induces G2-M cell cycle arrest and miR-1469 moderately arrested G1 cell cycle when overexpressed in KCL22 cells molecular function CBC 27586591 hsa-miR-1972 Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma DNACR promoted ROCK1-meidated proliferation and metastasis through decoying both miR-335-5p and miR-1972 molecular function CBC 29753317 hsa-miR-197-5p Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes The expression level of 5 microRNAs (miR-197-5p, miR-4443, miR-642a-3p, miR-27b-3p and miR-100-5p) with the most differential expression were verified by qRT-PCR;microRNAs in exosomes may be involved in the drug resistance of lung cancer cells to cisplatin molecular function CBC 28178672 hsa-miR-197-5p miR-197-5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101 MiR-197-5p acts as an oncosuppressor miRNA in fibrosarcoma through target regulation of KIAA0101, which can be exploited for developing RNA-based therapeutic strategies for the cure of this malignancy molecular function CBC 31001891 hsa-miR-200 hsa-miR-200-containing extracellular vesicles promote breast cancer cell metastasis Promote mesenchymal-to-epithelial transition and colonisation of metastatic sites molecular function MFBCE 28038441 hsa-miR-200 miR-200 enhances mouse breast cancer cell colonization to form distant metastases Expression of miR-200, which promotes a mesenchymal to epithelial cell transition (MET) by inhibiting Zeb2 expression, unexpectedly enhances macroscopic metastases in mouse breast cancer cell lines molecular function CBC 19787069 hsa-miR-200 Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state These results indicate that the miR-200 family plays a crucial role in the transition between stem-like and non-stem phenotypes and that distinct epigenetic-based mechanisms regulate each miR-200 gene in this process molecular function CBC 23525011 hsa-miR-200 MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways These findings highlight the context-dependent effects of miR-200 in breast cancer metastasis and demonstrate the existence of a moesin-dependent pathway, distinct from the ZEB1-E-cadherin axis, through which miR-200 can regulate tumour cell plasticity and metastasis molecular function CBC 24037528 hsa-miR-200 miR-200-containing extracellular vesicles promote breast cancer cell metastasis In murine cancer and human xenograft models, miR-200-expressing tumors and extracellular vesicles from these tumors promoted metastasis of otherwise weakly metastatic cells either nearby or at distant sites and conferred to these cells the ability to colonize distant tissues in a miR-200-dependent manner molecular function CBC 25401471 hsa-miR-200 MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells molecular function CBC 29137351 hsa-miR-20b-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-20b-5p miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells The VEGF expression in breast cancer cells is mediated by HIF-1 and STAT3 in a miR-20b-dependent manner. molecular function CBC 20232316 hsa-miR-20b-5p MicroRNA-20b promotes cell growth of breast cancer cells partly via targeting phosphatase and tensin homologue (PTEN) Dysregulation of miR-20b plays critical roles in the breast cancer tumorigenesis, at least in part via targeting the tumor suppressor PTEN molecular function CBC 25364498 hsa-miR-20b-5p miR-20b-5p may be a biomarker for early detection and prognosis prediction, as well as a therapeutic target for RCC MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis biomarker CBC 26708577 hsa-miR-20b-5p Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3 MiR-17, miR-20b and NCOA3 may serve as some predictive biomarkers and potential therapeutic targets in taxol-resistant breast cancer treatmen molecular function CBC 27831559 hsa-miR-21 Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-21 has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-21 Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy Higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells;Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis biomarker BBCE 30728048 hsa-miR-21 Plasma exosome microRNAs are indicative of breast cancer Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer biomarker BBCE 27608715 hsa-miR-21 MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Mir-21 may promote tumor invasion and metastasis by simultaneously downregulating multiple metastasis-related tumor suppressor genes operating at distinct steps of tumor progression. molecular function CBC 18270520 hsa-miR-21 MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. MiR-21 overexpression was correlated with specific breast cancer biopathologic features, such as advanced tumor stage, lymph node metastasis, and poor survival of the patients, indicating that miR-21 may serve as a molecular prognostic marker for BC and disease progression. biomarker CBC 18812439 hsa-miR-21 MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Among the 113 BC cases, high level expression of miR-21 was significantly correlated with advanced clinical stage (P = 0.006, Fisher's exact text), lymph node metastasis (P = 0.007, Fisher's exact text), and shortened survival of the patients (hazard ratio [HR]=5.476, P < 0.001). molecular function CBC 18812439 hsa-miR-21 High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. High miR-21 was associated with poor disease-free survival in early stage patients (HR = 2.08, 95% CI: 1.08-4.00) despite no value for prognosis. biomarker CBC 18932017 hsa-miR-21 High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Elevated miR-21 expression may facilitate tumor progression, and TGF-beta may up-regulate its expression. molecular function CBC 18932017 hsa-miR-210 Visualization of exosome-mediated hsa-miR-210 transfer from hypoxic tumor cells Hsa-miR-210 can proliferate endothelial cells and promote tumor growth and invasion molecular function MFBCE 28038441 hsa-miR-210 Hypoxic enhancement of exosome release by breast cancer cells The hypoxically regulated miR-210 was identified to be present at elevated levels in hypoxic exosome fractions molecular function MFBCE 22998595 hsa-miR-210 hsa-miR-210 overexpression is induced by hypoxia in a HIF-1alpha- and VHL-dependent fashion Hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer biomarker CBC 18316553 hsa-miR-210 hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer Hsa-miR-210 overexpression is induced by hypoxia in a HIF-1αand VHL-dependent fashion and its expression levels in breast cancer samples are an independent prognostic factor. biomarker CBC 18316553 hsa-miR-210 hsa-miR-210 overexpression is induced by hypoxia in a HIF-1alpha- and VHL-dependent fashion Expression levels of hsa-miR-210 in breast cancer samples are an independent prognostic factor molecular function CBC 18316553 hsa-miR-210 High Expression Levels of miR-21 and miR-210 Predict Unfavorable Survival in Breast Cancer: A Systemic Review and Meta-Analysis MiRNAs such as miR-21 and miR-210 can predict poor survival rates in breast cancer patients biomarker CBC 26349663 hsa-miR-222 Exosome-mediated hsa-miR-222 transferring: An insight into NF-B-mediated breast cancer metastasis Hsa-miR-222 contributes to tumorigenicity of BCa cells through down-regulation of PDLIM2 and consequently activating NF-κB molecular function MFBCE 29778754 hsa-miR-222 Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs Hsa-miR-222-rich D/exo could alter PTEN expression in acquired cells that may spread resistance capacity molecular function MFBCE 24740415 hsa-miR-222 Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy Higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells;Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis biomarker BBCE 30728048 hsa-miR-222 MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer MiR-221/222 in breast cancer metastasis, drug resistance and RAS pathways could potentially have applications in medical practice molecular function CBC 21888691 hsa-miR-222 miR-221/222: promising biomarkers for breast cancer MiR-221/222 act as promising biomarkers for BCa and they would offer a new way in molecular targeting cancer treatment biomarker CBC 23529451 hsa-miR-222 MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway Inhibition of miR-222 may improve the prognosis of breast cancer patients biomarker CBC 27746366 hsa-miR-222 MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway MiR-222 mediated ADR-resistance of breast cancer cells partly through regulation of PTEN/Akt/FOXO1 signaling pathway molecular function CBC 27746366 hsa-miR-222 Expression Analysis of MicroRNA-222 in Breast Cancer Our findings on miR-222 suggest that it could be a potentially useful target for control and management of breast malignancy biomarker CBC 29739090 hsa-miR-222 miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer MiR-221/222 activate the Wnt/β-catenin signaling to promote the aggressiveness and TNBC properties of breast cancers, and thus reveal a new prospect for TNBC treatment molecular function CBC 30053090 hsa-miR-223 Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells MiR-223 promoted the invasion of breast cancer cells via the Mef2c-β-catenin pathway molecular function MFBCE 21939504 hsa-miR-223 Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer MiR-29a, miR-181a, miR-223 and miR-652 were validated with altered expression in the blood of women with Luminal A-like breast cancer biomarker CBC 24498016 hsa-miR-223-3p Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer Exosomal miR-223-3p may be a useful preoperative biomarker to identify the invasive lesions of DCIS patients diagnosed by biopsy biomarker BBCE 29805680 hsa-miR-223-3p MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer Increasing SEPT6 expression might reverse the biological activity induced by miR-223-3p, which might be a potential therapeutic target for PCa molecular function CBC 25519054 hsa-miR-223-3p MicroRNA-223-3p inhibits human bladder cancer cell migration and invasion MiR-223-3p as a previously unrecognized microRNA that inhibits bladder carcinoma invasiveness via nuclear receptor coactivator 1, and this finding may be important for developing innovative therapeutic targets in treating bladder carcinoma molecular function CBC 28222670 hsa-miR-223-3p MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression MiR-223-3p could be a potential therapeutic for ovarian cancer biomarker CBC 28587313 hsa-miR-223-3p MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression MiR-223-3p regulated OC cell proliferation and invasion through targeting SOX11 expression molecular function CBC 28587313 hsa-miR-223-3p MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma Expression levels of miR-223-3p can be evaluated as an indicator of eligibility for non-treatment of HNSCC patients with cetuximab biomarker CBC 28915663 hsa-miR-223-3p MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop MiR-223-3p, as a tumor suppressor gene, markedly inhibited cell proliferation and migration via miR-223-3p-mutant p53 feedback loop, which suggested miR-223-3p might be a new therapeutic target in LSCC bearing p53 mutations molecular function CBC 30755230 hsa-miR-223-3p MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers MiR223-3p is a negative regulator of the aNHEJ DNA repair and represents a therapeutic pathway for BRCA1- or BAP1-deficient cancers molecular function CBC 31395736 hsa-miR-25-5p Genome-Wide Uncovering of STAT3-Mediated miRNA Expression Profiles in Colorectal Cancer Cell Lines MiR-25-5p was the most abundant miRNA among those significantly downregulated miRNAs in both samples molecular function CBC 25126546 hsa-miR-25-5p Silencing protein kinase C ζ by microRNA-25-5p activates AMPK signaling and inhibits colorectal cancer cell proliferation Exogenous expression of miR-25-5p silenced PKCζ to activate AMPK signaling, which inhibited HT-29 cell proliferation. In vivo studies showed that HT-29 xenograft growth in mice was inhibited after expressing PKCζ shRNA or miR-25-5p molecular function CBC 29029434 hsa-miR-27a Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-27a has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-27a MiR-27 as a prognostic marker for breast cancer progression and patient survival. High miR-27a expression is associated with poor overall survival in patients with breast cancer, which suggests that miR-27a could be a valuable marker of breast cancer progression. biomarker CBC 23240057 hsa-miR-27a microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. MiR-27a and miR-27b expression may be pharmacologically relevant modulators of DPD enzyme function in the liver. biomarker CBC 24401318 hsa-miR-27a microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Increased accumulation of RNA-induced silencing complex (RISC) proteins on DPYD mRNA in cells overexpressing the highly homologous microRNAs (miRNA) miR-27a and miR-27b. These miRNAs were shown to repress DPD expression through two conserved recognition sites in DPYD. molecular function CBC 24401318 hsa-miR-27a MicroRNA-27a promotes tumorigenesis via targeting AKT in triple negative breast cancer. MiR-27a exhibits an essential role in tumor development and progression in TNBC and may be used as a potential biomarker to predict radiotherapy response and prognosis for the disease. biomarker CBC 29115608 hsa-miR-27a MicroRNA-27a promotes tumorigenesis via targeting AKT in triple negative breast cancer. MiR-27a inhibited radiation induced apoptosis in TNBC cells by regulation of caspase 3/7 and Bcl-2 expression. Furthermore, the expression levels of PTEN and phosphorylated protein kinase B in MDA-MB-231 and MDA?MB?468 cells was altered following overexpression of miR-27a. The luciferase assay demonstrated that miR?27a regulated PTEN and BAX expression by binding to 3'?untranslated regions. molecular function CBC 29115608 hsa-miR-27a miR-27a promotes human breast cancer cell migration by inducing EMT in a FBXW7-dependent manner The important function of miR-27a in regulating the metastasis of breast cancer in a FBXW7-dependent manner, and provide evidence for the potential application of miR-27a in breast cancer therapy. biomarker CBC 30365154 hsa-miR-27a miR-27a promotes human breast cancer cell migration by inducing EMT in a FBXW7-dependent manner Overexpression of miR-27a resulted in enhanced cell migration by inducing epithelial-to-mesenchymal transition, while its knockdown effectively reversed these cellular events.F-box and WD repeat domain containing 7 (FBXW7) is a downstream target gene of miR-27a in human breast cancer cells.the ectopic expression of FBXW7 may effectively suppress the epithelial-to-mesenchymal transition and migratory activity of breast cancer cells, in addition to reversing the cell migration mediated by miR-27a. molecular function CBC 30365154 hsa-miR-29b-3p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-29b-3p LncRNA H19/miR-29b-3p/PGRN Axis Promoted Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Acting on Wnt Signaling The lncRNA H19/miR-29b-3p/PGRN/Wnt axis counted a great deal for seeking appropriate diagnostic biomarkers and treatment targets for CRC biomarker CBC 29754471 hsa-miR-29b-3p The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14 molecular function CBC 30915884 hsa-miR-29b-3p miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3 The miR-29b-3p expression was significantly increased in MDA-MB-231 compare with MCF-10A. miR-29b-3p inhibitor reduced the cell viability of MDA-MB-231 and inhibited cell migration and invasion. Cell cytoskeleton integrity destroyed after miR-29b-3p inhibitor treatment. Furthermore, we identified the mechanism and found miR-29b-3p targets the TRAF3 and activates NF-魏B signaling pathway molecular function CBC 31349873 hsa-miR-29b-3p Sulforaphane modulates microRNA expression in colon cancer cells to implicate the regulation of oncogenes CDC25A, HMGA2 and MYC MiR-29b-3p is predicted to target a number of tumour-suppressing genes, further investigation of which could be informative regarding the potential of sulforaphane to suppress tumour progression molecular function CBC hsa-miR-301a Molecular characterization of exosome-like vesicles from breast cancer cells MCF-Exo contains a higher amount of hsa-miR-301a,and overexpression has been considered a negative prognostic indicator in lymph node-negative (LNN) invasive ductal breast cancer molecular function MFBCE 24468161 hsa-miR-301a MicroRNA-301 mediates proliferation and invasion in human breast cancer MiR-301 as a crucial oncogene in human breast cancer that acts through multiple pathways and mechanisms to promote nodal or distant relapses molecular function CBC 21393507 hsa-miR-301a Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling MiR-301a might be a potential target in breast cancer therapy biomarker CBC 24315818 hsa-miR-301a Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling MiR-301a directly targeted and suppressed PTEN, one negative regulator of the Wnt/β-catenin signaling cascade molecular function CBC 24315818 hsa-miR-301a Elevated miR-301a expression indicates a poor prognosis for breast cancer patients MiR-301a should be considered, and novel therapeutic options are needed to target this aggressive miR-301a-positive type of breast cancer to reduce recurrence and the mortality rate biomarker CBC 29396508 hsa-miR-301a MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer ESR1 as a direct target of miR-301a-3p and suggest that miR-301a-3p likely contributes to development of estrogen independence, which leads to a more invasive phenotype of breast cancer molecular function CBC 29763890 hsa-miR-301a hsa-miR-301a- and SOX10-dependent miRNA-TF-mRNA regulatory circuits in breast cancer Regulatory motifs involving miRNAs and TFs may be useful for understanding breast cancer regulation and for predicting new biomarkers biomarker CBC 30814872 hsa-miR-301a hsa-miR-301a- and SOX10-dependent miRNA-TF-mRNA regulatory circuits in breast cancer The following significant circuits were characterized and validated bioinformatically by using web-based tools: SOX10-sa-miR-301a-OXA3, SOX10-sa-miR-301a-IT, and SOX10-sa-miR-301a-FIB molecular function CBC 30814872 hsa-miR-30a Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs Target gene prediction and pathway analysis showed the involvement of miR-100, miR-222, and miR-30a in pathways implicated in cancer pathogenesis, membrane vesiculation and therapy failure,the transmition of chemoresistance by a horizontal transfer of miRNAs molecular function MFBCE 24740415 hsa-miR-30a MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells MiR30-family regulates the growth of breast cancer cells in non-attachment conditions molecular function CBC 23445407 hsa-miR-30a miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2 MiR-30a/Eya2 axis may play an important role in breast cancer development and progression and that miR-30a activation or Eya2 inhibition may be a useful strategy for cancer treatment molecular function CBC 24508260 hsa-miR-30a The Versatile Role of microRNA-30a in Human Cancer MiR-30a may serve as a potential target in the diagnosis and therapy of human cancer biomarker CBC 28359057 hsa-miR-30a miR-30a inhibits the biological function of breast cancer cells by targeting Notch1 MiR-30a attenuates the development of breast cancer by regulating the expression of the downstream target gene, Notch1 molecular function CBC 28765900 hsa-miR-30a A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness The existence of a novel axis linking p53 to EMT via miR-30a, and adds support to the notion that miRNAs represent key elements of the complex network whereby p53 inactivation affects TNBC clinical behavior molecular function CBC 29666469 hsa-miR-31 hsa-miR-31 shuttled by halofuginone-induced exosomes suppresses MFC-7 cell proliferation by modulating the HDAC2/cell cycle signaling axis Hsa-miR-31 modulates MCF-7 cells growth by specially targeting the histone deacetylase 2 molecular function MFBCE 30916359 hsa-miR-31 A Pleiotropically Acting microRNA, miR-31, Inhibits Breast Cancer Metastasis MiR-31 uses multiple mechanisms to oppose metastasis molecular function CBC 19524507 hsa-miR-31 miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status These results suggest that miR-155 and miR-31 are differentially expressed in breast cancer patients. Their correlation with the clinicopathological characteristics may aid the diagnosis and treatment of invasive intraductal breast cancer biomarker CBC 23162645 hsa-miR-31 A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer This regulation is dependent on the DNA-binding transcription factor ETS-1 which recruits EMSY and the histone demethylase KDM5B to the miR-31 promoter, thus repressing its transcription molecular function CBC 25927669 hsa-miR-31 MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer MiR-31 inhibited TNBC cells migration and invasion through suppressing SATB2 expression molecular function CBC 27593563 hsa-miR-3126-3p Evaluation of Plasma Extracellular Vesicle MicroRNA Signatures for Lung Adenocarcinoma and Granuloma With Monte-Carlo Feature Selection Method In EV, the top 10 discriminative miRNAs were hsa-miR-23b-3p, hsa-miR-548ac, hsa-miR-3126-3p, hsa-miR-15b-5p, hsa-miR-205-5p, hsa-miR-5010-5p, hsa-miR-331-5p, hsa-miR-1249-3p, hsa-miR-548c-5p, and hsa-miR-1827 molecular function CBC 31105742 hsa-miR-3147 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma Serum miR-3147 expression levels can predict metastasis in patients with early-stage cervical squamous cell carcinoma biomarker CBC 23799609 hsa-miR-3147 miR-3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression MiR-3147 may represent a novel potential therapeutic target marker for VSCC. biomarker CBC 29512734 hsa-miR-3147 miR-3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression MiR-3147 may serve an oncogenic role in VSCC by targeting Smad4 molecular function CBC 29512734 hsa-miR-3151-5p MicroRNAs Responsible for Inflammation in Obesity The analysis identified 19 high scoring microRNAs (miR-146, miR-378, miR-143, miR-145, miR-194, miR-1273, miR-190, miR-561, miR-151, miR-215, miR-196, miR-328, miR-208, miR-3155A, miR-933, miR-4685, miR-640, miR-4659, and miR-877) molecular function CBC hsa-miR-3153 Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles Twelve miRNAs were downregulated (miR-10a, miR-135a, miR-299-3p, miR-3126-5p, miR-3153, miR-411, miR-4321, miR-486-5p, miR-505, miR-598, miR-601, miR-939) after antroquinonol treatment molecular function CBC 21185843 hsa-miR-3153 Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI MiRNA microarray of plasma from patients' blood identified 16 differentially expressed miRNAs of which 15 (hsv2-miR-H19, hsa-miR-744-5p, hsa-miR-3196, hsa-miR-3153, hsa-miR-4791, hsa-miR-4803, hsa-miR-4796-3p, hsa-miR-372-5p, hsa-miR-138-2-3p, hsa-miR-16-1-3p, hsa-miR-1469, hsa-miR-585-3p, ebv-miR-BART14-5p, hsa-miR-769-3p, hsa-miR-548aq-5p) were down regulated while only hsa-miR-503-3p was up regulated in primary resistant patients' plasma molecular function CBC 29179454 hsa-miR-3155a MiRNA-3670 and miR-8078 Induce the Apoptosis Mediated by SERPINB5 in Lung Cancers MiRNA-3670 and miR-8078 Induce the Apoptosis Mediated by SERPINB5 in Lung Cancers molecular function CBC hsa-miR-3161 Differential exosomal microRNA profile in the serum of a patient with depression NCBI There were 12 up-regulated miRNAs: hsa-miR-1255a, hsa-miR-3161, hsa-miR-99a-3p, hsa-miR-205-5p, hsa-miR-26a-1-3p, hsa-miR-139-5p, hsa-miR-7849-3p, hsa-miR-195-5p, hsa-miR-125b-2-3p, hsa-miR-664a-3p, hsa-let-7c-5p, and hsa-miR-197-3p. molecular function CBC 29050253 hsa-miR-3161 Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy MiR-200c, miR-429, and miR-4701 were down-regulated, whereas miR-3161, miR-3605-5p, miR-378b, and miR-4451 were up-regulated in the death group compared with those in the alive group molecular function CBC 30103154 hsa-miR-3161 Identification of miR-708-5p in peripheral blood monocytes: Potential marker for postmenopausal osteoporosis in Mexican-Mestizo population We identified six candidate microRNAs: four were up-regulated (miR-708-5p, miR-34b-5p, miR-3161, miR-328-5p), while two were down-regulated (miR-4422 and miR-939-3p) in osteoporotic women molecular function CBC 30322266 hsa-miR-3175 Primary analysis and screening of microRNAs in gastric cancer side population cells There are key miRNAs expressed within the SP cells of the gastric cancer cell line MKN-45, and include hsa-miR-3175, hsa-miR-203, hsa-miR-130a, hsa-miR-324-5p, hsa-miR-34a, and hsa-miR-25-star molecular function CBC 25834316 hsa-miR-3175 Detection of Potential Metastatic Prostate Cancer Circulating Biomarkers by Comparison of miRNA Profiles in DU145 Cells and Culture Medium Three of these miRNA, hsa-miR-4417, hsa-miR-3175, and hsa-miR-6782-5p, exhibit the highest expression and are candidate circulating biomarkers for metastatic activity of prostate cancer. biomarker CBC 28429232 hsa-miR-3176 Exosome-derived microRNAs contribute to prostate cancer chemoresistance The hub AR and PTEN target genes mainly regulated by upregulated miRNAs (hsa-miR-16-5p, -23c, -32-5p, -3915, -5004-5p, -488-3p, -3673 and -3654) and downregulated miRNAs (hsa-miR-3176 and -141-3p) molecular function CBC 27278879 hsa-miR-3176 A microRNA expression signature for clinical response in locally advanced cervical cancer The miRNAs reported here, including miR-3176, miR-3676, miR-502, miR-128, miR-145, miR-651, miR-299, miR-548, and miR-345, are for the first time associated with the development of resistance in LACC patients molecular function CBC 27423381 hsa-miR-3185 MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance MiRNAs -454, -3131 and -3185 are noted for the first time to be deregulated during progression of CRPC molecular function CBC 24387052 hsa-miR-3185 MicroRNAs are part of the regulatory network that controls EGF induced apoptosis, including elements of the JAK/STAT pathway, in A431 cells MiRNAs (miR-663, miR-499-5p, miR-494, miR-602, miR-2861, miR-675 and miR-3185) may have crucial functions in A431 cell apoptosis through a process involving epidermal growth factor (EGF) involvement molecular function CBC 25781916 hsa-miR-3185 microRNA miR-3185 mediated alternative translation initiation of peroxiredoxin 5 mRNA in human breast cancer cells Increase in the oxidation state leads to an increased expression of hsa-miR-3185. Increase amount of miR-3185 leads to an increase in short form of PRDX5 translation from the second AUG perhaps by blocking the translation initiation from the first AUG codon molecular function CBC hsa-miR-3188 miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-PI3K/AKT-c-JUN As a tumour suppressor, miR-3188 directly targets mTOR to stimulate its own expression and participates in FOXO1-mediated repression of cell growth, tumorigenesis and NPC chemotherapy resistance molecular function CBC 27095304 hsa-miR-3188 miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway MiR-3188 may serve as a potential therapeutic agent for the treatment of breast cancer biomarker CBC 28560951 hsa-miR-3188 miR-3188 Regulates Cell Proliferation, Apoptosis, and Migration in Breast Cancer by Targeting TUSC5 and Regulating the p38 MAPK Signaling Pathway MiR-3188 affects breast cancer cell proliferation, apoptosis, and migration by targeting TUSC5 and activating the p38 MAPK signaling pathway molecular function CBC 28560951 hsa-miR-3188 Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma The HBx-miR-3188-ZHX2-Notch1 signaling pathway plays an important role in the pathogenesis and progression of HBV-related HCC with family history of HCC molecular function CBC 28574502 hsa-miR-3188 MiR-3188 Inhibits Non-small Cell Lung Cancer Cell Proliferation Through FOXO1-Mediated mTOR-p-PI3K/AKT-c-JUN Signaling Pathway MiR-3188 interacts with mTOR and FOXO1 to inhibit NSCLC cell proliferation through a mTOR-p-PI3K/AKT-c-JUN signaling pathway molecular function CBC 30618730 hsa-miR-3188 Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression The potential therapeutic value of exosomal miR-3188 for inhibiting HNC growth. molecular function CBC 30961650 hsa-miR-3196 MicroRNA-3196 is inhibited by H2AX phosphorylation and attenuates lung cancer cell apoptosis by downregulating PUM H2AX phosphorylation regulates apoptosis in lung cancer cells via the miR-3196/PUMA pathway molecular function CBC 27780918 hsa-miR-3196 Overexpression of miR-3196 suppresses cell proliferation and induces cell apoptosis through targeting ERBB3 in breast?cancer MiR-3196 can serve as a potential biomarker and therapeutic target for breast cancer biomarker CBC 30556879 hsa-miR-3196 Overexpression of miR-3196 suppresses cell proliferation and induces cell apoptosis through targeting ERBB3 in breast?cancer MiR-3196 was lowly expressed in breast cancer tissues. Overexpression of miR-3196 could repress the proliferation and induce the apoptosis of breast cancer cells via targeting the 3'UTR of ERBB3 molecular function CBC 30556879 hsa-miR-3196 Long noncoding RNA ADPGK-AS1 promotes cell proliferation, migration, and EMT process through regulating miR-3196/OTX1 axis in breast cancer ADPGK-AS1 acted as a competing endogenous RNA (ceRNA) via modulating miR-3196/OTX1 axis in BC molecular function CBC 31264061 hsa-miR-3196 Genome-wide analysis of microRNA signature in lung adenocarcinoma with EGFR exon 19 deletion MicroRNAs associate with EGFR exon 19 deletion and miR-3196 can be further explored for potential predictor and targeted biomarker when it is difficult to get the tumors biomarker CBC hsa-miR-328 Molecular characterization of exosome-like vesicles from breast cancer cells MDA-Exo also contains significant amounts of hsa-miR-328,which has been shown to target CD44,reduce cell adhesion,enhance cell migration and regulate capillary structure formation molecular function MFBCE 24468161 hsa-miR-328 MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells MiR-328 targets ABCG2 3'-UTR and controls ABCG2 protein expression and influences drug disposition in human breast cancer cells molecular function CBC 19270061 hsa-miR-328 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells MiR-519c and -328 have greater impact on ABCG2 expression than miR-520h in MCF-7 human breast cancer cells, and the presence of proximal miR-519c MRE explains the action of miR-519c on shortened ABCG2 3'UTR molecular function CBC 21219875 hsa-miR-328 Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer The prognostic RNAs included PIK3CA, one of the two most frequently mutated genes in IDC, and miRNAs such as hsa-miR-328, hsa-miR-484, and hsa-miR-874 biomarker CBC 23589849 hsa-miR-338-3p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-338-3p miR-338-3p Suppresses Gastric Cancer Progression through a PTEN-AKT Axis by Targeting P-REX2a MiR-338-3p affects gastric cancer progression through PTEN-AKT signaling by targeting P-Rex2a in gastric cancer cells, which posits miR-338-3p as a novel strategy for gastric cancer treatment molecular function CBC 24375644 hsa-miR-338-3p MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4 MiR-338-3p may act as a tumor suppressor in breast cancer by targeting SOX4, suggesting miR?338-3p as a novel strategy for breast cancer treatment molecular function CBC 26252944 hsa-miR-338-3p The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis MiR-338-3p/EYA2 axis contributes to EGFR-mediated tumor growth and lung metastasis and that miR-338-3p activation or EYA2 inhibition or combination therapy targeting EGFR/miR-338-3p/EYA2 axis may be a promising way to treat patients with metastatic cancer molecular function CBC 28703807 hsa-miR-338-3p miR-338-3p inhibits the invasion of renal cell carcinoma by downregulation of ALK5 MiR-338-3p acts as a novel tumor suppressor to inhibit the invasion of RCC by regulating ALK5 expression molecular function CBC 28969055 hsa-miR-338-3p miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells MiR-338-3p acts as a tumor suppressor in prostate cancer by directly targetingRAB23 molecular function CBC 30662812 hsa-miR-340-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-340-5p MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma MiR-340-5p enhanced the sensitivity to CDDP by targeting LPAATβ molecular function CBC 28443990 hsa-miR-340-5p MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3 MiR-340-5p might represent a novel prognostic biomarker and therapeutic target for CRC biomarker CBC 30070320 hsa-miR-340-5p MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3 MiR-340-5p exerted its tumor-suppressive function by directly targeting ANXA3 in CRC molecular function CBC 30070320 hsa-miR-340-5p MicroRNA-340-5p suppresses non-small cell lung cancer cell growth and metastasis by targeting ZNF503 MiR-340-5p inhibits NCI-H1650 cell proliferation and invasion by directly targeting ZNF503 and that miR-340-5p can serve as a potential therapeutic target for treating NSCLC molecular function CBC 31160893 hsa-miR-340-5p miR-340-5p Suppresses Aggressiveness in Glioblastoma Multiforme by Targeting Bcl-w and Sox2 Our novel findings highlight the potential utility of miR-340-5p as a therapeutic agent for glioblastoma multiforme through inhibitory effects on Bcl-w-induced PDGF-A and Sox2 activation molecular function CBC 31272074 hsa-miR-34a Molecular characterization of exosome-like vesicles from breast cancer cells MCF-Exo also contains mir-34a, which regulates several genes including p53 molecular function MFBCE 24468161 hsa-miR-34a MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer MiR-34a expression activation is a marker of aggressive breast tumour phenotype it exerts an independent effect for a lower risk of recurrence or death from breast cancer biomarker CBC 22102859 hsa-miR-34a MicroRNA-34a: a potential therapeutic target in human cancer Early studies have shown that miR-34a acts as a tumor-suppressor gene by targeting many oncogenes related to proliferation, apoptosis and invasion molecular function CBC 25032850 hsa-miR-34a The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis MiR-34a is a promising non-invasive biomarker in diagnosing BC biomarker CBC 28423566 hsa-miR-34a miR-34a directly targets tRNAiMet?precursors and affects cellular proliferation, cell cycle, and apoptosis MiR-34a directly targets tRNAiMet precursors via AGO2-mediated cleavage, and that tRNAiMet functions as an oncogene, potentially representing a target molecule for therapeutic intervention molecular function CBC 29941603 hsa-miR-34a MicroRNA-34 family in breast cancer: from research to therapeutic potential MiR-34s will open new opportunities for the development of novel therapeutic strategies and define a new approach in identifying potential biomarkers for early diagnosis of breast cancer molecular function CBC 30405848 hsa-miR-34a Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women MiR-9 and miR-34a have the capability for distinguishing tumor tissues from healthy tissues and the study of their expression levels in tissue may be used as a biomarker for the diagnosis of breast cancer patients from healthy women biomarker CBC 30468908 hsa-miR-34a MicroRNA 34a suppresses breast cancer cell proliferation and invasion by targeting Notch1 MiR-34a inhibitor transfection resulted in the opposite effects. In conclusion, the presented data indicated that miR-34a suppressed breast cancer cell proliferation and invasion, and its effect may partly be exerted by targeting Notch1 molecular function CBC 30542388 hsa-miR-34a Overexpression of miR-34a and miR-16 Synergistically Promotes Apoptosis in Breast Cancer Cells MiR-16 or miR-34a induced apoptosis individually molecular function CBC hsa-miR-3622a-5p A novel microRNA regulator of prostate cancer epithelial-esenchymal transition Here we provide the first direct evidence that miR-3622a-5p (major form of miR-3622a, referred to as miR-3622a) inhibits PCa EMT, progression and metastasis;we found that miR-3622a directly targets EMT effectors ZEB1 and SNAI2;miR-3622a is a novel PCa biomarker and potential drug target for developing therapeutic regimens against advanced PCa molecular function CBC 28498363 hsa-miR-3622a-5p Aberrantly Expressed Genes and miRNAs in Slow Transit Constipation Based on RNA-Seq Analysis Downregulated expression of hsa-miR-3622a-5p in colon tissue of STC. And adrenoceptor alpha (ADRA1D) was one of target genes of hsa-miR-3622a-5p in STC molecular function CBC 30186855 hsa-miR-3654 Exosome-derived microRNAs contribute to prostate cancer chemoresistance We found that hub hsa-16-5p, hsa-miR-3915, hsa-miR-488-3p, hsa-miR-5004-5p, hsa-miR-23c, hsa-miR-3673, hsa-miR-3654, and hsa-miR-32-5p were potential targets to hub androgen receptor (AR) and phosphatase and tensin homolog (PTEN) molecular function CBC 27278879 hsa-miR-3654 In Silico Identification of Human miR 3654 and its Targets Revealed its Involvement in Prostate Cancer Progression MiR-3654 involved in prostate cancer progression using computational approach and hypothesized that the down regulation of miR-3654 could be responsible for a solid tumor to get cancer stem-like cell phenotype molecular function CBC 27297584 hsa-miR-3663-3p Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi Hsa-miR-3663-3p and -4281 conversely were found upregulated in malignant melanoma molecular function CBC 23111773 hsa-miR-3663-3p MicroRNA expression profiling in placenta and maternal plasma in early pregnancy loss The comparison between EPL and control group samples by microarray and RT-qPCR revealed that miR-125a-3p, miR-3663-3p and miR-575 were significantly upregulated in tissue samples molecular function CBC 29393376 hsa-miR-3667-5p Association of Cigarette Smoking and microRNA Expression in Rectal Cancer: Insight into Tumor Phenotype Eight of the miRNAs (hsa-miR-139-3p, hsa-miR-3667-5p, hsa-miR-425-3p, hsa-miR-4298, hsa-miR-4429, hsa-miR-4481, hsa-miR-4685-5p, and hsa-miR-4783-3p) increased risk of colorectal cancer death among rectal cancer cases with expression increases in carcinoma tissue, and these miRNAs had higher expression in carcinoma tissue with subjects who smoked more pack-years molecular function CBC 27780077 hsa-miR-3690 Alcohol-dysregulated miR-30a and miR-934 in head and neck squamous cell carcinoma MiR-3164 and miR-3690 demonstrate no previous connections to cancer, establishing them as potentially fruitful targets for future investigation molecular function CBC 26472042 hsa-miR-3690 Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas MiR-3690, miR-561 and miR-621 were independent prognostic factors for the liver cancer patients biomarker CBC 30065560 hsa-miR-372 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients The levels of exosomal miR-101 and miR-372 were tumor-specifically increased and higher in breast cancer patients than in healthy women molecular function MFBCE 25333260 hsa-miR-372 Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells Hsa-miR-302b and hsa-miR-372 promote human somatic cell reprogramming molecular function CBC 21490602 hsa-miR-372 miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis MiR-372 suppressed the expression of ATAD2, which was highly expressed in HCC and exerted a proto-oncogene effect in hepatic carcinogenesis molecular function CBC 24552534 hsa-miR-372 Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma MiR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or method to detect and treat HCC in the future molecular function CBC 25880458 hsa-miR-372 miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma MiR-372 seemed to function as a tumour suppressor in renal cell carcinoma progression by inhibiting the IGF2BP1 expression molecular function CBC 26332146 hsa-miR-372 miR-372 promotes breast cancer cell proliferation by directly targeting LATS2 MiR-372 functions as an oncogenic miRNA in breast cancer by targeting LATS2 molecular function CBC 29456685 hsa-miR-372 MicroRNA expression profile in HER2-positive breast cancer patients submitted to neoadjuvant chemotherapy. Mir-135b, mir-372 and mir-520h as potential candidates markers for trastuzumab resistance in HER2-positive breast cancer. biomarker CBC hsa-miR-373 Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis Hsa-miR-373 has significantly up-regulated and has been extensively implicated in cancer progression molecular function MFBCE 25446899 hsa-miR-373 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients In conclusion, our findings suggest cell-free miR-101 and miR-373 as breast cancer-specific markers biomarker BBCE 25333260 hsa-miR-373 The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. MiR-373 and miR-520c stimulated cancer cell migration and invasion in vitro and in vivo, and that certain cancer cell lines depend on endogenous miR-373 activity to migrate efficiently. biomarker CBC 18193036 hsa-miR-373 The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. The migration phenotype of miR-373 and miR-520c can be explained by suppression of CD44,significant upregulation of miR-373 in clinical breast cancer metastasis samples that correlated inversely with CD44 expression. molecular function CBC 18193036 hsa-miR-373 The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Circulating miRNA-10b and miRNA-373 are potential biomarkers for detecting the lymph node status of breast cancer. biomarker CBC 23238818 hsa-miR-373 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Serum levels of exosomal miR-373 are linked to triple negative and more aggressive breast carcinomas. biomarker CBC 25333260 hsa-miR-373 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Overexpression of miR-373 by transfection of MCF-7 cells showed downregulated protein expression of the estrogen receptor, and inhibition of apoptosis induced by camptothecin. Our data indicate that serum levels of exosomal miR-373 are lin molecular function CBC 25333260 hsa-miR-378d Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche Thirteen miRNAs were overexpressed in exosomes from bulk cells: hsa-miR-218-5p, hsa-miR-7-5p, hsa-miR-1290, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-503-5p, hsa-miR-30c-5p, hsa-miR-125b-1, hsa-miR-21-5p, hsa-miR-93-5p, hsa-miR-378c, hsa-miR-378d and hsa-miR-25-3p molecular function CBC 26675257 hsa-miR-378d Genomic characterization of liver metastases from colorectal cancer patients In turn, the CLCA4, CA1, SLC4A4, AQP8, and ZG16 mRNAs together with the miR-215, miR-139, miR-133a, miR-378c and miR-378d miRNAs were those genes showing the strongest down-regulated levels across all primary tumor samples analyzed molecular function CBC 27662660 hsa-miR-378e Identification of microRNA signature and potential pathway targets in prostate cancer The miRNAs 378e and 378i can potentially target homeobox?NKX-3.1?mRNA and inhibit its selective prostate tumor suppressor activity molecular function CBC 27903835 hsa-miR-378e Cancer-associated fibroblasts?release?exosomal?microRNAs that dictate an aggressive phenotype in breast cancer Breast cancer cells exposed to CAF exosomes containing miR-21, miR-378e, and miR-143, exhibited a significantly increased capacity to promote stemness properties, EMT phenotype, and anchorage-independent cell growth molecular function CBC 28121625 hsa-miR-378e Exosomal microRNA: a novel biomarker for breast?cancer MiR-21, miR-378e, miR-143, miR-222, miR-223, miR-16, miR-100, miR-23b, miR-19a and miR-503 from breast stromal cells increased stemness, epithelial-esenchymal transition, brain metastasis, drug resistance, and dormancy and regulated angiogenesis of cancer cells molecular function CBC 29151358 hsa-miR-382 Presence of Circulating hsa-miR-145, hsa-miR-155, and hsa-miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors Our study showed that serum-circulating miR-145, miR-155, and miR-382 are present in exosomes. These miRNAs were previously proposed as noninvasive biomarkers to distinguish between BC patients and healthy individuals biomarker BBCE 30891102 hsa-miR-382 miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma A novel functional pathway controlled by miR-382 and its direct targets, KLF12 and HIPK3, that coordinate tumor growth and chemosensitivity, respectively, in OS. molecular function CBC 25344865 hsa-miR-3922-5p Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple?negative breast cancer: An in silico study A 4 miRNA signature consisting of hsa-miR-148b, hsa-miR-203a, hsa-miR-203b and hsa-miR-3922 was constructed for prediction of prognosis molecular function CBC 30942465 hsa-miR-3922-5p miR-1915-3p inhibits Bcl-2 expression in the development of gastric cancer Previous microRNA microarray results suggest that miR-338-5p, miR-1915-3p, miR-3621, miR-3178 and miR-3196 were down-regulated in MKN-45 cells, whereas the expression of miR-3173-3p, miR-3922-5p and miR-609 were up-regulated molecular function CBC 31036603 hsa-miR-3936 Variation in MicroRNA Expression Profile of Uterine Leiomyoma with Endometrial Cavity Distortion and Endometrial Cavity Non-Distortion The qRT-PCR results showed that miR-1260b, miR-3936, miR-4267, miR-4638-5p, miR-4695-3p, miR-4734, miR-5096, and miR-8603 were significantly up-regulated in LNG-treated cells molecular function CBC ?30149651 hsa-miR-3960 MiR-3960 binding sites with mRNA of human genes MiR-3960 has more than 1000mRNA binding sites with high affinity (with △G/△Gm values greater than or equal to 90%) for 375genes. The miR-3960 has 565 binding sites in the 5'UTRs and 515 sites in theCDS of mRNAs;miR-3960 has binding sites in 73 mRNAs of target genesencoded transcription factors molecular function CBC 25187682 hsa-miR-3960 Runx2/miR-3960/miR-2861 Positive Feedback Loop Is Responsible for Osteogenic Transdifferentiation of Vascular Smooth Muscle Cells Runx2/miR-3960/miR-2861 positive feedback loop plays an important role in osteogenic transdifferentiation of VSMCs and contributes to vascular calcification biomarker CBC 26221600 hsa-miR-3960 Downregulation of long noncoding RNA HOTAIRM1 promotes monocyte/dendritic cell differentiation through competitively binding to endogenous miR-3960 HOTAIRM1 competitively binds to miR-3960 and finally regulates the process of hematopoiesis, which reveals a novel regulatory mechanism of lncRNA function biomarker CBC 28280365 hsa-miR-3960 Circulating miRNA panels for specific and early detection in bladder cancer We found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy biomarker CBC 30382619 hsa-miR-4261 Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins MiR-4261 and miR-298 had seed match with ZNF207 3'-UTR and ILF3 3'-UTR, and in turn, ZNF207 and ILF3 are transcription factors of EZH2 promoter, suggesting that miR-4261 and miR-298 might indirectly regulate the expression of EZH2 through intermediate factors molecular function CBC 25285018 hsa-miR-4261 Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC Inhibition of miR-4261 through targeting of MCC might exert a therapeutic effect for colorectal cancer molecular function CBC 28918036 hsa-miR-4261 Downregulated MEG3 contributes to tumour progression and poor prognosis in oesophagal squamous cell carcinoma by interacting with miR-4261, downregulating DKK2 and activating the Wnt/β-catenin signalling Our study for the first time elaborated the critical role of MEG3-miR-4261-DKK2-Wnt/β-catenin signalling axis in ESCC, and MEG3 could represent a novel diagnostic and prognostic biomarker and therapeutic target in ESCC molecular function CBC 30990378 hsa-miR-4269 Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer We found four putative extended EST sequences that show high similarity to seven additional small RNAs: hsa-mir-1259, hsa-mir-326, hsa-mir-4269, hsa-mir-675, SNORD12, SNORD12B and SNORD12C molecular function CBC 22078386 hsa-miR-4269 TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis The nuclear accumulated TEAD4 and downregulated miR-4269 are proposed to serve as novel prognostic biomarkers in GC biomarker CBC 28759040 hsa-miR-4269 TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis Downregulation of miR-4269 was associated with poor disease-specific survival and showed a negative correlation with TEAD4 molecular function CBC 28759040 hsa-miR-4269 Targeting BTK through microRNA in chronic lymphocytic leukemia A set of six miRNAs predicted to target BTK with high specificity by several algorithms (miR-147b, miR-210, miR-425, miR-1253, miR-4269, and miR-4667-3p) substantially decreased BTK expression in Mec2 cell lines derived from CLL patients molecular function CBC ?27756747 hsa-miR-4271 When the T minor allele is present in the cell, miR-4271 is able to bind to the 3'UTR of APOC3, and this leads to a decreased translation of APOC3 When the T minor allele is present in the cell, miR-4271 is able to bind to the 3'-UTR of APOC3, and this leads to a decreased translation of APOC3 molecular function CBC 28381629 hsa-miR-4277 Identification of chemoresistance-associated miRNAs in breast cancer Expression levels of miR-3617-3p, miR-3136-3p, miR-4277, and miR-92a-1-5p in Bats-72 cell were obviously much higher than the Bcap37 cell, whereas miR-520b was significantly downregulated in the Bats-72 cell? molecular function CBC 30425571 hsa-miR-4278 SNP rs3202538 in 3'UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population Further genotyping was performed to detect the distribution of allele gene of the SNP in our research, among all this SNPs, rs3202538 which can be potentially regulated by miR-204 miR-211 and miR-4278 were in Hardy-Heinberg equilibrium distribution pattern in the healthy control group (P?<?0.0001) molecular function CBC 28924391 hsa-miR-4278 MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma MiR-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma. The appropriate regulation of miR-4728 might be vital to improve BL treatment molecular function CBC ?30108451 hsa-miR-4280 MicroRNA signature of breast cancer brain metastasis for novel targeted therapies The upregulated miRNAs included miR-3927-5p, miR-216b and miR-10b and the down regulated miRNAs were miR-4280, miR-3174 and miR-1244 and miR20b molecular function CBC hsa-miR-4294 MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers MiR-6075, miR-4294, miR-6880-5p, miR-6799-5p, miR-125a-3p, miR-4530, miR-6836-3p, and miR-4476suggested as early diagnostic biomarkers to detect pancreatobiliary cancers biomarker CBC 25706130 hsa-miR-4298 Identification of microRNAs Specifically Expressed in Hepatitis C Virus-Associated Hepatocellular Carcinoma Four (miR-4298, miR-575, miR-33b-3p and mir-610_x) and two (mir-517a_x, miR-21-3p) miRNAs were found to be exclusively expressed by liver donors and normal livers, respectively molecular function CBC 23390000 hsa-miR-4298 MiR-23a in amplified 19p13.13 loci targets metallothionein 2A and promotes growth in gastric cancer cells We identified eight miRNAs (miR-1274a, miR-196b, miR-4298, miR-181c, miR-181d, miR-23a, miR-27a and miR-24-2) that were located in the amplified regions and were upregulated in GC molecular function CBC 23553990 hsa-miR-4298 Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma No significant correlation was found between survival rates (PFS and OS) and the expression levels of miR-451a and miR-4298 in GBM patients biomarker CBC 28931080 hsa-miR-4298 Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma Based on the profiling result of serum miRNAs in GBM patients, we first carried out qRT-PCR on 3 miRNAs (miR-451a, miR-485-3p and miR-4298) in an new cohort (24 GBM patients and 12 healthy volunteers) to validate the microarray data molecular function CBC 28931080 hsa-miR-4324 Identification of circulating microRNA signatures for breast?cancer?detection MicroRNAs that were upregulated (miR-720, miR1274b and miR-1260), or downregulated (miR-30c, miR-376c and miR-4324), in breast cancer tumours will be likely candidates for novel oncomirs or tumor suppressors, respectively molecular function CBC 23797906 hsa-miR-4324 A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p molecular function CBC 30026881 hsa-miR-4440 Genomic characterization of liver metastases from colorectal cancer patients Newly deregulated metastatic transcripts included overexpression of APOA1, HRG, UGT2B4, RBP4 and ADH4 mRNAS and the miR-3180-3p, miR-3197, miR-3178, miR-4793 and miR-4440 miRNAs, together with decreased expression of the IGKV1-39, IGKC, IGKV1-27, FABP4 and MYLK mRNAS and the miR-363, miR-1, miR-143, miR-27b and miR-28-5p miRNAs molecular function CBC 27662660 hsa-miR-4443 miR-4443 Participates in the Malignancy of Breast Cancer MiR-4443 induced malignancy of breast cancer mainly in chemo-resistance aspect for the very first time, providing a novel biomarker in breast cancer diagnosis and therapy biomarker CBC 27504971 hsa-miR-4443 Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells MiR-4443 acts in a tumor-suppressive manner by down-regulating TRAF4 and NCOA1 downstream of MEK-C/EBP-mediated leptin and insulin signaling, and that insulin and/or leptin resistance (e.g. in obesity) may suppress this pathway and increase the risk of metastatic CRC molecular function CBC 27842582 hsa-miR-4443 MicroRNA-4443 Causes CD4+ T Cells Dysfunction by Targeting TNFR-Associated Factor 4 in Graves Disease The increased expression of miR-4443 induced CD4+ T cells dysfunction by targeting TRAF4, which may cause GD molecular function CBC 29163513 hsa-miR-4443 Downregulation of miR-4443 and miR-5195-3p in ovarian cancer tissue contributes to metastasis and tumorigenesis Further investigation can help to suggest miR-4443 and miR-5195-3p as diagnostic biomarkers or therapeutic targets in OC biomarker CBC 30810880 hsa-miR-4443 Downregulation of miR-4443 and miR-5195-3p in ovarian cancer tissue contributes to metastasis and tumorigenesis MiR-4443 and miR-5195-3p may contribute to suppressing tumor, so that decrease in their expression is associated with increased cell proliferation and invasion molecular function CBC 30810880 hsa-miR-4443 CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443 CircASS1 suppresses invasion and migration capacity of BC cells by increasing expression of ASS1 and circASS1 could harbor miR-4443, suggesting that circASS1 could be a potential target in BC treatment and a prospective prognostic biological marker in BC. molecular function CBC hsa-miR-4445-3p miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder?cancer MiR-4324-RACGAP1-STAT3-ESR1 feedback loop could be a critical regulator of BCa progression molecular function CBC 30511377 hsa-miR-4451 Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy Upregulated miR-4451 in HC samples were frequently found and is significantly associated with advanced stage and poor survival of HC, which may indicate an association of this miRNA with the carcinogenesis process in this tumor site; and they could serve as a prognostic biomarker as well as help develop potential new targets for therapy molecular function CBC 30103154 hsa-miR-4462 Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription Meanwhile, some other mitomiRs, including miR-371a-5p, miR-4271, miR-4462, miR-1290, and miR-4449, had no effect on apoptosis in both TSCC cell lines molecular function CBC hsa-miR-4470 Association of cigarette smoking and microRNA expression in rectal cancer: Insight into tumor phenotype Ten miRNAs (hsa-miR-1914-3p, hsa-miR-4327, hsa-miR-4470, hsa-miR-4665-3p, hsa-miR-4673, hsa-miR-548q, hsa-miR-550b-2-5p, hsa-miR-6074, hsa-miR-6165, and hsa-miR-939-5p) were upregulated in tumors of rectal cases of current smokers and the differential expression of these miRNAs was previously shown to be associated with worse survival when expression in carcinoma tissue increased molecular function CBC 27780077 hsa-miR-4497 Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions Comparing miRNA profiles in exosomes derived from melanoma cells grown at high (21%) and low (1%) concentrations of oxygen revealed that 15 miRNAs were significantly more abundant under hypoxic conditions, with miR-494, miR-6087, miR-513a, and miR-4497 being the most dramatically enriched molecular function CBC 29187456 hsa-miR-4497 MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. MiR-4497 may play a suppressive role in LSCC by targeting GBX2, which offer new insights into the tumorigenesis of LSCC molecular function CBC 29843929 hsa-miR-4529-3p miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma MiR-16 as present and miR-4529-3p as absent using qRT-PCR as part of our initial approach to describe the general miRNOME landscape of miRNAs in the on/off state molecular function CBC 28668075 hsa-miR-4539 Expression Profiles of miRNA Subsets Distinguish Human Colorectal Carcinoma and Normal Colonic Mucosa We identified 16 miRNAs for colon and 17 miRNAs for rectal carcinoma that appear to differentiate between carcinoma and normal mucosa; of these, 12 were important for both colon and rectal cancer, hsa-miR-663b, hsa-miR-4539, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-4506, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-145-5p, hsa-miR-3651, hsa-miR-378a-3p, and hsa-miR-378i molecular function CBC 26963002 hsa-miR-4539 Comprehensive circular RNA profiling identifies CircFAM120A as a new biomarker of hypoxic lung adenocarcinoma According to this network, the top six predicted miRNA targets of each differentially expressed circRNAs were hsa-miR-12119, hsa-miR-370-3p, hsa-miR-370-3p, hsa-miR-4539, hsa-miR-6511a-5p, hsa-miR-6772-3p and hsa-miR-9851-3p molecular function CBC 28710406 hsa-miR-4656 Identification of dysregulated miRNAs and their regulatory signature in glioma patients using the partial least squares method The expression levels of hsa-miR-1908, hsa-miR-4656 and hsa-miR-4680 have been identified to significantly correlate with the survival rate biomarker CBC 25452796 hsa-miR-4656 Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets The most downregulated target mRNA was TSPAN7, a putative target of miR-4656 molecular function CBC 27027350 hsa-miR-4656 MicroRNA-4656 is a prognostic factor and tumor suppressor in human pancreatic cancer through a downstream target of TrkA MiR-4656 is expressed to a low extent and is a potential biomarker in PC biomarker CBC 27936486 hsa-miR-4656 MicroRNA-4656 is a prognostic factor and tumor suppressor in human pancreatic cancer through a downstream target of TrkA Overexpressing miR-4656 has tumor suppressive effects on PC development both in vitro and in vivo, likely through its downstream target of the TrkA gene molecular function CBC 27936486 hsa-miR-466 A New MicroRNA Expression Signature for Cervical Cancer The aberrant expression of miR-466 is closely associated with the occurrence and development of cervical cancer biomarker CBC 27870701 hsa-miR-466 MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2 MiR-466-mediated attenuation of RUNX2 as a novel therapeutic approach to regulate PCa growth, particularly metastasis to bone molecular function CBC 28125091 hsa-miR-466 MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC) MiR-466 functions as a suppressor miRNA in CRC and may be used as a prognostic factor in these patients biomarker CBC 29338680 hsa-miR-466 MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC) MiR-466 suppressed cell proliferation and migration/invasion, as well as induced G0/G1 arrest and apoptosis in SW-620 cells molecular function CBC 29338680 hsa-miR-466 CREB1 induced lncRNA HAS2-AS1 promotes epithelial ovarian cancer proliferation and invasion via the miR-466/RUNX2 axis The CREB1/HAS2-AS1/miR-466/RUNX2 axis in the in the EOC tumorigenesis, providing the novel insight for the molecular mechanism of EOC molecular function CBC 31082772 hsa-miR-466 HPV E6/E7 oncoprotein promotes cervical cancer by promoting miR-466 expression via P53 pathway HPV E6/E7 oncoprotein probably promotes miRNA-466 expression via P53 pathway molecular function CBC hsa-miR-4669 Novel circulating microRNAs expression profile in colon cancer: a pilot study Clinical analysis of miR-31, miR-141, miR-224-3p, miR-576-5p, and miR-4669 expression in patients with colon cancer may facilitate the diagnosis of colon cancer biomarker CBC 29187262 hsa-miR-4674 Cell-specific post-transcriptional regulation of γ-synuclein gene by micro-RNAs Expression of miR-4437 and miR-4674 for which putative targets in 3'-UTR were predicted caused a 61.2% and 60.1% reduction of endogenous γ-synuclein expression confirming their role in gene expression regulation molecular function CBC 24040069 hsa-miR-4674 MicroRNA hsa-miR-4674 in Hemolysis-Free Blood Plasma Is Associated with Distant Metastases of Prostatic Cancer The metastatic form of prostatic cancer was found to be associated with increased levels of hsa-miR-22-3p, hsa-miR-663a, and hsa-miR-4674 in comparison with non-metastatic form. Common candidate target genes of these microRNA include JUNB, KMT2A, and XPO6 molecular function CBC 27265126 hsa-miR-4674 miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death We found that the 8p23.3 locus contains not only miR-596, but also miR-4674 and miR-7160 molecular function CBC 29183729 hsa-miR-4684-3p Genetic variants in the TGFβ-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue MiR-4684-3p was upregulated in the variant allele of NFκB1 rs230510 while downregulated in the presences of the variant allele of NFκB1 rs3821958 molecular function CBC 28061442 hsa-miR-4689 Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer MiR-4689 may be a promising therapeutic agent in mutant KRAS CRC biomarker CBC 25756961 hsa-miR-4689 Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer Mutant KRAS functions as a broad regulator of the EGFR signaling cascade by inhibiting miR-4689, which negatively regulates both RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways molecular function CBC 25756961 hsa-miR-4689 Serum microRNA microarray analysis identifies miR-4429 and miR-4689 are potential diagnostic biomarkers for biliary atresia Differentially expressed miRNAs including hsa-miR-4429 and hsa-miR-4689 might play critical roles in BA by regulating their target genes, and these two miRNAs may have the potential to become diagnostic biomarkers biomarker CBC 26879603 hsa-miR-4692 The Pharmacological Effects of Spatholobi Caulis Tannin in Cervical Cancer and Its Precise Therapeutic Effect on Related circRNA. The RegRNA analysis led to the following predictions: circE2F3 binds hsa-miR-211-5p, hsa-miR-4459, hsa-miR-3960, hsa-miR-4632, hsa-miR-4739, and hsa-miR-5006-3p and circFANCB binds hsa-miR-4692 molecular function CBC 31194163 hsa-miR-4716-3p The Sequence and Structure Determine the Function of Mature Human miRNAs MiR-4290, miR-1281, miR-4716-5p, miR-483-3p and miR-877-3p containing almost only UC nucleotides and miR-6124, miR-483-5p, miR-4271, miR-4644, miR-4716-3p and miR-1234-5p purine-rich molecular function CBC 27031951 hsa-miR-4723-5p Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development We found that expression of 19 miRNAs, most strongly miR-4723-5p, was significantly correlated with the 6-min walk distance following adjustment for multiple testing molecular function CBC 29981854 hsa-miR-4723-5p MicroRNA 4723-5p is novel tumor suppressor microRNA in prostate cancer that directly regulates Abelson family of nonreceptor protein tyrosine kinases MiR-4723-5p may be an attractive target for therapeutic intervention in prostate cancer biomarker CBC hsa-miR-4726-5p Circular RNA Expression Profile in Laryngeal Squamous Cell Carcinoma Revealed by Microarray Competitive endogenous RNA network prediction and bioinformatics functional analysis revealed that hsa_circ_0044520 and hsa_circ_0044529 play important regulatory roles by sponging hsa-miR-4726-5p and hsa-miR-4640-5p, thereby providing novel insights into the tumorigenesis of LSCC molecular function CBC 30282067 hsa-miR-4732-5p miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion MiR-144-3p, miR-451a, miR-4732-3p and miR-4732-5p inhibited cell migration molecular function CBC 21199797 hsa-miR-4732-5p Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the?ERBB2/Her2?Gene Two of the 5, miR-3150b-3p and miR-4732-5p, were not detected in any other tissue, suggesting that they may be specific to breast molecular function CBC 21199797 hsa-miR-4732-5p Overlapping region of p53/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p By binding with the 5'-untranslated region of WRAP53, hsa-miR-4732-5p promoted breast cancer progression molecular function CBC 23886136 hsa-miR-4732-5p Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy MiR-92b, miR?422a, miR-4732-5p and miR-4758-3p are closely associated with relapse following S-1 adjuvant chemotherapy in gastric cancer molecular function CBC 24317477 hsa-miR-4732-5p Bioinformatics analysis of dysregulated microRNAs in the nipple discharge of patients with breast cancer The predicted target genes of miR-3646, -4484 and -4732-5p were identified to serve a role in cancer-associated signaling pathways and TF-mRNA networks, indicating that they serve a role in breast carcinogenesis and progression molecular function CBC 28521415 hsa-miR-4732-5p miR-732-p promotes breast cancer progression by targeting TSPAN13 MiR-4732-5p may serve as a tumour suppressor in the initiation of breast cancer, but as a tumour promoter in breast cancer progression by targeting TSPAN13 molecular function CBC 30701690 hsa-miR-4745-5p Novel miRNAs as potential biomarkers in stage II colon cancer: microarray analysis Of 32 identified miRNAs, an increase in three microRNAs (hsa-miR-4745-5p, hsa-miR-6126, and hsa-miR-1469) was observed in tumor tissues relative to that in control tissues molecular function CBC 31123908 hsa-miR-4778-5p miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers MiR-4778-5p, miR-4433, miR-5010-5p, miR-1287, miR-663b, and miR-4688 (up-regulated in BRCA2-associated breast carcinomas compared to their normal counterparts, and not consequently deregulated in sporadic breast carcinomas); molecular function CBC 26378051 hsa-miR-4790-3p Identification of microRNA signature and potential pathway targets in prostate cancer The endogenous levels of miR-30d-5p, 603, 363-3p, 3120, 1299, let-7b-5p, and 200a-3p were found to be downregulated, whereas those of miR-4790-3p, 1305, 19a-3p, and 548 were found to be upregulated in C4-2B cells compared to RWPE-1 cells molecular function CBC ?27903835 hsa-miR-486-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-486-5p MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells MiR-486-5p/PIM-1 axis provides insight into the pathogenesis of BC and might be therapeutic targets for prevention or treatment of BC molecular function CBC 25104088 hsa-miR-486-5p Down-regulated miR-486-5p acts as a tumor suppressor in breast cancer patients by targeting the metastatic mediator ICAM-1 MiR-486-5p decreases the metastatic property of ICAM-1. In addition, miR-486-5p acts as a tumor suppressor in BC;increasing the levels of the under-expressed miR-486-5p in TNBC tissues can be a possible therapeutic approach for halting BC progression molecular function CBC 27882172 hsa-miR-486-5p S-Adenosylmethionine regulates apoptosis and autophagy in MCF-7 breast cancer cells through the modulation of specific microRNAs MiR-486-5p inhibitor induces autophagy and enhances AdoMet-induced autophagic process by increasing PTEN expression and by inhibiting AKT signaling molecular function CBC 30533999 hsa-miR-486-5p MiR-486-5p prevents migration, invasion and EMT by regulating Smad2 in breast cancer MiR-486-5p may represent as a new treatment target and prognostic marker for breast cancer biomarker CBC hsa-miR-5001-5p Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer 15 specific plasma miRNAs, let-7d-3p,miR-106b-5p,miR-144-3p,miR-197-3p,miR-19b3p, miR-211-3p, miR-30e-5p, miR-345-3p, miR-3679-3p, miR-423-5p, miR-451a, miR-4787-5p, miR-5001-5p, miR5100 and miR-6068, could be promising biomarkers of lung squamous cell carcinoma, and nine specific plasma miRNA biomarker CBC 27148421 hsa-miR-5001-5p Identification of MicroRNAs Involved in Growth Arrest and Apoptosis in Hydrogen Peroxide-Treated Human Hepatocellular Carcinoma Cell Line HepG2 The top six miRNAs were hsa-miR-4763-3p, hsa-miR-149-3p, hsa-miR-762, hsa-miR-5001-5p, hsa-miR-5787, and hsa-miR-6791-5p, while the top six target genes were CPLX2, ZNF385A, NFIX, CNIH2, SOX12, and WDTC1 molecular function CBC 27597883 hsa-miR-503 Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer Our data are the first to reveal the involvement of the endothelium in the modulation of tumor development via the secretion of circulating miR-503 in response to chemotherapy treatment molecular function MFBCE 25860935 hsa-miR-503 miR-503 represses human cell proliferation and directly targets the oncogene DDHD2 by non-canonical target pairing MiR-503 may act as a tumor suppressor in breast cancer by its direct non-canonical targeting of DDHD2 molecular function CBC 25653011 hsa-miR-503 MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression Our findings provide new knowledge regarding the role of miR-503 in the progression of breast cancer and indicate the role of miR-503 as a tumor suppressor microRNA (miRNA) in breast cancer molecular function CBC 26047605 hsa-miR-503 miR-503-3p promotes epithelial-mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin Our findings support a critical role for miR-503-3p in induction of breast cancer EMT and suggest that plasma miR-503-3p may be a useful diagnostic biomarker for breast cancer biomarker CBC 28161325 hsa-miR-503 miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy MiR-424(322)/503 as a tumor suppressor in breast cancer and provide a link between mammary epithelial involution, tumorigenesis, and the phenomenon of chemoresistance molecular function CBC 28404630 hsa-miR-5088-5p MiR-630 acts as a tumor suppressor in cervical cancer and inhibits epithelial-mesenchymal transition in cervical cancer 8 miRNAs genes including miR-5194, miR-5088-5p, miR-192- 5p, miR-331-5p, miR-183-3p were down-regulated in both cell lines molecular function CBC hsa-miR-5091 Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma MiR-5091, miR-513b are promising biomarkers for NPC diagnosis molecular function CBC 31159814 hsa-miR-5091 Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy The following 11 prognostic miRNAs were used for the construction of the prognostic signature: hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421 molecular function CBC ?30127641 hsa-miR-5091 Profiling of plasma circulating miRNA in coronary heart disease patients detected by next-generation small RNA sequencing Five miRNAs were differentially expressed, miR-30c-2-3p and miR-5091 were upregulated and miR-125b-5p, miR501-3p, and miR-31-5p downregulated in plasma of patients with coronary heart disease than in controls molecular function CBC hsa-miR-583 Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B MiR-583 and miR-663 may be potential markers for ZHENG differentiation in CHB;ROC curve analysis revealed that miR-583 and miR-663 were sensitive and specific enough to distinguish LGDHS from LKYDS biomarker CBC 23554832 hsa-miR-593-5p Regulation of cell proliferation and metastasis by microRNA-593-5p in human gastric cancer MiR-593-5p inhibited cell proliferation, migration, and invasion and also arrested cell cycle at the G0/G1 phase in SGC-7901 and MGC-803 cells in vitro molecular function CBC 30425531 hsa-miR-595 Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression IL-22 induces miR-595 expression in papillary thyroid carcinoma, which, in turn, promotes migration and invasion by targeting Sox17, a member of the SRY-related?high-mobility group?(HMG)-box transcription factor superfamily that modulates proliferation, differentiation, migration and invasion in cancers molecular function CBC 25106407 hsa-miR-595 Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC Circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment biomarker CBC 26509672 hsa-miR-595 MiR-595 targeting regulation of SOX7 expression promoted cell proliferation of human glioblastoma MiR-595 expression was significantly upregulated could promote cell proliferation by targeting SOX7 molecular function CBC 27133048 hsa-miR-595 Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer MiR-595 expression might be a novel potential prognostic biomarker for EOC biomarker CBC 29077170 hsa-miR-595 MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1 MiR-595 acted a tumor suppressor role in ovarian cancer development and increased the sensitivity of ovarian cancer to cisplatin molecular function CBC ?27893429 hsa-miR-605-3p Identification of colorectal cancer-restricted microRNAs and their target genes based on high-throughput sequencing data A total of eight common miRNAs (miRNA-1, miRNA-1265, miRNA-133a-3p, miRNA-133a-5p, miRNA-133b, miRNA-338-3p, miRNA-497-5p, and miRNA-605-3p) were found in tumor and metastasis tissues compared with normal tissues molecular function CBC 27069368 hsa-miR-605-3p Circular RNA circ-VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR-605-3p/VANGL1 pathway Our study demonstrated circ-VANGL1/miR-605-3p/VANGL1 as a novel essential signaling pathway involved in BC progression molecular function CBC 30146736 hsa-miR-6068 Urinary exosomal miRNA signature in type II diabetic nephropathy patients Sixteen urinary exosomal miRNAs were reported to be differentially regulated in a small cohort of T2DKD compared to healthy controls, although only two miRNAs were validated in subsequent replication (miR-320c and miR-6068) molecular function CBC 26930277 hsa-miR-6068 Exosomal transfer of tumor-associated macrophage derived miR-6068 promote ovarian cancer progression MiR-6068 has an oncogenic role in ovarian cancer progression by targeting PTPN4 and may be a novel effective therapeutic target for ovarian cancer molecular function CBC hsa-miR-6090 Discovery and Characterization of Novel MicroRNAs During Endothelial Differentiation of Human Embryonic Stem Cells The expression of 5 miRNAs, specifically hsa-miR-6086, hsa-miR-6087, hsa-miR-6088, hsa-miR-6089 and hsa-miR-6090, were specifically downregulated during endothelial differentiation of human ES cells molecular function CBC 22142236 hsa-miR-6090 Serum MicroRNA-Based Risk Prediction for Stroke MiR-1228-5p, miR-1268a, miR-1268b, miR-4433b-3p, miR-6090, miR-6752-5p, and miR-6803-5p could predict the risk of cerebrovascular disorder before the onset of stroke biomarker CBC 31136284 hsa-miR-6090 MicroRNA profiling of peripheral blood enriched for circulating tumor cells (CTCs) in testicular germ cell tumors (TGCTs) MicroRNA expression profiling of PB enriched for CTCs in TGCTs is feasible, and show great promise in identifying new therapeutic targets and gene expression signature associated with treatment resistance molecular function CBC hsa-miR-6126 Ubiquitous Release Of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells MiR-6126 inhibition promoted oncogenic behavior by leading ovarian cancer cells to release more exosomes molecular function CBC 27742688 hsa-miR-615-3p miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma MiR-615-3p in DTCs may play an important role in postoperative HCC recurrence, which suggests that?miR-615-3p?is a potential target molecule for regulating postoperative HCC recurrence molecular function CBC 26137255 hsa-miR-615-3p Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade A negative correlation between miR-615-3p levels and IGF2 has been identified in NSCLC specimens, with IGF2/IGFR1 interaction acting as a mediator of metastasis in several types of tumors molecular function CBC 26429980 hsa-miR-615-3p Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54) biomarker CBC 28969022 hsa-miR-615-3p miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer MiR-615-3p promotes gastric cancer proliferation and migration by suppressing CELF2 expression for the first time, providing clues for future clinical practices molecular function CBC 29501762 hsa-miR-615-3p MicroRNA 615-3p Inhibits the Tumor Growth and Metastasis of NSCLC via Inhibiting IGF2 MiR-615-3p played important roles in the regulation of NSCLC growth and metastasis by targeting IGF2 molecular function CBC 29562959 hsa-miR-615-3p Identification of microRNA-615-3p as a novel tumor suppressor in non-small cell lung cancer MiR-615-3p functions as a tumor suppressor in NSCLC, and may be a novel potential molecular therapeutic target for patients with NSCLC;The results revealed that overexpressed miR-615-3p markedly inhibited cell proliferation and colony formation in the 3 NSCLC cell lines compared with the cells overexpressing the negative control sequence (NC). Additional investigation revealed that miR-615-3p overexpression significantly induced apoptosis and cell cycle arrest at the G1 phase in the A549, H1299 and H1650 cell lines compared with the cells overexpressing NC. Finally, ectopic expression of miR-615-3p was found to repress the cell migration and invasion of the 3 lung cancer cell lines molecular function CBC ?28454411 hsa-miR-6165 Experimental Verification of a Predicted Intronic MicroRNA in Human NGFR Gene with a Potential Pro-Apoptotic Function Some of the previously attributed functions of NGFR could be explained indirectly by co-transcription of mir-6165 in the cells. molecular function CBC 22558167 hsa-miR-6165 Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers MiR-6165 functions on its target genes, including neural stem cell-derived dendrite regulator (DAGLA) and Polycistin-1 (PKD1), but not on any p75NTR downstream pathways molecular function CBC 25544363 hsa-miR-638 miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy That serum miR-638 levels are associated with the survival of NSCLC patients and may be considered a potential independent predictor for NSCLC prognosis biomarker CBC 25952770 hsa-miR-638 MiR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival MiR-146a and miR-638 are potential biomarkers for improved overall survival in patients with BRCA1-deficient TNBC tumors biomarker CBC 26835710 hsa-miR-638 MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3 Our data in clinical tissue samples highlight miR-638 and?DACT3?as histological marker for cancer detection and their potentially therapeutic implications biomarker CBC 28108314 hsa-miR-638 MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients MiR-638 might serve as a tumor suppressor. In the future, miR-638 might be regarded as a therapeutic target and a potential prognostic factor in human CC biomarker CBC 29271990 hsa-miR-638 MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients In vitro assay showed that miR-638 overexpression suppressed cell migration and invasion of HeLa cells. The results of Western blot indicated that over-expression of miR-638 inhibited the activation of Wnt/β-catenin signaling pathway. molecular function CBC 29271990 hsa-miR-638 MiR-638 acts as a tumor suppressor gene in gastric cancer In the cell lines, aberrant expression of miR-638 was related to the cell proliferation, cell cycle and invasion. We also found that SOX2 had a negative correlation with miR-638 in GC tissues, and miR-638 overexpression could decrease SOX2 expression level by directly binding the 3'-UTR of SOX2.in vitro, down-regulating SOX2 by siRNA could counteract the effect of miR-638 inhibitor on GC cells proliferation and invasion molecular function CBC 29296232 hsa-miR-638 Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients The miR-638 could be considered as an independent prognostic factor for the patients (HR =0.321, 95% CI =0.117-0.882, P=0.027) biomarker CBC 30349320 hsa-miR-638 Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients Downregulation of miR-638 was capable of promoting cell proliferation, migration, and invasion in MDA-MB-231 and MCF-7 cells molecular function CBC 30349320 hsa-miR-638 miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2 MiR-638 represses the characteristics and behaviors of BCSCs by targeting E2F2. MiR-638 may be a potential target for breast cancer therapy molecular function CBC 31410735 hsa-miR-638 Exosomes released from pancreatic cancer cells are heterogeneous particle populations Exosomes form heterogeneous particle populations and nSMase2 may be involved in the exosomal uptake of miR-638 molecular function CBC hsa-miR-639 miR-639 promotes the proliferation and invasion of breast cancer cell in vitro A key role of miR-639 in breast cancer metastasis and support biological and clinical links between miR-639 and breast cancer. molecular function CBC 24917697 hsa-miR-639 miR-639 is differentially expressed in NPC tissues of varying cancer stages, and suggests that quantifying circulating miR-639 may be of importance for non-invasive diagnosis and prognostic evaluation, and may have potential therapeutic utility MiR-639 upregulation was associated with development of TC, miR-639 promoted cell proliferation and cell cycle by targeting CDKN1A in TC. molecular function CBC 27829546 hsa-miR-639 miR-639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma MiR-639 is differentially expressed in NPC tissues of varying cancer stages, and suggests that quantifying circulating miR-639 may be of importance for non-invasive diagnosis and prognostic evaluation, and may have potential therapeutic utility molecular function CBC ?30546422 hsa-miR-639 MiR-10b, miR-133a, miR-155 and miR-639 as non-invasive potential biomarkers in breast cancer MiR-10b, miR-133a, miR-155 and miR-639 have a significant signature in the pathogenesis of breast cancer and can be used as non-invasive molecular biomarkers for breast cancer detection. biomarker CBC hsa-miR-664b-5p PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer MiR-664b-5p functions as a tumour suppressor and has an important role in the regulation of PARP inhibitors to increase chemosensitivity by targeting CCNE2 molecular function CBC 28176879 hsa-miR-6727-5p Influence of hsa-miR-6727-5p on the proliferation, apoptosis, invasion and migration of Caski, Hela and SiHa cervical cancer cells Hsa-miR-6727-5p promoted the proliferation, invasion and migration of cervical cancer cells and inhibited the apoptosis through the overexpression or inhibition of hsa-miR-6727-5p molecular function CBC 28952216 hsa-miR-6727-5p High-throughput sequencing of circRNAs reveals novel insights into mechanisms of nigericin in pancreatic cancer For example, the up-regulated circRNA_06429 had the potential biding sites of miR-1307-3p, miR-5002-3p, miR-6727-5p and miR-744-5p simultaneously molecular function CBC 31533620 hsa-miR-6734-5p miR-6734 Up-Regulates p21 Gene Expression and Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Cells MiR-6734 inhibits the growth of colon cancer cells by up-regulating p21 gene expression and subsequent induction of cell cycle arrest and apoptosis, suggesting its role as an important endogenous regulator of cancer cell proliferation and survival molecular function CBC 27509128 hsa-miR-6738-5p Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples The hsa-miR-200b-3p expression levels progressively increased whereas those of hsa-miR-6738-5p gradually decreased going from the healthy to the adenoma to the CRC group molecular function CBC 31530647 hsa-miR-6778-5p CircRNA CBL.11 suppresses cell proliferation by sponging miR-6778-5p in colorectal?cancer CircRNA CBL.11 was increased in CRC cells and could function as a competing endogenous RNA (ceRNA) to regulate YWHAE expression by sponging miR-6778-5p, resulting in regulation the proliferation of CRC cells molecular function CBC 31438886 hsa-miR-6797-5p Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p MiR-6797-5p controls osteoblast differentiation by targeting Runx2 expression molecular function CBC 30562548 hsa-miR-6805-5p Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen MiR-6805-5p, miR-584-5p, miR-1228-5p, miR-501-5p, and miR-668-5p were also strongly up-regulated in other PR-A-Positive cell lines, including parental T47D cells, BT474 cells, and ZR-75-1 cells molecular function CBC 29162724 hsa-miR-6875-5p Novel combination of serum microRNA for detecting breast cancer in the early stage MiRNA expressions were compared between patients with breast cancer and non-Breast cancer, and a combination of five miRNA (miR-246, miR-307-p, miR-634, miR-861-p and miR-875-p) was found to be able to detect breast cancer biomarker CBC 26749252 hsa-miR-6875-5p MicroRNA-6826 and 6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer Although further clarification is needed regarding the functions of miR-6826 and miR-6875 and their relationship to immune-related molecules, plasma miR-6826 and miR-6875 may be useful negative biomarkers for predicting the efficacy of vaccine treatment biomarker CBC 27878288 hsa-miR-6875-5p Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery Using microarray analysis, we successfully identified six specific miRNAs (miR-1225-3p, miR-1234-3p, miR1260b, miR-1470, miR-6834-3p, and miR-6875-5p) associated with recurrence and prognosis of BTC after radical surgery biomarker CBC 30976046 hsa-miR-6882-3p Circular RNA Expression Profile and Analysis of Their Potential Function in Psoriasis The top five MREs of hsa_circ_0061012 were hsa-miR-7157-5p, hsa-miR-4769-3p, hsa-miR-6817-5p, hsa-miR-4310, and hsa-miR-6882-3 molecular function CBC 30278433 hsa-miR-720 MicroRNAs are exported from malignant cells in customized particles Hsa-miR-720 is characterized by excessive release from breast cancer cells while retaining relatively low concentrations of miRNA in the cells and could be used to detect the presence of malignant cells in the body molecular function MFBCE 22772984 hsa-miR-720 miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1 MiR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1 biomarker CBC 24085799 hsa-miR-720 miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1 MiR-720 is frequently decreased in breast cancer and manifests antimetastatic activity by downregulating TWIST1, presenting a novel mechanism of miRNA-mediated regulation of tumor metastasis molecular function CBC 24085799 hsa-miR-720 miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells Hsa-miR-720 promise as a biomarker for early detection of or treatment response of ADAM8-positive TNBC biomarker CBC 27039296 hsa-miR-720 miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells MiR-720 is elevated in serum of patients with ADAM8-high TNBC and, in a group with other miRNAs downstream of ADAM8 molecular function CBC 27039296 hsa-miR-7-2-3p A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas The identified two-miR-classifier combining miR-486-5p and miR-7-2-3p had the accuracy of 62%, sensitivity of 82.1%, and specificity of 48.8% molecular function CBC 25258301 hsa-miR-7-2-3p Integrative microRNA-mRNA and protein-protein interaction analysis in pancreatic neuroendocrine tumors In the miRNA-target gene regulatory network, hsa-miR-7-2-3p demonstrated the highest connectivities whereas KLF12 was the mRNAs with the highest connectivities. It suggested that hsamiR-7-2-3p and KLF12 may affect the tumorigenesis of pancreatic cancer molecular function CBC 27424984 hsa-miR-760 miRNA expression patterns in chemoresistant breast cancer tissues MiR-760 might be biomarkers for the prognosis of breast cancer chemoresistance biomarker CBC 25451164 hsa-miR-760 miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells MiR-760 modulated chemoresistance through the epithelial-mesenchymal transition in breast cancer cells, providing a potential therapeutic target for treatment of drug-resistant breast cancer molecular function CBC 27981531 hsa-miR-760 The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study Serum level of miR-92a, miR-375, and miR-760 may serve as biomarkers of colorectal cancer in Egyptian patients with high diagnostic power for miR-760 and high prognostic power for miR-92a molecular function CBC 28618945 hsa-miR-760 MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling MiR-760 inhibited CRC growth by downregulating BATF3/AP-1/ cyclinD1 signaling molecular function CBC 29661228 hsa-miR-760 MiR-760 enhances TRAIL sensitivity in non-small cell lung cancer via targeting the protein FOXA1 MiR-760 should be considered as a tumor suppressor since it negatively regulates the oncogene protein FOXA1 and regulated TRAIL sensitivity in NSCLC cells molecular function CBC 29665655 hsa-miR-7704 Human adipose mesenchymal stem cell-derived exosomal-miRNAs are critical factors for inducing antiproliferation signalling to A2780 and SKOV-3 ovarian cancer cells Several other miRNAs which belong to top 20 known exosomal miRNAs, have not been extensively investigated for their oncogene regulatory properties; these miRNAs include hsa-miR-7704, hsa-miR-6087, hsa-miR-22-3p, hsa-miR-4466, hsa-miR-4532, hsa-miR-7641, hsa-miR-4448, hsa-miR-3960, and hsa-miR-3687 molecular function CBC 27929108 hsa-miR-7704 Infection of Epstein-barr Virus in Type III Latency Modulates Biogenesis of Exosomes and the Expression Profile of Exosomal miRNAs in the Burkitt Lymphoma Mutu Cell Lines MiR-7704 is upregulated in macrophages treated with a combination of interleukin-27 (IL-27) and macrophage colony stimulating factor. molecular function CBC 30029522 hsa-miR-7704 Small RNA sequences derived from pre-microRNAs in the supraspliceosome? Nuclear miR-7704 negatively regulates the expression of the lincRNA HAGLR molecular function CBC 30203035 hsa-miR-8064 OCT4B1 Promoted EMT and Regulated the Self-renewal of Cancer Stem Cells (CSCs) in Colorectal Cancer: Effects Associated with the Balance of miR-8064/PLK1 OCT4B1 may be involved in regulating the self-renewal of colorectal CSCs through EMT, which is at least partially due to the miR-8064/PLK1 balance. This study indicates that OCT4B1 is a potential therapeutic target for CRC by targeting CSCs molecular function CBC hsa-miR-8078 MicroRNA Expression Profile on Solid Subtype of Invasive Lung Adenocarcinoma Reveals a Panel of Four miRNAs to Be Associated with Poor Prognosis in Chinese Patients There are also novel, differentially expressed miRNAs that had never before been identified as differentially expressed associated in malignancy, including miR-629.5p, miR-4428, miR-4647, and miR-8078 molecular function CBC 27698898 hsa-miR-93-5p Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence biomarker BBCE 29050253 hsa-miR-93-5p miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1 Further in vivo studies are required to ascertain the miR-93-WNK1-metastasis cascade, that has potential implications in breast cancer therapy molecular function CBC 27840899 hsa-miR-93-5p MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3 MiR-93-5p regulates MKL-1 and STAT3 to affect EMT controlling breast cancer cell migration molecular function CBC 28499590 hsa-miR-93-5p MicroRNA-93 promotes proliferation and metastasis of gastric cancer via targeting TIMP2 MiR-93 might be a promising biomarker and therapeutic target for treatment of gastric cancer biomarker CBC 29220395 hsa-miR-93-5p MicroRNA-93 promotes proliferation and metastasis of gastric cancer via targeting TIMP2 MiR-93 serves as a tumor promoter in human gastric carcinogenesis by targeting TIMP2 molecular function CBC 29220395 hsa-miR-93-5p miR-93-5p Transferred by Exosomes Promotes the Proliferation of Esophageal Cancer Cells?via?Intercellular Communication by Targeting PTEN Upregulation of plasma miR-93-5p expression significantly increases the risk of esophageal cancer and is associated with poor prognosis biomarker CBC 29673440 hsa-miR-93-5p miR-93-5p Transferred by Exosomes Promotes the Proliferation of Esophageal Cancer Cells?via?Intercellular Communication by Targeting PTEN MiR-93-5p transferred by exosomes promotes the proliferation of recipient esophageal cancer cells and affects the expression of PTEN and its downstream proteins p21 and cyclin D1 molecular function CBC 29673440 hsa-miR-93-5p miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L. MiR-93 promotes LACC cell migration, invasion, and proliferation via targeting downregulation of BRMS1L through regulation of Wnt signaling pathway molecular function CBC 29760585 hsa-miR-937-5p miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers MiR-3676-5p and miR-937-5p (up-regulated in BRCA1/2- associated breast carcinomas and not deregulated in sporadic breast carcinomas) molecular function CBC 26378051 hsa-miR-937-5p miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression Hsa-miR-937-5p was downregulated in our RTHF-treated A549 cells, and it has been observed to be highly expressed in paclitaxel-resistant A549 cells molecular function CBC 28487996 hsa-miR-939 Breast cancer-secreted hsa-miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers Hsa-miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers and an extracellular tumorigenic effect molecular function MFBCE 27693459 hsa-miR-939 Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC In the validation set, miR-939, miR-595 and miR-519d were shown to differentiate cirrhotic patients with and without HCC. MiR-939 and miR-595 are independent factors for HCC. ROC curves of miR-939, miR-595 and miR-519d displayed that AUC was higher than AFP molecular function CBC 26509672 hsa-miR-939 Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted?=?0.049) molecular function CBC 27485175 HTR7 Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer Stemness markers and enhance proliferation,migration and invasion abilities of neighboring cells molecular function MFBCE 26528758 HTR7 Expressed pseudogenes in the transcriptional landscape of human cancers Parent genes HTR7, CNN2, MSN, and TAGLN2 are DE; they generate pseudogenes, which are specifically expressed in prostate cancer samples molecular function CBC 22726445 HTR7 Breast Cancer Gene Expression Profile in Post-Menopausal Patients Supplemented with Vitamin D Differentially expressed genes were involved in the regulation of cell cycle (SMAD2, cyclin E, YWHAQ , 14-3-3 family ) and calcium signalling (HTR7, PTGER1?and?PTGER2) molecular function CBC IGF1R Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 IGF1R Prognostic significance of insulin growth factor-I receptor and insulin growth factor binding protein-3 expression in primary breast cancer IGF-IR expression in primary breast cancer is an independent favorable prognostic factor. biomarker CBC 20204283 IGF1R Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes IGF-1R correlates with good prognostic markers among patients with early breast cancer and is differentially expressed with variable prognostic impact among breast cancer subtypes. biomarker CBC 21574055 IGF1R The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis IGF-1R expression has different prognostic values for patients with breast cancers of different molecular subtypes. It was a favorable prognostic indicator in unselected breast cancers and hormone-receptor-positive cancers, but indicated poor survival in triple-negative breast cancers biomarker CBC 25674003 IGF1R Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation The reduction in mammary gland morphogenesis observed upon loss of IGF1/IGF1R signaling is a result of decreased cell cycle progression and increased apoptosis biomarker CBC 25964777 IL1RAP Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 IL1RAP Selective killing of candidate AML stem cells by antibody targeting of IL1RAP IL1RAP is a promising new therapeutic target in AML molecular function CBC 23479569 IL1RAP Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia Collectively, these results provide important evidence in support of IL1RAP as a target for antibody-based treatment of AML molecular function CBC 26261316 IL1RAP Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia Critical evidence in support of a rapid clinical development of an antibody-based anti-IL1RAP therapy in AML molecular function CBC 26261316 IL1RAP SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis SRSF10-mIL1RAP-CD47 axis could be an attractive therapeutic target for the treatment of cervical cancer molecular function CBC 29429992 IL1RAP IL1RAP potentiates multiple oncogenic signaling pathways in AML Our study provides a new mechanistic basis for the efficacy of IL1RAP targeting in AML and reveals a novel role for this protein in the pathogenesis of the disease molecular function CBC 29773641 ITGB1 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 ITGB1 β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo Beta(1) integrin is a promising therapeutic target, and that the three-dimensional lrECM culture assay can be used to effectively distinguish malignant and normal tissue response to therapy biomarker CBC 16452209 ITGB1 β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo ITGB1 inhibition resulted in a significant loss of cancer cells, associated with a decrease in proliferation and increase in apoptosis, and a global change in the composition of residual colonies molecular function CBC 16452209 ITGB1 Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential candidate biomarker for breast cancer cells migration, invasion and TNBC patients-survival in triple negative?breast cancer biomarker CBC 26675717 ITGB1 Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer Silencing of ITGB1 inhibited TNBC cell migration, invasion and store-operated calcium influx molecular function CBC 26675717 ITGB1 β1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression There was a significant relationship between fascin and ITGB1 co-expression and short disease-free as well as overall survival in chemo-treated breast cancer patients biomarker CBC 30719702 ITGB1 β1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression Fascin-mediated regulation of ITGB1 was critical for several breast cancer cell functions including adhesion to different extracellular matrix, self-renewability and chemoresistance. molecular function CBC 30719702 ITGB1 Tenascin C interacts with integrin receptors to promote breast cancer metastasis to the lungs Two integrin receptors of the mammary gland (ITGB1 and ITGB3) as the receptors mediating the TNC pro-metastatic signaling in triple-negative breast cancer molecular function CBC ITGB7 Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion Our findings support a role for integrin-β7 in MM-cell adhesion, migration, and BM homing, and pave the way for a novel therapeutic approach targeting this molecule. biomarker CBC 21474670 ITGB7 Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion ITGB7 knockdown inhibited focal adhesion kinase (FAK) and Src phosphorylation, Rac1 activation, and SUMOylation, reduced VEGF production in MM-BM stem cell cocultures and attenuated p65-NF-κB activity. molecular function CBC 21474670 ITGB7 β7 integrins contribute to intestinal tumor growth in mice. Using chemically induced and spontaneous intestinal tumor models we showed that lack of β7 integrin significantly impairs tumor growth without affecting tumor frequencies, with a mild translatable effect on overall survival. biomarker CBC 30235302 IVL Keratoacanthoma and squamous cell carcinoma of the skin: Immunohistochemical localization of involucrin and keratin proteins Involucrin may serve as a diagnostic aid in differentiating between squamous cell carcinomas and keratoacanthoma biomarker CBC 2419374 IVL Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites Involucrin, a marker of terminal keratinocyte differentiation, was expressed in a subset of tumours biomarker CBC 9166948 IVL Brk expression may affect the differentiation status of breast cancer cells Brk and involucrin may be coregulated and that inducers of differentiation such as vitamin D3 could be considered potential therapeutic strategies molecular function CBC 3300779 KISS1R Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer Stemness markers and enhance proliferation,migration and invasion abilities of neighboring cells molecular function MFBCE 26528758 KISS1R GPR54 (KISS1R) Transactivates EGFR to Promote Breast Cancer Cell Invasiveness The stability of the receptor complex formation was increased upon treatment of cells by Kp-10. Taken together, our findings suggest a novel mechanism by which Kp signaling via GPR54 stimulates breast cancer cell invasiveness molecular function CBC 21738726 KISS1R Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression, and lung metastasis Kiss1r attenuation was sufficient to delay breast tumor initiation, progression, and metastasis through inhibitory effects on the downstream G伪q-p63RhoGEF-RhoA signaling pathway molecular function CBC 21852382 KISS1R KISS1R Induces Invasiveness of Estrogen Receptor-Negative Human Mammary Epithelial and Breast Cancer Cells The ERα status of mammary cells dictates whether KISS1R may be a novel clinical target for treating breast cancer metastasis molecular function CBC 23525242 KISS1R Kisspeptin/KISS1R System in Breast Cancer KP/KISS1R pathway plays detrimental roles in breast cancer molecular function CBC 24155777 KISS1R KISS1R signaling promotes invadopodia formation in human breast cancer cell via β-arrestin2/ERK Targeting the KISS1R signaling axis might be a promising strategy to inhibit invasiveness and metastasis molecular function CBC 26721186 KISS1R G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients molecular function CBC 28422142 KRT14 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 KRT14 Collective invasion in breast cancer requires a conserved basal epithelial program Similarly, KRT14-expressing breast cancer cells are only capable of leading invasion through a stromal ECM that is rich in fibrillar collagen and deficient in collagen IV? molecular function CBC 24332913 KRT14 Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy ΔNp63α knockdown in human bladder or breast cancer cells result in down regulated expression of basal biomarkers such as CD44, KRT5, KRT14, and CDH3 molecular function CBC 24525232 KRT14 Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters To dissect this list further, we next ranked genes by their association with Krt14 transcript levels [487 genes at a false-discovery rate (FDR) < 0.05]. The top four genes most correlated with Krt14 transcript expression were enriched for multiple major metastasis effector genes that promote metastatic niche remodeling (Tnc, AdamTs1, Jag1) and metastasis survival molecular function CBC 26831077 KRT14 Foxa1 is essential for mammary duct formation A potentially powerful model for complete ablation of Foxa1 in mammary epithelial cells using Krt14-driven Cre expression in an inducible manner, such as Krt14-rtTA;Tet-On-Cre molecular function CBC 26919034 KRT14 Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade RNA-seq and PAM50-intrinsic subtype clustering identified these cell lines as the "normal" counterparts of luminal A, basal, and normal-like subtypes and validated via immunostaining with basal-enriched KRT14 and luminal-enriched KRT19 molecular function CBC 29997232 LDHA Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 LDHA Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth Overexpression of ErbB2 increased the expression of glycolysis-regulating molecules lactate dehydrogenase A (LDH-A) and heat shock factor 1 (HSF1). ErbB2 activated HSF1, indicated by the increased HSF1 trimer formation, and promoted HSF1 protein synthesis. HSF1 bound to LDH-A promoter and the downregulation of HSF1 reduced the expression of LDH-A and subsequently decreased cancer cell glycolysis and growth. molecular function CBC 19668225 LDHA High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer LDHA and AMPK as promising prognostic biomarkers for breast cancer. biomarker CBC 27598996 LDHA Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis Tumor LDH-A expression, serum LDH status, and the slope of serum LDH status were closely associated with triple negative breast cancer brain metastasis and brain metastasis free survival. molecular function CBC 28729678 LINC00536 Long non-coding RNAs as prognostic markers in human breast cancer LINC00536 may serve as prognostic markers for breast cancer biomarker CBC 26942882 LINC00536 Identification of an lncRNA-miRNA-mRNA interaction mechanism in breast cancer based on bioinformatic analysis The network of lncRNA miRNA mRNA interactions (LINC00536) will facilitate further experimental studies and may be used to refine biomarker predictions for developing novel therapeutic approaches in breast cancer. biomarker CBC 28849135 LINC00536 Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer 4 lncRNA biomarkers in the ceRNA network may be independent prognostic signatures in predicting the survival of breast cancer patients biomarker CBC 30261893 LINC00536 High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer LINC00536 promoted BC progression by modulating the Wnt3a/β-Catenin signaling. molecular function CBC 30851243 LINC00536 Identification of competitive endogenous RNAs network in breast cancer The expression levels of LINC00536 (P = 8.1918e-4) and ADAMTS9-S1 (2.94e-3) were associated with poor overall suvival molecular function CBC 30932362 LINC00536 Comprehensive analysis of the aberrantly expressed lncRNA associated ceRNA network in breast cancer LINC00536 and WT1-AS, were associated with overall survival molecular function CBC 31059025 LINC00578 LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma LINC00578 act as oncogenes and lncRNA-regulating transcription factors provide novel targets for anti-lung cancer therapeutics molecular function CBC 27903974 LINC00578 Long non-coding RNA LINC00346,?LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer LINC00578 was novel prognostic markers for pancreatic cancer biomarker CBC 30210701 LINC00578 Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma Computational analysis entailing integration of expression and copy number alteration data revealed five prognostic lincRNAs: RBPMS-S1, TDRKH-S1, LINC00578, RP11-70 M17.2 and LINC00941 molecular function CBC 30226269 LINC00578 Expression profiles of long noncoding RNAs in lung adenocarcinoma LINC00578 was identified as a promising biomarker and therapeutic target for lung adenocarcinoma. biomarker CBC 30233202 LINC00637 A combined epigenome- and transcriptome-wide association study of the oral masticatory mucosa assigns CYP1B1 a central role for epithelial health in smokers. LINC00673 was significantly hypomethylated in smokers in our study at three individual CpGs, which was shown to be upregulated in tongue squamous cell carcinoma molecular function CBC 31331382 LINC00658 Copy number variations of colorectal cancer by whole exome sequencing data LINC00658 has copy number variations of colorectal cancer molecular function CBC LINC00992 Identification and Validation of Long Noncoding RNA Biomarkers in human non-small-cell lung carcinomas LINC00992 could be further exploited for the development of useful biomarkers in diagnosis, prognosis, and treatment of NSCLC. biomarker CBC 25590602 LINC00992 Bronchial epithelial cells from cystic fibrosis patients express a specific long non-coding RNA signature upon Pseudomonas aeruginosa infection LINC00992 has been shown to be expressed in lungs, kidneys and salivary glands molecular function CBC 28611953 LINC00992 Systematic identification of non-coding pharmacogenomic landscape in cancer LINC00992 in primary tumors increases along with the disease progression and correlates with poor patient survivals in multiple cancer types that are routinely treated with chemotherapy molecular function CBC 30093685 LINC01354 Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma LINC01354 was mainly involved in vascular smooth muscle contraction and the cGMP-PKG signaling pathway molecular function CBC 29565464 LINC01354 Identification of differential expressed lnc RNA s in human thyroid cancer by a genome-wide analyses The dysregulated lncRNAs genomic loci contains copy number amplification or deletion, such as LINC01354, LINC01341, LINC00595, and LINC01519, suggesting that genomic alterations might involve in part of these lncRNAs dysregulation in thyroid cancer. molecular function CBC 29923329 LINC01354 A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer LINC01354 expression signature was discovered as a prognostic indicator for patients with CRC, which may act as competing endogenous RNA (ceRNAs) to play a crucial role in the modulation of cancer-related pathways. molecular function CBC 30510449 LINC01354 LINC01354 interacting with hnRNP-D contributes to the proliferation and metastasis in colorectal cancer through activating Wnt/β-catenin signaling pathway Novel regulatory axis of LINC01354/hnRNP-D/Wnt/β-catenin might be in favor of exploring novel therapeutic regimens for the clinical treatment of colorectal cancer molecular function CBC 30987669 LINC01354 Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma LINC01354 could be used as independent prognostic markers and thus might be potential drug targets biomarker CBC 31264288 MEF2A The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro In cells transformed by the oncogene HER2 (ERBB2), acini morphogenesis is altered, MEF2 transcription is repressed and HDAC7 is continuously expressed molecular function CBC 26403201 MEF2A The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness In leiomyosarcomas (LMS), this two-faced trait of MEF2 is relevant for tumor aggressiveness molecular function CBC 28419090 MEF2A MEF2 signaling and human diseases MEF2 family is closely associated with various signaling pathways, including Ca2+ signaling, MAP kinase signaling, Wnt signaling, PI3K/Akt signaling, etc. microRNAs also contribute to regulate the activities of MEF2 molecular function CBC 29340119 MEF2A MEF2 plays a significant role in the tumor inhibitory mechanism of encapsulated RENCA cells via EGF receptor signaling in target tumor cells Factors secreted by RENCA macrobeads significantly up-regulated the activity of the MEF2 transcription factor as well as altered the transcription of MEF2b and MEF2d isoforms in targeted tumor cells. Suppression of individual or multiple MEF2 isoforms in target tumor cells markedly reduced the growth inhibitory effects of RENCA macrobeads molecular function CBC 30514247 MIR7-3HG MIR7-HG, a MYC-dependent modulator of cell proliferation, inhibits autophagy by a regulatory loop involving AMBRA1 MIR7-3HG as an anti-autophagic MIRNA that may affect oncogenesis through the regulation of the tumor suppressor AMBRA1 molecular function CBC 28059583 MIR7-3HG A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma Our study revealed that the MIR7-3HG could be used to predict the prognosis of UCEC and for postoperative treatment and follow-up. molecular function CBC 31168849 MRPL15 Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics MRPL15 had the best prognostic value biomarker CBC 28978152 MRPL21 The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma MRPL21 (rank 6), which is located near GAL in locus 11q13.2, has been suggested to play a role in carcinogenesis molecular function CBC 18973137 MRPL21 Gene expression profiling: Canonical molecular changes and clinicopathological features in sporadic colorectal cancers Amongst 47 differentially expressed genes, seven (PISD, NIBP, BAI2, STOML1, MRPL21, MRPL16, and MKKS) were newly found to correlate with tumorigenesis and tumor growth molecular function CBC 19034969 MRPL21 Mitochondrial ribosomes in cancer Among the proteins associated with these processes, mammalian mitochondrial ribosomal proteins (i.e. MRPL9, MRPL21, MRPL39) showed high correlation, which function in RNA synthesis and processing as well as protein synthesis and translation in cytosol and/or mitochondria and are necessary for the fast growth of tumor cells molecular function CBC 28445780 MRPL4 An Integrating Approach for Genome-Wide Screening of MicroRNA Polymorphisms Mediated Drug Response Alterations a new discovery that an SNP (rs751012151) in MRPL4 can be downregulated by hsa-miR-6089 and decrease drug resistance in our database (?kcal/mol) molecular function CBC 28480217 MRPL4 Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment IDH3G, UQCRH, MRPL4 and ACADSB, as well as cellular redox regulation (GSR) (Fig. 3B), explaining enrichment for the functional terms mitochondrion,metabolic pathways,and oxidation-reduction process in the NPF group (Fig. 2) molecular function CBC 31061140 MRPS30 Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists The radiation-associated breast cancer risk varied significantly by linked markers in 5p12 (rs930395, rs10941679, rs2067980 and rs4415084) in the mitochondrial ribosomal protein S30 (MRPS30) gene (P(interaction) = 0.04) molecular function CBC 20095854 MRPS30 Genetic variants in the MRPS30 region and postmenopausal breast cancer risk Combined main effect and intervention interaction analyses raise novel hypotheses concerning the MRPS30 genomic region and the effects of hormonal and dietary exposures on postmenopausal breast cancer risk molecular function CBC 21702935 MRPS30 The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors The 5p12 risk allele affects MRPS30 expression in estrogen-responsive tumor cells after tumor initiation by a mechanism affecting chromatin availability molecular function CBC 24388359 MRPS30 Evidence that the 5p12 Variant rs10941679 confers susceptibility to estrogen-receptor-positive breast cancer through FGF10 and MRPS30 regulation. 5p12 is mediated through coordinated activation of FGF10 and MRPS30, two candidate genes for breast cancer pathogenesis molecular function CBC 27640304 MRPS30 Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084 MRPS30 encodes a member of the mitochondrial ribosomal proteins, implicating the role of risk SNP in modulating mitochondrial activities in breast cancer molecular function CBC 29351903 MTDH Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 MTDH MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk biomarker CBC 19111877 MTDH Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer MTDH overexpression contributes to an aggressive phenotype, thus leading to a poor prognosis for primary invasive breast cancer molecular function CBC 22903204 MTDH Knockdown of metadherin inhibits angiogenesis in breast cancer MTDH is a viable therapeutic target for anti-angiogenesis in breast cancer molecular function CBC 25902416 MTDH Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin MTDH gene plays a promoting role in the proliferation of breast cancer cells and its high expression may be associated with doxorubicin sensitivity of breast cancer molecular function CBC 25993398 MTDH Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-like Cell Traits in Breast Cancer MTDH promotes CSC accumulation and breast tumorigenicity by regulating TWIST1, deepening the understanding of MTDH function in cancer molecular function CBC 26141861 MTDH Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro NP-based co-delivery approach can effectively knock down the MTDH gene both in vitro and in vivo, which dramatically inhibits breast tumor growth, achieving effective TAX chemotherapy treatment without overt side effects molecular function CBC 30227879 MTDH Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab High MTDH expression was closely correlated with poor prognosis of patients and was an important factor affecting tumor progression molecular function CBC 31490377 NANOG Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer Stemness markers and enhance proliferation,migration and invasion abilities of neighboring cells molecular function MFBCE 26528758 NANOG RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells NANOG protein can bind to the promoter region of cyclinD1 and regulate cells cycle molecular function CBC 22381696 NANOG Prognostic significance of NANOG and KLF4 for breast cancer Strong expression of NANOG is an indicator of a poor prognosis for breast cancer patients, whereas KLF4 is a favorable prognostic indicator biomarker CBC 22528804 NANOG Prognostic significance of NANOG and KLF4 for breast cancer NANOG stimulates the growth and metastasis of breast cancer cells, whereas KLF4 inhibits these processes. molecular function CBC 22528804 NANOG The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis The involvement of Nanog in breast cancer metastasis, and provide the basis for the reported correlation between Nanog expression and poor prognosis of human breast cancer patients biomarker CBC 23770853 NANOG The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis Nanog promotes the migration and invasion of breast cancer cells molecular function CBC 23770853 NANOG PD-1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation PD-1 positive effect on OCT-A and Nanog was dependent on AKT activation molecular function CBC 28614911 NANOG Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma Nanog is a biomarker for prognostic prediction in patients with breast cancer. However, further studies of Nanog are suggested to provide novel therapeutic targets for curing breast cance biomarker CBC 30220190 NEUROD1 Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer Stemness markers and enhance proliferation,migration and invasion abilities of neighboring cells molecular function MFBCE 26528758 NEUROD1 Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer NEUROD1 methylation is a chemosensitivity marker in estrogen receptor-negative breast cancer molecular function CBC 18519782 NEUROD1 DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery NEUROD1 was one of the genes that did not show statistically significant differences in the methylation levels between TUC and TUP, suggesting it is homogeneously methylated within the tumour. molecular function CBC 19353266 NEUROD1 Whole genome DNA methylation signature of HER2-positive breast cancer Top candidate biomarker genes are involved in transcription (HIST1H4, NEUROD1, IRF4, mir129, FOXC2, POU4F1),?neural signaling/development/differentiation (GABRA4, INA, NEUROD1, WDR69, POU4F1),?glucose metabolism (AKR1B1),?and epidermal growth factor signaling (CDKL2) molecular function CBC 25089541 NEUROD1 Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients For following genes assays were designed using the Pyromark Assay Design Software Version 2 (Qiagen): AKR1B1, BMP6, CST6, HOXB4, HIST1H3C, ITIH5, NEUROD1, RASSF1, SOX17. All of these genes have been previously shown to be hypermethylated in breast cancer patients molecular function CBC 29190932 NEUROD1 MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer Analysis of possible targets for miR-29b-1-5p reveals that the top 4 targets, USP28, NEUROD1, LIN9 and WDR26 have all been previously associated with breast cancer molecular function CBC 30323900 NOC2L Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of?NOC2L?as a pancreatic cancer susceptibility gene molecular function CBC 29422604 NOC2L Deconvolution of DNA methylation identifies differentially methylated gene regions on 1p36 across breast cancer subtypes We identified nineteen differentially methylated gene regions (DMGRs) in early stage tumors across eleven genes (AGRN, C1orf170, FAM41C, FLJ39609, HES4, ISG15, KLHL17, NOC2L, PLEKHN1, SAMD11, WASH5P) molecular function CBC ?28912426 PIGR Uterine stromal cell suppression of pIgR production by uterine epithelial cells in vitro: a mechanism for regulation of pIgR production Stromal cells can provide a signal that leads to the regulation of pIgR production molecular function CBC 9234210 PIGR Characterization of the human polymeric immunoglobulin receptor(PIGR)3'UTR and differential expression of PIGR mRNA during colon tumorigenesis The entire 1.8 kb 3'UTR of human PIGR, and found it to contain multiple repetitive elements as well as elements that could affect the processing and stability of PIGR mRNA molecular function CBC 14631119 PIGR Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer High tumour-specific expression of PIGR was found to be associated with a favourable prognosis in unadjusted, but not in adjusted, analysis molecular function CBC 24568264 PIGR Polymeric immunoglobulin receptor expression is predictive of poor prognosis in glioma patients PIgR could be a novel predictor for poor prognosis of patients with glioma after surgical resection biomarker CBC 25232405 PIGR Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease PIgR-mediated transcytosis of antagonistic antibodies in dIgA format can be exploited for targeted therapy in ADPKD molecular function CBC 25922073 PIK3R5 Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma The PIK3R5 gene serves a role in cell growth, differentiation, proliferation, motility, survival and intracellular transport, and its route is associated with the progression of melanoma. The PIK3R5 gene is associated with inhibition of autophagy (promoting tumor growth) and certain authors have suggested that autophagy also works as a cytoprotective mechanism. molecular function CBC 28123587 PKN2 Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells. PKN2, one of the PKC subtypes, was highly expressed in TNBC cell lines, and knocking down PKN2 in TNBC cells inhibited colony formation and xenograft growth. This indicates that PKN2 is required for the survival of TNBC cells, and could be the target mediates the selective activity of chelerythrine. biomarker CBC 28515445 PKN2 PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway The expression of PKN2 in colon cancer cells predicted a favorable prognosis and was associated with low M2 macrophage content in human colon cancer tissues. biomarker CBC 29368606 PKN2 PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway PKN2 suppresses the expression of IL4 and IL10 from colon cancer cells by inhibiting Erk1/2 phosphorylation, which is required for phosphorylation and binding of CREB and Elk-1 to the promoters of IL4 and IL10. DUSP6, which is phosphorylated and activated through direct association with PKN2, suppresses Erk1/2 activation. molecular function CBC 29368606 Plau Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 Plau Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer We unveil a heretofore-unsuspected transcriptional complexity at Plau in a reference metastatic breast cancer cell line with pleiotropic effects for Fra-1, providing novel information on AP-1 transcriptional action molecular function CBC 25200076 Plau Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer Fourteen genes were identified as significantly differentially expressed between CTC+ and CTC- patients (KRT19, FLT1, EGFR, EPCAM, GZMM, PGR, CD24, KIT, PLAU, ALDH1A1, CTSD, MKI67, TWIST1, and ERBB2). KRT19 was highly expressed in CTC+ patients and ADAM17 in the NR at TP1 molecular function CBC 28778937 Plau HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells From an inspection of the HMGA1-dependent secreted factors it turned out that HMGA1 influences the presence in the extra cellular milieu of key components of the Plasminogen activation system (PLAU, SERPINE1, and PLAUR) that has a prominent role in promoting metastasis molecular function CBC 28924209 Plau Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study Transcriptomic changes and predicted pathways supported and consolidated some of the earlier understanding in the context of PLAUR signaling; including our recent observations in DNA damage and repair process. In addition, we have identified several novel pathways where PLAUR is implicated molecular function CBC 29254187 Plau Fluid shear stress stimulates breast cancer cells to display invasive and chemoresistant phenotypes while upregulating PLAU in a 3D bioreactor Pulsatile shear stress promotes breast cancer cell proliferation, invasive potential, chemoresistance, and PLAU signaling molecular function CBC 31317530 PLCB4 Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4 PLCB4 hotspot mutation is similarly a gain-of-function mutation leading to activation of the same signaling pathway, promoting UM tumorigenesis molecular function CBC 26683228 PLCB4 PLCB4 copy gain and PLC4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival YAP1 increased PLCB4 mRNA and protein expression, and both molecules significantly promoted cell proliferation molecular function CBC 28212550 PLCB4 RNA Sequencing Uncovers Molecular Mechanisms Underlying Pathological Complete Response to Chemotherapy in Patients with Operable Breast Cancer We found key genes that may contribute to pCR to chemotherapy, such as PLCB4, ADCY6, and CNR1, as well as some transcription factors molecular function CBC 28880852 PLCB4 Diagnostic and prognostic value of mRNA expression of phospholipase C β family genes in hepatitis B virus?associated hepatocellular carcinoma Validation using GEPIA revealed that PLCB1 and PLCB2 were associated with OS and PLCB1 and PLCB4 were associated with RFS biomarker CBC 30896816 PLCB4 Distinct Prognostic Values of Phospholipase C Beta Family Members for Non-Small Cell Lung Carcinoma PLCB1, PLCB2, PLCB3, and PLCB4 appear to be potential biomarkers for the prognosis of patients with NSCLC biomarker CBC 31080817 POLR2K Identification of Potential Driver Genes in Human Liver Carcinoma by Genomewide Screening Of the 11 genes, 5 siRNAs for SCRIB, NCSTN, HSF1, TATDN1, and POLR2K significantly reduced the viability of both HepG2 and HuH-7 liver cancer cell lines molecular function CBC 19366792 POLR2K An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers In HER2 cancers, the nucleotide Excision Repair Pathway was significantly enriched for genes whose expression correlates with copy number (P = 0.0214), with recurrent gains and amplifications of POLR2K and losses of RPA2 molecular function CBC 19688261 POLR2K The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study Oxidative phosphorylation and pyrimidine metabolism were identified as the most dysregulated pathways in lethal tumors (p<0.007), and within these pathways, a number of novel differentially expressed genes were identified including?POLR2K?and?APT6V1A molecular function CBC 27980733 POLR2K Identification of miRNA biomarkers of pneumonia using RNA sequencing and bioinformatics analysis POLR2K and APP were predicted targets of has-let-7f-1. The results of the present study demonstrated that has-let-7f-1 may serve a role in the development of cancer and the Notch signaling pathway molecular function CBC 28413462 POSTN Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes Periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis biomarker BBCE 27589561 POSTN Cancer Stem Cell-Related Gene Periostin: A Novel Prognostic Marker for Breast Cancer Periostin was found to be related to the CSC and an independent prognostic factor for breast cancer. It is also perhaps a potential target to breast cancer. biomarker CBC 23056395 POSTN Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma. POSTN might be a factor playing an important role in the mechanism of IDC progression. biomarker CBC 27633896 POSTN Expression of periostin in breast cancer cells. POSTN expression in the cytoplasm of IDC cancer cells may play an important role in cancer transformation mechanism. biomarker CBC 28902360 POSTN Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma. Periostin may play an important role in the progression of breast tumor, and epithelial periostin expression may serve as a new parameter for prediction of prognosis in patients with invasive breast carcinoma(IBC). biomarker CBC 29161296 POU4F1 AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukaemia POU4F1/BRN3A as a novel potential up-regulated AML1/ETO target gene whose dramatically high expression may co-operate with AML1/ETO in t(8;21) cells molecular function CBC 20460523 POU4F1 Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis In tumors, median methylation levels of BCAN, HOXD1, KCTD8, KLF11, NXPH1, POU4F1, SIM1, and TCF7L1 were 30% higher than in normal samples, representing potential biomarkers for tumor diagnosis biomarker CBC 22930747 POU4F1 DNA methylation in ductal carcinoma in situ of the breast Eleven genes (BCAN, HOXD1, KCTD8, KLF11, NXPH1, PCDH10, POU4F1, RYR2, SIM1, TAC1, and TCF7L1) were validated as being aberrantly methylated in DCIS and IDC compared with normal breast tissue molecular function CBC 23826974 POU4F1 POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature Among the most highly differentially expressed genes, half are known AML1/ETO targets, implying that the unique transcriptional signature of t(8;21) AML is, in part, attributable to POU4F1 and not AML1/ETO?itself. molecular function CBC ?20376082 PRPF3 An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth Knockdown of the tri-snRNP protein PRPF31, PRPF8, BRR2, or PRPF3 in colon cancer cells led to reduced growth specifically in cell lines that expressed high levels of PRPF6? molecular function CBC 24788092 PSMC5 A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes Several seed genes for the ER network, including APPBP2, ASH2L, BAG4, CCND1, CLTC, DDX5, DEDD, EPN3, GPAA1, PHB, PRKAR1A, PRKDC, PSMC5, PTK2, RPS6KB1, SPOP, and YWHAZ were not significantly over- or under-expressed in ER+ cancers relative to other subtypes but showed copy number abnormalities molecular function CBC 22343619 PSMC5 Radiosensitizing effect of PSMC5, a 19S proteasome ATPase, in H460 lung cancer cells PSMC5 facilitates the damaging effects of radiation in radiation-responsive H460 cancer cells and therefore may serve as a prognostic indicator for radiotherapy and molecular targeted therapy in lung cancer patients molecular function CBC 26592665 PSMC5 Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer We further interrogated these proteins in over 80 GVAX-treated patients' pancreases and uniformly found a significant increase in the expression of MYPT1, PSMC5, and TFRC in neoplastic compared with non-neoplastic pancreatic ductal epithelium molecular function CBC 26842750 PSMC5 Circulating protein and antibody biomarker for personalized cancer immunotherapy Using this assay, several new tumor antigens (MYPT1, PSMC5 and TRFR) were identified that were found to have significantly different expression in tumors compared with normal tissue molecular function CBC 27532021 PSMD2 PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation Upregulated PSMD2 is a valuable predictor for clinical outcomes in BC and may have an essential role in BC tumorigenesis. biomarker CBC 29777785 PSMD2 PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation Transcriptome signatures involving proliferation, cell cycle, and apoptosis were critically enriched in specimens with elevated PSMD2. Consistently, PSMD2 knockdown inhibited cell proliferation and arrested cell cycle at G0/G1 phase in vitro, as well as suppressed tumor growth in vivo.The cell cycle arrest caused by silencing PSMD2 partially resulted from increased p21 and/or p27. Mechanically, PSMD2 physically interacted with p21 and p27 and mediated their ubiquitin-proteasome degradation with the cooperation of USP14. molecular function CBC 29777785 RAB13 Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing RAB13 distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 RAB13 Rab35 promotes the recruitment of Rab8, Rab13 and Rab36 to recycling endosomes through MICAL-L1 during neurite outgrowth We further showed by functional ablation experiments that each of these downstream Rabs regulates neurite outgrowth in a non-redundant manner downstream of Rab35 and MICAL-L1, e.g. by showing that knockdown of Rab36 inhibited recruitment of Rab36-specific effector JIP4 to Arf6-positive recycling endosomes, and caused inhibition of neurite outgrowth without affecting accumulation of Rab8 and Rab13 in the same Arf6-positive area molecular function CBC 25086062 RAB13 DENND2B activates Rab13 at the leading edge of migrating cells and promotes metastatic behavior Blocking Rab13 activation by DENND2B may provide a novel target to limit the spread of epithelial cancers molecular function CBC 25713415 RAB13 Regulation of Cancer Cell Behavior by the Small GTPase Rab13 Rabs have been implicated in all steps of membrane trafficking ranging from vesicle formation and transport to vesicle docking/tethering and fusion. Vesicle trafficking controls the localization and levels of a myriad of proteins, thus regulating cellular functions including proliferation, metabolism, cell-cell adhesion, and cell migration molecular function CBC 27044746 RAB13 Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMT Rab13 is activated by its effector MICAL-L2 to recruit actin-binding proteins to promote migrating cell molecular function CBC 29483957 RAB13 RAB13 as a novel prognosis marker promotes proliferation and chemotherapeutic resistance in gastric cancer RAB13 promotes the proliferation and confers CDDP and 5-FU resistance to GC cells, which provides experimental support to target this protein in future clinical practice molecular function CBC 31474334 RANBP1 Ran-binding protein 1 (RanBP1) forms a ternary complex with Ran and karyopherin beta and reduces Ran GTPase-activating protein (RanGAP) inhibition by karyopherin beta RanBP1 and karyopherin β interact with distinct sites of Ran and suggest that RanBP1 plays an essential role in nuclear transport by permitting RanGAP-mediated hydrolysis of GTP on Ran complexed to karyopherin β molecular function CBC 8995296 RANBP1 RANBP1 localizes a subset of mitotic regulatory factors on spindle microtubules and regulates chromosome segregation in human cells RANBP1 activity is required for the proper localization of specific factors that regulate microtubule function; loss of this activity contributes to the generation of aneuploidy in a microtubule-dependent manner molecular function CBC 17940066 RANBP1 RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent molecular function CBC 19270727 RANBP1 Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells SGK1 also affects mitotic stability in colon carcinoma cells by regulating the expression of RANBP1 (Ran-specific binding protein 1), the pivotal regulator of GTPase RAN. SGK1 modulates RAN/RANBP1 abundance at the transcriptional level via SP1 activation and phosphorylation on Serine 59, thus affecting taxol sensitivity in these cells molecular function CBC 23108393 RANBP1 Distinct RanBP1 nuclear export and cargo dissociation mechanisms between fungi and animals The key feature for the two mechanistic changes from fungi to animals was the loss of affinity between RanBP1-RanGTP and CRM1, since residues mediating their interaction in fungi were not conserved in animals molecular function CBC 31021318 RBM10 mRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer A significant (p=0.03) inverse correlation between BRMS1 mRNA expression and expression of the mRNA corresponding to the large variant of the X-chromosome RBM10 gene was found molecular function CBC 21737612 RBM10 RBM5, 6, and 10 Differentially Regulate NUMB Alternative Splicing to Control Cancer Cell Proliferation RBM10 mutations identified in lung cancer cells disrupt NUMB splicing regulation to promote cell growth molecular function CBC 24332178 RBM10 Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing Changes in proliferation rates of LUAD-derived cells caused by these RBM10 missense mutants correlated with alterations in RNA splicing of?RBM10?target genes molecular function CBC 28091594 RBM10 Expression of RNA-binding motif 10 is associated with advanced tumor stage and malignant behaviors of lung adenocarcinoma cancer cells RNA-binding motif 10 regulates many gene pathways involving in the tumor development or progression molecular function CBC 28347232 RBM10 Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene The accumulated and stable overexpression of RBM10 in the xenograft BALB/c nude mice model significantly inhibited the tumor growth rate molecular function CBC 29085465 RHO Rhodopsin and retinoblastoma. A monoclonal antibody histopathologic study Some well-differentiated retinoblastomas express both rhodopsin and S-antigen, and as such express proteins that participate in the initial events in the phototransduction of visio molecular function CBC 3942531 RHO Mechanisms of photoreceptor cell death in cancer-associated retinopathy These observations suggest that anti-recoverin antibody is incorporated into rod photoreceptor cells and modulates rhodopsin phosphorylation, which in turn produces activation of caspase-dependent apoptotic pathways molecular function CBC 11222531 RHO Photoreceptor proteins as cancer-retina antigens Melanocytes also express mRNA of all photoreceptor genes besides transducin, but were devoid of the corresponding protein, which was tested for rhodopsin, cGMP-phosphodiesterase, guanylyl cyclase and recoverin molecular function CBC 17187367 RIPK1 RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis These findings identify the RIPK1-MCU pathway as a promising target to treat colorectal cancer. molecular function CBC 29531160 RIPK1 Differential involvement of TAK1, RIPK1 and NF-κB signaling in Smac mimetic-induced cell death in breast cancer cells TAK1, receptor-interacting kinase 1 (RIPK1) as well as canonical and non-canonical NF-κB signaling are differentially involved in SM-induced cell death in breast cancer cells. These findings contribute to a better understanding of SM-induced signaling pathways molecular function CBC 30391931 RIPK1 FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation FKBP12 may target RIPK1 and RIPK3 to mediate necroptosis in vitro and in vivo Collectively, our data demonstrate that FKBP12 could be a potential therapeutic target for the clinical treatment of necroptosis-associated diseases molecular function CBC 31028177 RIPK1 Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis PK68 is a potent and selective inhibitor of RIPK1 and also highlights its great potential for use in the treatment of inflammatory disorders and cancer metastasis molecular function CBC 31235688 RN7SL1 Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer Unshielded RN7SL1 in exosomes acts as a DAMP and activates breast cancer RIG-I to promote aggressive features of cancer molecular function MFBCE 28709002 RN7SL1 Exosomal proteins as potential markers of tumor diagnosis Breast cancer cells can stimulate stromal fibroblasts to produce stromal exosomes, which contain unshielded endogenous RNA (RN7SL1), via triggering NOTCH-MYC pathways. Delivering unshielded RN7SL1 to breast cancer cells facilitates cancer growth, metastasis, and therapy resistance through retinoic acid-inducible gene I (RIG-I) signaling molecular function CBC 29282096 RN7SL1 The decade of exosomal long RNA species: an emerging cancer antagonist Assessments of the blood samples of breast cancer patients revealed the presence of unshielded RN7SL1 in exosomes. Thus, exosomal content can be utilized to identify patients with more aggressive cancers by detecting exosome-binding RN7SL1 molecular function CBC 29558960 RN7SL1 Exosomes From The Tumor Microenvironment Promote Breast Cancer Progression And Therapy Resistance Through Unshielded Non-Coding Rna Unshielded stromal RN7SL1 in exosomes, which is also found in cancer patients, is transferred to breast cancer cells to stimulate the pattern recognition receptor RIG-I and activate STAT1-dependent anti-viral signaling molecular function CBC RPL26L1 Patterns of ribosomal protein expression specify normal and malignant human cells Among these, RPL26L1 and RPS27L were exclusively up-regulated in breast and thyroid carcinomas, respectively, whereas RPL21 had decreased expression in breast and uterine cancers molecular function CBC 27884178 RPL26L1 Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings In the IMiD-based cohort, C14orf2 and RPL26L1 were significantly increased in responders (n=32) vs. non-responders (n=7, p<0.05). In the PI+IMiD treatment group, ACVC1C, CRYGS, FUNDC1, PSMB3, RPL26L1, HIST1H3B, PSMB10 and STUB1?were significantly increased whereas TMC8, MAPK4, CCNB1IP1, SAP18, ANK3, JAK1, RUNX3, IKZF1, CUL4B, HNRNPC and WIPF2 were significantly decreased in responders (n=361) vs. non-responders (n=18) (p<0.05-<0.001) biomarker CBC RPL28 Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing RPL28 distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 RPL28 Long non-coding RNA GAS5 and ZFAS1 are prognostic markers involved in translation targeted by miR-940 in prostate cancer GAS5 and ZFAS1 are targeted by miR-940 via NAA10 and RPL28 molecular function CBC 29416676 RPL28 Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance Depleting RPL6 decreases ubiquitin-dependent peptide presentation, whereas depleting RPL28 increases ubiquitin-dependent and -independent peptide presentation molecular function CBC 30712990 RPL28 Germline variability and tumor expression level of ribosomal protein gene?RPL28?are associated with survival of metastatic colorectal cancer patients Repression of RPL28 reduced proliferation by 1.4-fold to 5.6-fold (P < 0.05) in colon cancer HCT116 and HT-29 cells. Our findings suggest that the ribosomal RPL28 protein may influence mCRC outcome molecular function CBC 31506518 RPPH1 Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing RPPH1 distinguish exosomes produced by low metastatic breast cancer cell line (MDA-MB-436) from that produced by highly metastatic breast cancer cell line (MDA-MB-231) molecular function MFBCE 24255815 RPPH1 Inhibition of breast cancer cell proliferation and tumorigenesis by long non-coding RNA?RPPH1?down-regulation of miR-122 expression Breast cancer progression can be promoted by directly targeting miR-122 through lncRNA RPPH1 molecular function CBC 29200969 RPS10 Morin suppresses cachexia-induced muscle wasting by binding to ribosomal protein S10 in carcinoma cells Morin indirectly prevents muscle wasting induced by cancer cachexia by suppressing cancer growth via binding to RPS10 molecular function CBC 30389140 RPS10 Cancer-Associated Eukaryotic Translation Initiation Factor 1A Mutants Impair Rps3 and Rps10 Binding and Enhance Scanning of Cell Cycle Genes These mutations diminished the eIF1A interaction with Rps3 and Rps10 implicated in scanning arrest molecular function CBC 30420357 S1PR2 The sphingosine 1-phosphate receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts. S1P2 is released from breast cancer cells in exosomes and is processed by fibroblasts to promote ERK signaling and proliferation of breast cancer cells molecular function MFBCE 30034630 S1PR2 Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 Jekyll Hidden behind Hyde S1PR2 expressed in host endothelial cells and tumor-infiltrating myeloid cells in concert mediates potent inhibition of tumor angiogenesis and tumor growth?in vivo, with inhibition of VEGF expression and MMP9 activity molecular function CBC 21984966 S1PR2 Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis Local tumour growth is regulated by both S1P from the tumour and systemic S1P, whereas lung colonization and metastasis is selectively controlled via systemic S1P and downregulation of breast cancer metastasis suppressor 1 (BRMS1; a master suppressor of metastasis) through S1PR2 signalling molecular function CBC 22707406 S1PR2 The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma Uncover an important novel tumor suppressive function of the TGF-β/TGF-βR2/SMAD1/S1PR2 axis in DLBCL, and show that DLBCL cells have evolved to inactivate the pathway at the level of SMAD1 expression molecular function CBC 29615404 SDHA SDHA is a tumor suppressor gene causing paraganglioma SDHA gene should be added to the list of genes encoding tricarboxylic acid cycle proteins that act as tumor suppressor genes and can now be considered as a new paraganglioma/pheochromocytoma susceptibility gene molecular function CBC 20484225 SDHA Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes?SDHA,?TMEM127,?MAX, and?SDHAF2?for Gene-Informed Prevention The SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma molecular function CBC 28384794 SDHA Germline SDHA mutations in children and adults with cancer Immunohistochemical staining and assessment of patient tumors for second hits and loss of heterozygosity in SDHA confirmed GIST as an SDHA-associated tumor and suggests SDHA germline mutations may be a driver in neuroblastoma tumorigenesis molecular function CBC 30068732 SDHA Succinate dehydrogenase expression in breast cancer Loss of SDHA or SDHB expression was observed in about 3% of breast cancers in this study. Low SDH expression status in breast tumor cells was associated with younger age at diagnosis and low-grade histology molecular function CBC ?23888270 SF3A2 Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia SF3A2 is part of the U2 snRNP, and another member of this complex (SF3B1) is recurrently mutated in myelodysplastic syndrome, acute myeloid leukemia, and chronic lymphocytic leukemia molecular function CBC 23327988 SF3B4 Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma High SF3B4 expression is significantly associated with intrahepatic metastasis and poor prognosis biomarker CBC 27127115 SF3B4 Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma SF3B4 expression was significantly higher in cancerous than in non-cancerous tissues and positively correlated with SF3B4 DNA copy number molecular function CBC 27127115 SF3B4 Synchronous bilateral breast cancer in a patient with Nager syndrome Somatic inactivating mutations of SF3B4 occur occasionally in breast cancer, and these findings support the idea that SF3B4 is a tumor suppressor molecular function CBC 28139434 SF3B4 SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells Splicing factor 3b subunit 4 acted as a suppressive role in pancreatic cancer and indicated that restoring the function of splicing factor 3b subunit 4 might be a strategy for cancer therapy molecular function CBC 28351319 SF3B4 SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma SF3B4 indicates early-stage HCC in precancerous lesions, and also functions as an early-stage driver in the development of liver cancer. molecular function CBC 29397868 SFN Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer The 14-3-3 proteins are a family of widely expressed regulatory molecules. Their ability to bind a variety of functionally diverse signaling proteins, including kinases, phosphatases, and transmembrane receptors, allows 14-3-3 proteins to play important roles in a wide range of regulatory processes, such as mitogenic signal transduction, cell cycle control, and apoptotic cell death. molecular function CBC 11423985 SFN Quantitative assessment of promoter hypermethylation during breast cancer development For RASSF1A and 14-3-3 promoter methylation was demonstrated in epithelial hyperplasia and intraductal papillomas. molecular function CBC 11839581 SFN Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis SFN (stratifin), a TSG involved in cell-cycle control and regulated by TP53, is frequently epigenetically silenced in breast cancer.Similar to RASSF1A, SFN methylation frequently occurs in microdissected atypical hyperplasia and DCIS. SFN methylation, however, has also been scored in physiological breast proliferations and stromal breast tissue, emphasizing the importance of selective tissue sampling when using SFN methylation as a biomarker of breast cancer risk biomarker CBC 19452229 SFN Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis The relationship of 14-3-3-sigma with breast cancer metastasis and progression found in this study suggests a possible application of 14-3-3-sigma as a biomarker to screen for metastasis and to follow up patients treated for metastatic breast cancer, monitoring their disease status and treatment response biomarker CBC 20487521 SFTA1P Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications SFTA1P is identified to be associated with tumor subtypes and their functions as well as the associated proteins are predicted by constructing coding-non-coding co-expression network molecular function CBC 25307233 SFTA1P Co-expression network analysis of long noncoding RNAs (IncRNAs) and cancer genes reveals SFTA1P and CASC2 abnormalities in lung squamous cell carcinoma SFTA1P and CASC2 were found to be related with most of the oncogenes and tumor supressor gene by co-expression analysis molecular function CBC 28118064 SFTA1P The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma molecular function CBC 28231733 SFTA1P Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell molecular function CBC 29228625 SFTA1P The pseudogene-derived long non-coding RNA SFTA1P suppresses cell proliferation, migration, and invasion in gastric cancer SFTA1P suppresses cell proliferation, migration, and invasion in gastric cancer molecular function CBC 29523596 SNRPA1 Classification and Biomarker Genes Selection for Cancer Gene Expression Data Using Random Forest The SNCA, USP20, and SNRPA1 genes were selected for prostate cancer with the accuracy of 73.33 and precision of 66.67 molecular function CBC 29563929 SNRPA1 An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer These novel findings identified new roles played by SNRPA1 in the progression of CRC and it may become a potential therapeutic target in the treatment of CRC molecular function CBC 31203132 TAC1 Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides The oncogenic property of Tac1 in breast cells involves concomitant expression of NK1-Tr and vice versa, consequently leading to the production of cytokines with growth promoting functions molecular function CBC 16291810 TAC1 Stromal-derived factor-1α induces a non-canonical pathway to activate the endocrine-linked?Tac1?gene in non-tumorigenic breast cells Tac1 is relevant to breast cancer metastasis, to bone marrow where stromal cells have a significant facilitating function molecular function CBC 18316470 TAC1 RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells REST knockdown in low-metastatic T47D cells and nontumorigenic MCF12A cells resulted in increases in TAC1 induction, proliferation, and migration molecular function CBC 19246391 TAC1 Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen Methylation of CDO1, CKM, CRIP1, KL and TAC1 correlated with clinical prognostic variables and was a significant prognosticator for poor overall survival in BC patients. biomarker CBC 22647880 TGFBR1 Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential Presumably aid in targeting the primary cancer cells to specific metastatic sites molecular function MFBCE 29115712 TGFBR1 TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study No overall associations between the L10P polymorphism of TGFB1 or the TGFBR1 microsatellite were detected. However, we observed an inverse association between the -509 C/T polymorphism of TGFB1 (p-trend = 0.04), which was stronger and more significant among women with estrogen receptor positive breast cancer. molecular function CBC 17848193 TGFBR1 TGFBR1*6A and Int7G24A variants of transforming growth factor-β receptor 1 in Swedish familial and sporadic breast cancer TGFBR1*6A variant may be associated with an increased risk of low-risk familial breast cancer and might be a marker for poorly differentiated breast cancer molecular function CBC 17848956 TGFBR1 TGFBR1 signaling and breast cancer TGFBR1 signaling in breast cancer may have an impact on breast cancer risk assessment and breast cancer prevention molecular function CBC 21461994 TGFBR1 TGFBR1 polymorphism and risk of breast cancer in Iranian women The allelic length of TGFBR1 polymorphisms had no significant association with the age at onset or the grade of disease, nor with the expression of progesterone and estrogen receptors and HER2 molecular function CBC 26165686 TGFBR1 Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition Inhibiting TGFβ signaling shifts the balance toward the former, which may have unanticipated implications for the therapeutic use of TGFβ/TGFBR1 inhibitor molecular function CBC 31257133 TLR5 Activation of Toll-Like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth TLR5 activation by flagellin mediates innate immune response to elicit potent antitumor activity in breast cancer cells themselves, which may serve as a novel therapeutic target for human breast cancer therapy molecular function CBC 21427357 TLR5 MAP1S Controls Breast Cancer Cell TLR5 Signaling Pathway and Promotes TLR5 Signaling-based Tumor Suppression Elevated expression of MAP1S in response to flagellin feed-back regulated tumor inflammatory microenvironment in the late stages of TLR5 signaling through degradation of MyD88 in autophagy process molecular function CBC 24466264 TLR5 TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining 125 I-antiTLR5 mAb was an ideal agent for non-invasive imaging of TLR5+ tumours; TLR5 may be as a novel molecular target for TNBC non-invasive diagnosis molecular function CBC 31576678 TLR5 TLR5 is a potential target in vivo monitoring triple-negative breast cancer TLR5 expressed on triple-negative breast cancer could be a molecular target for monitoring tumor growth in vivo and Flavopiridol may carry out its anti-tumor effect through CDK9-TLR5-NF-κB pathway. molecular function CBC TPP2 Tripeptidyl-peptidase II controls DNA damage responses and in vivo gamma-irradiation resistance of tumors. TPPII can be targeted for inhibition of tumor therapy resistance. biomarker CBC 17671184 TPP2 Tripeptidyl-peptidase II controls DNA damage responses and in vivo gamma-irradiation resistance of tumors. TPPII contains a BRCA COOH-terminal-like motif, contained within sequences of several proteins involved in DNA damage signaling pathways, and this motif was important for nuclear translocation of TPPII and stabilization of p53.TPPII connects signaling by cytosolic/mitochondrial and nuclear PIKK-dependent pathways molecular function CBC 17671184 TPP2 Tripeptidyl peptidase II in human oral squamous cell carcinoma. Overexpression of TPP2 occurs frequently during oral carcinogenesis and might be associated with OSCC progression via SAC activation. biomarker CBC 22986808 TRIOBP The actin-bundling protein TRIOBP-4 and -5 promotes the motility of pancreatic cancer cells A novel role of TRIOBP-4/-5 that promotes the motility of pancreatic cancer cells via regulating actin cytoskeleton reorganization in the filopodia of the cells molecular function CBC 25130170 TRIOBP The roles of TRIO and F-actin-binding protein in glioblastoma cells The present data indicate that TrioBP expression is increased in glioblastoma cell lines and in patients with glioma, suggesting that TrioBP has potential as a diagnostic marker or therapeutic agent for glioma molecular function CBC 29363730 TRPC5 Increasing circulating exosomes carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients CirExo-TRPC5 might act as a noninvasive chemoresistance marker and might serve as an adjuvant to the current imaging examination-based chemoresistance biomarker BBCE 28032400 TRPC5 Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells In an athymic nude mouse model of adriamycin-resistant human breast tumor, suppressing TRPC5 decreased the growth of tumor xenografts. Nuclear factor of activated T cells isoform c3 (NFATc3) was the transcriptional factor that links the TRPC5 activity to P-gp production molecular function CBC 22988121 TRPC5 Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance TrpC5-containing circulating EVs may transfer chemoresistance property to nonchemoresistant recipient cells molecular function CBC 24733904 TRPC5 A Methylation-Based Regulatory Network for MicroRNA 320a in Chemoresistant Breast Cancer MiR-320a is a mediator of chemoresistance by targeting TRPC5 and NFATC3. Expression of miR-320a is regulated by methylation of its promoter and that of ETS-1 molecular function CBC 25159093 TRPC5 TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway A novel role of TRPC5 as an inducer of autophagy, and this suggests a novel mechanism of drug resistance in chemotherapy for breast cancer molecular function CBC 28600513 TRPC5 Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer We demonstrated the essential role of glycolysis in TRPC5 induced chemoresistance in human CRC cells via maintaining [Ca2+]?i?homeostasis molecular function CBC 29463225 TSC2 Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2 Overexpression of TSC2 rescues the migration phenotype of myr-Akt1-expressing tumor cells, and high levels of TSC2 in breast cancer patients correlate with increased metastasis and reduced survival molecular function CBC 16537497 TSC2 ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway ARD1 functions as an inhibitor of the mTOR pathway and that dysregulation of the ARD1-TSC2-mTOR axis may contribute to cancer development molecular function CBC 20145209 TSC2 Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes TSC1 acts coordinately with TSC2 in a complex to inhibit mTOR, an emerging therapeutic target and known promoter of cell growth and cell cycle progression molecular function CBC 20658316 TSC2 Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma1 Loss of TSC2 may predict improved response to everolimus in HCC patients, but further studies are needed to confirm the predictive role of TSC2 expression for everolimus treatment biomarker CBC 27751352 TSC2 ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis ARD1 prevents mTOR activity and breast cancer cell growth by stabilizing tuberous sclerosis complex 2 (TSC2) to induce autophagy molecular function CBC 30154412 TSG101 Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC Tumour-derived exosomes interfere with the tumour-specific function of immune cells and constitute an additional mechanism how tumours escape from immune surveillance molecular function MFBCE 21293856 TSG101 The breast cancer gene product TSG101: a regulator of ubiquitination? As the UBC active site residue is replaced in the TSG101 sequence in a similar manner to several other members of the UBC family, we propose a role for TSG101 in regulating the ubiquitination of short-lived gene products molecular function CBC 9253709 TSG101 Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers Truncated TSG101 transcripts that probably represent splice variants are present in some breast and ovarian cancers, but there is no evidence to suggest that loss of this putative tumor suppressor gene plays a role in the molecular pathogenesis of these cancers molecular function CBC 9773405 TSG101 Aberrant expression of TSG101 in Taiwan Chinese breast cancer The aberrant expression of TSG101 in breast cancer is associated with altered cell growth molecular function CBC 10930114 TSG101 Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway TSG101 may play a biological role through modulation of the MAPK/ERK signaling pathway in breast cancer molecular function CBC 21117030 TSG101 A knockout of the Tsg101 gene leads to decreased expression of ErbB receptor tyrosine kinases and induction of autophagy prior to cell death. Defining particular functions for Tsg101 in processes such as signal transduction and lysosomal/endosomal trafficking molecular function CBC 22479596 TTTY14 Complex integrated analysis of lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma TTTY14 were related with elated with overall survival (OS) and relapse-free survival (RFS) molecular function CBC 28939059 TTTY14 Comprehensive analysis of a novel four-lncRNA signature as a prognostic biomarker for human gastric cancer The study indicates that this novel lncRNA expression signature (TTTY14) may be a useful biomarker of the prognosis for GC patients, based on bioinformatics analysis. biomarker CBC 29088841 TTTY14 Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma This subnetwork consists of hub genes, including lncRNA MEG3, lncRNA Prader-Willi region non-protein coding RNA 1 (PWRN1), hsa-miR-508 and hsa-miR-21, plus certain first neighbors, including neurotrophin 3 (NTF3), tissue inhibitor of metalloproteinase 3 (TIMP3), GRM5-AS1, AP002478.1, TTTY14 and hsa-miR-489. molecular function CBC 30957192 TYR Loss of tyrosinase activity confers increased skin tumor susceptibility in mice In vitro mechanistic studies demonstrated that transfection of the Tyr(Cys) allele in a human squamous cell carcinoma cell line (NCI-H520) increases tyrosinase enzyme activity and confers resistance to hydrogen peroxide-induced oxidative DNA damage molecular function CBC 15007389 TYR MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis Adjustment for all clinical potential confounders showed that melanoma risks attributable to MC1R and SLC45A2 variants strongly persisted (OR: 2.01 95% CI: 1.49-2.72 and OR: 0.50, 95% CI: 0.31-0.80, respectively), while the association of TYR p.Arg402Gln was no longer significant molecular function CBC 22464347 TYR Tyrosinase as a multifunctional reporter gene for Photoacoustic/MRI/PET triple modality molecular imaging In vivo PAI/MRI/PET imaging studies showed that MCF-7-TYR tumors achieved significant higher signals and tumor-to-background contrasts than those of MCF-7 tumor. Our study demonstrates that TYR gene can be utilized as a multifunctional reporter gene for PAI/MRI/PET both?in vitro?and?in vivo molecular function CBC 23508226 TYR The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis Arg-Leu-Tyr-Glu (RLYE) effectively inhibited vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, migration and tube formation, with an IC50 of 0.06-0.08?nM, which was about ten-fold lower than that of the control peptide KLYD (0.79?nM), as well as suppressed developmental angiogenesis in a zebrafish model molecular function CBC 26051280 UCHL1 UCHL1 containing exosomes mediate chemotherapeutic resistance transfer in breast cancer UCH-L1-containing exosomes can transfer chemoresistance to recipient cells and these exosomes may be useful as non-invasive diagnostic biomarkers for detection of chemoresitance in breast cancer patients, achieving more effective and individualized chemotherapy molecular function MFBCE 28334432 UCHL1 The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast Cancer UCHL1 exerts its tumor suppressive functions by inducing G0/G1cell cycle arrest and apoptosis in breast tumorigenesis, requiring its deubiquitinase activity. Its frequent silencing by promoter CpG methylation may serve as a potential tumor marker for breast cancer molecular function CBC 22279545 UCHL1 Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance The high expression of UCHL1 in metaplastic carcinomas of the breast, which is pathogenically related to epithelial-mesenchymal transition, may implicate an association between UCHL1 expression and the epithelial-mesenchymal transition in breast cancer molecular function CBC 23664488 UCHL1 UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α UCHL1 promotes metastases as a deubiquitinating enzyme for HIF-1α, which justifies exploiting it as a prognostic marker and therapeutic target of cancers molecular function CBC 25615526 UCHL1 UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway UCH-L1 promotes invasion of breast cancer cells and might serve as a potential therapeutic target for treatment of human patients with breast cancers molecular function CBC 28636190 UCHL1 UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization Cancer cells acquire antioxidant and radioresistant phenotypes through UCHL1-HIF-1-mediated metabolic reprogramming including the activation of PPP and provide a rational basis for targeting this gene network for radiosensitization molecular function CBC 28761052 USF1 The pro-metastasis effect of circANKS1B in breast cancer USF1 transcriptionally elevated ESRP1 and TGF-β1 expression through directly binding to their promoters, thereby activating TGF-β1 signaling to enhance EMT and metastasis-SF1 enhances breast cancer invasion and metastasis by transcriptionally elevating TGF-β1 expression molecular function CBC 30454010